<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Towards improved treatment planning for head and neck microwave hyperthermia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>Cappiello, Grazia</td>
</tr>
<tr>
<td><strong>Publication Date</strong></td>
<td>2019-10-08</td>
</tr>
<tr>
<td><strong>Publisher</strong></td>
<td>NUI Galway</td>
</tr>
<tr>
<td><strong>Item record</strong></td>
<td><a href="http://hdl.handle.net/10379/15491">http://hdl.handle.net/10379/15491</a></td>
</tr>
</tbody>
</table>
Towards Improved Treatment Planning for Head and Neck Microwave Hyperthermia

A dissertation presented by


to

Electrical and Electronic Engineering
College of Engineering and Informatics
National University of Ireland Galway

in fulfilment of the requirements for the degree of
Doctor of Philosophy

Supervisor
Dr. Edward Jones

Co-Supervisors
Dr. Martin Glavin
Dr. Martin O’Halloran

December 2018
Abstract

Hyperthermia is an emerging cancer treatment modality which involves applying heat to the malignant tumor. The heating can be delivered using electromagnetic energy, mostly in the radiofrequency or microwave range. Accurate patient-specific hyperthermia treatment planning is essential for effective and safe treatment, in particular for deep and loco-regional hyperthermia. An important aspect of hyperthermia treatment planning is the ability to focus microwave energy and heating into the tumour while reducing the occurrence of hotspots in surrounding healthy tissue. Typically, a multi-element antenna phase array hyperthermia system is used to focus the electromagnetic waves at the target region. This thesis presents methods for optimising the specific absorption rate distribution and resulting temperature distribution for head and neck cancer hyperthermia treatment.

Several optimisation algorithms and objective functions have been evaluated to optimise the antenna amplitudes and phases of the hyperthermia systems. Evolutionary optimisation algorithms have been considered in this thesis and compared with a particle swarm optimisation method already in clinical use for the treatment of head and neck cancers. A differential evolution algorithm is proposed to improve target coverage. The differential evolution algorithm is shown to offer improved performance compared to the particle swarm optimisation algorithm. Most optimisation techniques reported in literature use static antenna settings throughout the treatment; however, in this thesis a dynamic approach is investigated. A time-multiplexed hyperthermia strategy is developed in order to better focus heating on the tumour while preserving predetermined areas in the healthy tissue. First, a multi-objective genetic algorithm is introduced, which generates multiple antenna settings which are applied sequentially. Thermal simulations are used to evaluate the performance of time-multiplexed steering. The results demonstrate the ability to enhance target heating while reducing hotspot temperatures. Finally, the time-multiplexing steering is evaluated against thermal tissue properties variation and is shown to be robust to temperature dependent thermal tissue properties.
Acknowledgements

Firstly, I would like to thank my principal supervisor, Dr. Edward Jones and co-supervisors Dr. Martin O’Halloran and Dr. Martin Glavin for their valuable guidance and advice throughout my research work and for giving me the opportunity to pursue the PhD in Electrical & Electronic Engineering at NUI Galway. I would also like to thank Galway University Foundation for funding this research through the structured PhD programme in Biomedical Engineering and Regenerative Medicine (BMERM), directed by Professor Peter McHugh. I would also like to thank the European Union COST Programme (Action TD1301 MiMed and Action BM1309 EMF-MED) for providing travel grants to support this research. I am also grateful to the discipline of Electrical & Electronic Engineering at NUI Galway for providing facilities to conduct this research. Some of the simulation work carried out in this thesis was completed using the SEMCAD X software kindly made available on loan by ZTM Zurich MedTech AG.

I am very grateful to Dr. Brian Mc Ginley and Dr. Adnan Elahi for their constant support and constructive discussions during the duration of this project. My sincere thanks also go to Prof. Gerard van Rhoon and Dr. Maarten Paulides, who gave me the opportunity to spend time at their research team at the Hyperthermia Unit of the Erasmus MC Cancer Institute in Rotterdam, who provided patient data for use in this research and who contributed significantly throughout this research. I am also grateful to Dr. Tomas Drizdal for his support and highly constructive discussions and assistance. This collaboration proved to be extremely important, allowing a broader understanding of hyperthermia, its real clinical needs and the opportunities to contribute to the improvement of hyperthermia treatments.

The PhD has been a challenging experience during which I received great moral and practical support from my friends in Galway and in Italy. In particular, many thanks to Lilia, Milena, Alessandra, Lei, Maria Vittoria, Mykhaylo, Laura, Enza, Silvia, Adnan, Leonie, Ana, Dave. Thanks to Kieran who reminded me there is Life beyond the PhD and for his love.

Last but not the least, I would like to thank my family: my parents, my brothers and my nephews for their love and unconditional trust on me.
## Contents

**List of Figures**  
vi

**List of Tables**  
xi

### 1 Introduction

1.1 Motivation  
1.2 Thesis Contributions  
1.2.1 Contributions  
1.2.2 Publications  
1.3 Thesis Outline  
1

### 2 Background and Literature Review

2.1 Introduction  
2.2 Head and Neck Cancer  
2.3 Hyperthermia  
2.3.1 Definition  
2.3.2 Thermal Biology of Hyperthermia  
2.4 Hyperthermia Treatments and Systems  
2.4.1 Local Hyperthermia  
2.4.2 Interstitial and Intracavitary Hyperthermia  
2.4.3 Regional Hyperthermia  
2.4.4 Whole-body Hyperthermia  
2.4.5 Clinical Treatment Procedure  
2.5 Clinical Trials of Hyperthermia  
2.6 Hyperthermia Treatment Planning  
2.6.1 Objective Functions in Hyperthermia  
2.6.2 Overview of the Optimisation Techniques in Hyperthermia  
2.6.3 Discussion of Optimisation Techniques  
2.7 Treatment Quality Quantifiers  
2.7.1 SAR Target Coverage Indicators  
2.7.2 Bio-heat Equation and Temperature Indicators  
2.8 Discussion and Conclusions  
8
3 Hyperthermia Treatment Planning via Differential Evolution Optimisation 47

3.1 Introduction .................................................. 47

3.2 Methodology ................................................. 48

3.2.1 PSO Optimisation of SAR Distribution ............... 48

3.2.2 DE Optimisation of SAR Distribution ................. 49

3.2.3 Experimental Dataset .................................. 51

3.2.4 Optimisation Parameters ................................ 51

3.2.5 Temperature Simulations ............................... 52

3.3 Results ...................................................... 54

3.3.1 Performance of PSO versus DE as a Function of the Objective Function ........................................ 54

3.3.2 Performance of PSO versus DE as a Function of the SAR-Treatment Quantifiers ............................. 59

3.3.3 Thermal Performance .................................... 69

3.4 Discussion ................................................... 72

3.5 Conclusions .................................................. 73

4 Time-Multiplexed Steering in Phased Array Microwave Hyperthermia for Head and Neck Cancer Treatment 75

4.1 Introduction .................................................. 75

4.2 Methodology ................................................. 76

4.2.1 Multi-Objective GA Optimisation ....................... 77

4.2.2 Hotspot Specific Objective Function .................... 78

4.2.3 Temperature Simulations ............................... 79

4.2.4 Time-Multiplexed Steering Procedure .................. 79

4.2.5 Experimental Dataset and Evaluation Parameters 81

4.3 Results ...................................................... 82

4.3.1 SAR-Temperature Correlation ........................ 83

4.3.2 SAR Performance of MOGA against PSO .......... 84

4.3.3 Thermal Performance of Static and Time-multiplexed Configurations ........................................... 91

4.4 Discussion ................................................... 97

4.5 Conclusions .................................................. 99

5 Robustness of Time-multiplexed Hyperthermia to Temperature Dependent Thermal Tissue Properties 100

5.1 Introduction .................................................. 100

5.2 Methodology ................................................. 101

5.2.1 Temperature Properties ............................... 101
List of Figures

2.1 Head and neck cancer regions. Image from www.cancer.gov. (For the
National Cancer Institute © 2012 Terese Winslow LLC, U.S. Govt. has certain rights) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9

2.2 (a) Survival rate of Chinese hamster ovary cells (CHO-10B cell) (b)
Survival rate of human melanoma cells (HTB-66) heated over time.
Measurements were made invitro. (Reprinted from [33], Copyright
1991, with permission from Elsevier) . . . . . . . . . . . . . . . . . 12

2.3 Arrhenius plots for a number of human and rodent cell lines. (Reprinted
from [33], Copyright 1991, with permission from Elsevier) . . . . . . 13

2.4 Schematic view of any hyperthermia system. . . . . . . . . . . . . . 14

2.5 Scheme of a local hyperthermia system. (Reprinted from the Lancet, [36],
Copyright 2002, with permission from Elsevier) . . . . . . . . . . . 15

2.6 A 2x3 Lucite Cone Applicator (LCA) array and Water Bolus (WB).
(Reprinted from [40], www.tandfonline.com) . . . . . . . . . . . . . . 16

2.7 Block diagram of deep hyperthermia [37]. . . . . . . . . . . . . . . 18

2.8 HYPERcollar system. (Taken after [50]; copyright EurAAP; used
with permission) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19

2.9 HYPERcollar3D system. (Taken after [50]; copyright EurAAP; used
with permission) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19

2.10 Graphical user interface of the Visualisation Tool for Electromag-
etic Dosimetry and Optimisation (VEDO). (Reprinted from [51],
www.tandfonline.com.) . . . . . . . . . . . . . . . . . . . . . . . . . 24

3.1 Mean and standard deviation values of the fitness solutions obtained
by four Particle Swarm Optimisation (PSO) and Differential Evolu-
tion (DE) configurations using 50 run samples for six patient records.
PSO is in red, and DE in blue. . . . . . . . . . . . . . . . . . . . . . . 57

3.2 Cubic filtered Specific Absorption Rate (SAR) distributions in a
transversal cut through the target location (z = 58 mm), using the
optimised antenna and phase settings resulting from PSOCS best (a)
and worst optimisation (b) in patient P2 . . . . . . . . . . . . . . . . 63
3.3 Cubic filtered SAR distributions in a transversal cut through the target location (z = 58 mm), using the optimised antenna and phase settings resulting from DE_CS best (a) and worst optimisation (b) in patient P2. 64

3.4 Cubic filtered SAR distributions in a transversal cut through the target location (z = 20 mm), using the optimised antenna and phase settings resulting from PSO_CS best (a) and worst optimisation (b) in patient P4-T1. 65

3.5 Cubic filtered SAR distributions in a transversal cut through the target location (z = 20 mm), using the optimised antenna and phase settings resulting from DE_CS best (a) and worst optimisation (b) in patient P4-T1. 66

3.6 Cubic filtered SAR distributions in a transversal cut through the target location (z = 20 mm), using the optimised antenna and phase settings resulting from PSO_CS best (a) and worst optimisation (b) in patient P4-T2. 67

3.7 Cubic filtered SAR distributions in a transversal cut through the target location (z = 20 mm), using the optimised antenna and phase settings resulting from DE_CS best (a) and worst optimisation (b) in patient P4-T2. 68

3.8 Cumulative Temperature-Volume (T-V) histograms representing the 3-D temperature distribution within the tumour and healthy tissue for patient 3 (a), 4-T1 (b), and 5 (c). Best (solid line) and worst cases (dash-dot line) for PSO_CS and DE_CS are illustrated. 71

4.1 Schematic workflow of the time-multiplexed steering procedure. Two antenna settings, Static Setting (StaticS) and Pareto Optimal Solution (PoptS), are applied sequentially in the time-multiplexed thermal simulation. 81

4.2 Simulated cubic filtered SAR and corresponding temperature values (after 20 minutes of simulation) for Hotspot-Target SAR Quotient (HTQ) optimised antenna settings. Linear fits and $R^2$ values are shown for Patient 1. 83

4.3 Simulated Cubic Filtered Specific Absorption Rate (cfSAR) and corresponding temperature values (after 20 minutes of simulation) for HTQ optimised antenna settings. Linear fits and $R^2$ values are shown for Patient 1. 84

4.4 Normalised cfSAR distributions for 1W input power in the transversal cut at $z = 35$ mm through the target location obtained by the StaticS (a) and PoptS antenna settings (b) for Patient 1. 86
4.5 Normalised cfSAR distributions for 1W input power in the transversal cut at $z = 31$ mm through the target location obtained by the StaticS (a) and PoptS antenna settings (b) for Patient 2. 87

4.6 Normalised cfSAR distributions for 1W input power in the transversal cut at $z = 32$ mm obtained by the StaticS (a) and PoptS antenna settings (b) for Patient 3. 88

4.7 Normalised cfSAR distributions for 1W input power in the transversal cut at $z = 40$ mm through the target location obtained by the StaticS (a) and PoptS antenna settings (b) for Patient 4. 89

4.8 Normalised cfSAR distributions for 1W input power in the transversal cut at $z = 43$ mm through the target location obtained by the StaticS (a) and PoptS antenna settings (b) for Patient 5. 90

4.9 Point temperature (degrees Celsius) in the Clinical Target Volume (CTV) (a) and in Hotspot 1 (b) over the simulation period of 1200 s (axis is labelled in kiloseconds as produced by SEMCAD X). Static (magenta), Pareto optimal (yellow) and time-multiplexed thermal performance are compared varying the steering rate of five (red), twenty (green) and sixty (blue) seconds. 93

4.10 Cumulative Temperature-Volume (T-V) histograms representing the 3D temperature distribution within CTV (red), healthy tissue (blue), Hotspot 1 (violet), Hotspot 2 (green) for Patient 2 (a) and Patient 4 (b). The static (solid line) and the time-multiplexed (dash-dot line) thermal performances are compared. Hotspots 2 (green) arising in Patient 2 during time-multiplexed steering is also illustrated in (a). 95

4.11 Patient 1. Simulated 3D temperature distribution (range of 42-44.1 °C) on a coronal view obtained through the static (a), selected Pareto (b) and time-multiplexed (c) settings. Figures were produced by SEMCAD X software. CTV and Hotspot 1 are indicated in (a). Hotspot 1 suppression is evident in (b). Hotspot 1 reduction and the Hotspot 2 appearance are shown in (c) while a $T_{50}$ gain of 0.3 °C is achieved in the target region. 96

5.1 Linear temperature dependent perfusion scaling factors for fat, muscle and tumour [104]. 102

5.2 Patient 5. Three-dimensional (3D) temperature distribution on a transversal view obtained using StaticS settings with Constant Thermal Model (CTM) ($z=43$ mm) (a) and Thermal Dependent Perfusion Model (TDPM) ($z=44$ mm)(b). CTV and the location of maximum temperature achieved in the healthy tissue are in the oral cavity in both cases but with a difference of 1 mm in the $z$-location. 106
5.3  CTV (red) and Hotspot 1 (violet) cumulative Temperature-Volume (T-V) histograms for Patient 3. The static thermal performance using Constant Thermal Model (CTM) and Thermal Dependent Perfusion Model (TDPM) are shown in (a) and (b) respectively. . . . . . . . . . . 107

5.4  CTV (red), Hotspot 1 (violet) and Hotspot 2 (green) cumulative T-V histograms for Patient 3. The static (solid line) and the time-multiplexed (dash-dot line) thermal performances are compared using CTM (a) and TDPM (b). . . . . . . . . . . . . . . . . . . . 110
List of Tables

2.1 Results of randomised phase III trials on [Hyperthermia (HT)] for 
Head and Neck (H&N). RT: radiotherapy, CRT: chemo-radiotherapy, 
N: total number of included patient in the study, -HT: results without 
HT, +HT: results with HT, LC: local control, CR: complete response, 
PFS: progression free survival, OC: oral cavity, OP: oropharynx, 
HP: hypopharynx, NP: nasopharynx, QoL: quality of life. Results 
significant at the 5%-level are shown in bold. (After [61]) . . . . . . 22
2.2 Quality criteria from literature. (After [26]) . . . . . . . . . . . . . 27
2.3 Modified and new quality indicators for characterisation and SAR. 
(After [26]) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3.1 Pseudocode of the PSO algorithm. . . . . . . . . . . . . . . . . . . 49
3.2 DE Hyperthermia Parameters Relation. . . . . . . . . . . . . . . . . 50
3.3 Patient and treatment characteristics: Patient identification number, 
location and type of the tumour, treatment number . . . . . . . . . . 51
3.4 Optimisation technique parameters (common to PSO and DE). . . 52
3.5 Specific optimisation technique parameters of PSO and DE . . . . 52
3.6 Electromagnetic (EM) tissue properties at 434 MHz and thermal 
tissue properties for temperature simulations at 37 °C [112] and 
*thermal properties in [105]. . . . . . . . . . . . . . . . . . . . . . . 54
3.7 Best and maximum HTQ mean and standard deviation values over 
50 runs. Relative percent standard deviation improvements of DE 
over PSO are presented. . . . . . . . . . . . . . . . . . . . . . . . . 56
3.8 HTQ Maximum percentage errors for the PSOCS and DECS optimi-
sation strategies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3.9 Convergence rate for four PSO and DE individual and iteration 
configurations. Each result represents the number of iterations 
required for DE and PSO to reach PSO’s best solution . . . . . . . . . 59
3.10 Antenna amplitudes and phases of the best solution achieved by PSO 
and DE optimisations. . . . . . . . . . . . . . . . . . . . . . . . . . 60
3.11 TC25 Performance metric tested on six clinical records for the PSO 
and DE optimisation strategies. Percentage variation between best 
and worst cases are also given. . . . . . . . . . . . . . . . . . . . . . 61
3.12 *TC*$_{50}$ Performance metric tested on six clinical records for the PSO and DE optimisation strategies. Percentage variation between best and worst cases are also given. ............................... 61

3.13 $T_{\text{max}}$ and temperature indices $T_x$ that are exceeded by x percent of all temperature readings in the tumour target. $T_{\text{max}}$ and $T_x$ best and worst optimisation results arising from PSO$_{CS}$ and DE$_{CS}$ are given with their variation. ........................................ 70

4.1 HTQ performance metric for static and Pareto solutions and percentage variation tested on 5 patient models. ................................................... 85

4.2 *TC*$_{25}$ and *TC*$_{50}$ performance metrics for static and Pareto solutions and percentage variation tested on 5 patient models .......................... 85

4.3 Thermal quantifiers $T_x$ that are exceeded by x percent of all temperature readings in the CTV for a selection of worst cases treated with the HYPERcollar3D and $T_{\text{max}}$ in the hotspots. Temperature changes from StaticS (single SAR steering) to Time-Multiplexed Steering (TMS) (time-multiplexed steering) are given in bold. ............... 94

5.1 Euclidean distance between Hotspot 1-CTM (in constant thermal model distribution) and Hotspot 2-TDMP (in thermal dependent perfusion model) for five cases treated with the HYPERcollar3D. 105

5.2 Thermal quantifier $T_{50}$ that is exceeded by 50 percent of all temperature readings in the CTV and $T_{\text{max}}$ in the hotspot for five cases treated with the HYPERcollar3D. Temperature changes from StaticS (single SAR steering) to TMS (time-multiplexed steering) obtained by CTM (constant thermal model) and TDPM (thermal dependent perfusion model) are given in bold. ............................... 108
<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>$HTQ_{HS}$</td>
<td>Hotspot-Target SAR Quotient for a specific HotSpot.</td>
</tr>
<tr>
<td>2D</td>
<td>two-dimensional.</td>
</tr>
<tr>
<td>3D</td>
<td>three-dimensional.</td>
</tr>
<tr>
<td>cfSAR</td>
<td>Cubic Filtered Specific Absorption Rate.</td>
</tr>
<tr>
<td>CP</td>
<td>Crossover Probability.</td>
</tr>
<tr>
<td>CT</td>
<td>Computerised Tomography.</td>
</tr>
<tr>
<td>CTM</td>
<td>Constant Thermal Model.</td>
</tr>
<tr>
<td>CTV</td>
<td>Clinical Target Volume.</td>
</tr>
<tr>
<td>DE</td>
<td>Differential Evolution.</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid.</td>
</tr>
<tr>
<td>EM</td>
<td>Electromagnetic.</td>
</tr>
<tr>
<td>F</td>
<td>Factor.</td>
</tr>
<tr>
<td>FDTD</td>
<td>Finite Difference-Time Domain.</td>
</tr>
<tr>
<td>FIR</td>
<td>Finite Impulse Response.</td>
</tr>
<tr>
<td>GPU</td>
<td>Graphical Processing Unit.</td>
</tr>
<tr>
<td>H&amp;N</td>
<td>Head and Neck.</td>
</tr>
<tr>
<td>HSF-1</td>
<td>Heat Shock Factor.</td>
</tr>
<tr>
<td>HSPs</td>
<td>Heat Shock Proteins.</td>
</tr>
</tbody>
</table>
HT  Hyperthermia. 1, 6, 23, 26, 41, 48, 73

HTP  Hyperthermia Treatment Planning. 2, 4, 6, 21, 23, 24, 26, 43, 44, 48, 52

HTQ  Hotspot-Target SAR Quotient. 2, 6, 7, 25, 41, 47, 48, 52, 56, 61, 63, 73, 76, 79, 80, 83–85, 99, 106, 116

i-mf-OCPF  Independent Multi-Frequency OCPF. 40

LCA  Lucite Cone Applicator. 16

mf-OCPF  Multi-Frequency Optimal Constraint Power Focusing. 40

MOGA  Multi-Objective Genetic Algorithm. 4, 5, 75–80, 82–84, 91, 99, 100, 104, 113, 115, 116

MRI  Magnetic Resonance Imaging. 36

NSGA-II  Non-dominated Sorting Genetic Algorithm. 77, 78

OCPF  Optimal Constraint Power Focusing. 36, 39, 40

PDE  Partial Differential Equations. 35, 36

PoptS  Pareto Optimal Solution. 80, 81, 84, 92, 104, 105

PSO  Particle Swarm Optimisation. 3, 4, 6, 7, 48, 53, 55, 63, 70, 73, 75, 76, 79, 82, 99, 115, 116

RF  Radiofrequency. 6, 14, 20, 21, 41, 97

SAR  Specific Absorption Rate. 2, 7, 21, 23, 32, 37, 41, 43, 48, 55, 60, 63, 70, 73, 75, 76, 78, 80, 82, 85, 91, 94, 97, 99, 101, 102, 105, 106, 109, 114, 118

SF  Scaling Factor. 102, 103

StaticS  Static Setting. 79, 82, 86, 91, 104, 105, 109

T-V  Temperature-Volume. 70, 72, 92, 95, 105, 106, 108, 110, 111

TC  Target Coverage. 6, 48, 55, 60, 61, 73, 84

TDPM  Thermal Dependent Perfusion Model. 103, 113

TMS  Time-Multiplexed Steering. 3, 94, 109, 110, 112, 113, 116
Glossary

**UWB** Ultrawide Band. 37, 41

**VEDO** Visualisation Tool for Electromagnetic Dosimetry and Optimisation. 24, 25, 50, 60

**WB** Water Bolus. 14, 16
1

Introduction

1.1 Motivation

One of the most common cancer categories worldwide is Head and Neck (H&N) cancer [1]. The global incidence of H&N cancers has been estimated to be between 400,000 and 600,000 new cases each year, resulting in a mortality rate of between 223,000 and 300,000 deaths per year [2], [3]. Worldwide, the number of patients dying of H&N cancer is increasing each year. In Ireland, more than 500 new cases of cancers in the H&N regions are diagnosed annually, and surviving patients suffer significant side effects from conventional therapies. A demanding challenge is to preserve the organ function in locally advanced H&N tumours [4]. Moreover, high levels of toxicity have been observed in patients treated with conventional therapies such as radiotherapy and chemotherapy [4], [5]. In order to address this problem, other procedures have been investigated. Hyperthermia (HT) has been demonstrated to be a potent tumour cell sensitizer for radio- and chemotherapy [6], [7]. Clinical trials showed to improve treatment outcomes when Hyperthermia (HT) is used as an adjunct therapy [8], [9] and significant results have been reported for many types of cancers [10]–[14]. Over the last decades, several clinical radiofrequency hyperthermia systems have been developed to heat tumours [15]. Within the hyperthermia community, systems based on radiative transfer of Electromagnetic (EM) energy to
the patient are generally the most widely used [16]. Such systems typically consist of a conformal multi-element antenna array that focuses EM energy at the tumour location by constructive interference [17]–[19]. However, healthy tissue is also heated during hyperthermia, inducing the occurrence of over-heated areas, known as hotspots, which can hamper treatment quality and increase patient discomfort.

To control the EM energy deposition and the resulting temperature distribution in the tissue, a Hyperthermia Treatment Planning (HTP) stage is applied before the first treatment session. Predicted Specific Absorption Rate (SAR) calculated using appropriate amplitude and phase settings for individual antennas is used for simulation of the temperature distribution in the tissue. An important requirement in HTP and in hyperthermia systems using constructive interference to heat at depth is to heat the target regions without impairing the surrounding healthy tissue. Hence, in addition to maximising tumour heating, minimisation of hotspots in healthy tissue is also one of the major challenges in HTP. Different focusing strategies have been studied to optimise the Specific Absorption Rate (SAR) and the temperature distribution in hyperthermia systems, in terms of optimisation algorithms [20]–[25] and objective functions [26]–[28]. Most strategies employed in HTP result in fixed antenna settings that are applied throughout the treatment session. The quality of treatment depends on the balance between SAR in the target volume and SAR in the healthy tissue. Hence, during HTP the SAR distribution is optimised to maximise SAR in the tumour and minimise the energy in the hotspots.

The study in [26] found that the Hotspot-Target SAR Quotient (HTQ) was the most suitable objective function for SAR optimisation procedures and correlated best with the temperature with respect to other SAR indicators. HTQ is the ratio between the mean SAR in the 1% of healthy tissue volume with the highest SAR values, and the mean SAR in the target. However, the clinical exploitation of hyperthermia is still hampered by technical limitations. Furthermore, patients can still experience discomfort in practical application of hyperthermia. Despite HTP progress in recent years, the need for better control of EM power to minimise unwanted hotspots, as well as accurate predictions for HTP remain demanding
1. Introduction

aspects in practical clinical application. Given this need, the main purpose of this thesis is to investigate effective objective functions and optimisation algorithms that can improve the quality of hyperthermia treatment in clinical context.

The overall objective is attained with the investigation of evolutionary optimisation algorithms. Firstly, the Differential Evolution (DE) optimisation algorithm is investigated as part of H&N hyperthermia treatment planning. Its performance is evaluated with different optimisation parameters and compared to a Particle Swarm Optimisation (PSO) algorithm, clinically employed by the Erasmus MC hyperthermia group. Although results show that both algorithms are capable of finding the optimal power deposition, the proposed DE algorithm provides consistent improvements in terms of objective function and SAR indicators.

Then, a Time-Multiplexed Steering (TMS) approach is developed for H&N hyperthermia treatment to effectively suppress hotspots in healthy tissue. The proposed method involves the use of a multi-objective genetic algorithm to find multiple antenna settings which are then combined dynamically in a sequence in thermal simulations. The antenna settings are optimised based on a novel objective function, specifically formulated to suppress a pre-defined hotspot in the healthy region. It is shown that this novel method further intensifies the heating to the tumour region while reducing the hotspot prominence.

Finally, the robustness of time-multiplexed hyperthermia is demonstrated against thermal tissue properties variation. The performance of the algorithms proposed in this thesis is evaluated using real clinical data obtained from patients treated with HYPERcollar and HYPERcollar3D systems, designed and developed at Erasmus Medical Centre (Erasmus MC) Cancer Institute, Rotterdam, the Netherlands, who were collaborators on this project.

1.2 Thesis Contributions

1.2.1 Contributions

This thesis involves the development of techniques for targeting H&N cancer with microwave hyperthermia and the use of those methodologies to improve the quality
1. Introduction

of hyperthermia treatment planning. The principal contributions in the field of hyperthermia treatment are:

1. An algorithm for HTP based on the differential evolution is proposed. The algorithm is compared to the PSO method clinically employed at the Erasmus MC for the treatment of pelvic and H&N cancers in multiple scenarios on a group of patient treated with HYPERcollar system. The efficacy of the proposed technique is evaluated across a range of SAR and thermal performance metrics.

2. A Multi-Objective Genetic Algorithm (MOGA) is proposed for hotspot suppression. A novel objective function is formulated to focus the EM energy in the target and suppress a pre-defined hotspot. The optimisation method and the novel objective function are applied on a dataset of patients treated by HYPERcollra3D and their performance is assessed using PSO as benchmark algorithm and several SAR metric.

3. A time-multiplexed steering approach is developed for H&N cancer HTP. A detailed procedure is described to implement time-multiplexed hyperthermia which mainly consists of two steps; SAR optimisation by Multi-Objective Genetic Algorithm (MOGA) and thermal simulation. A constant thermal model is used to perform thermal simulations. The proposed method is applied on a number of patients treated by HYPERcollar3D system and the improvement is demonstrated by comparing with the static thermal performance obtained by using the optimal antenna settings generated by PSO.

4. The correlation between EM energy and temperature values is investigated to measure how well the highest simulated SAR values approximate the highest simulated temperatures. The results are analysed to support hotspot identification and selection for the implementation of time-multiplexed steering.
5. The robustness of the time-multiplexed hyperthermia is evaluated against temperature dependent thermal tissue properties. The temperature dependent thermal tissue model is outlined and the performance of the novel method under thermal tissue properties variation is evaluated using thermal quantifiers.

1.2.2 Publications

The publications resulting from this research are as follows:

**Journal Publications**


**Conference Publications**


1.3 Thesis Outline

The reminder of this thesis is organised as follows:

Chapter 2 describes the anatomy of the different regions where H&N cancer originate. Microwave hyperthermia treatment is described and the biological and technical aspects are discussed, together with the clinical experiences. Hyperthermia treatment planning is also outlined. The chapter provides background on current objective functions and optimisation techniques used to find the best antenna settings for hyperthermia treatment. The performance metrics used throughout this research are also introduced.

Chapter 3 proposes a differential evolution algorithm to improve H&N HTP by more effectively optimising the amplitudes and phases of Radiofrequency (RF) signals applied to the antennas. DE aims to optimise the specific SAR distribution, to avoid undesirable hotspots and better focus the heating on the target volume, while protecting healthy tissue. Data for six patients treated by the HYPERcollar applicator, developed at the Erasmus MC, have been used in order to compare the proposed DE algorithm to the PSO technique that is currently in use in clinical practice. The two techniques are evaluated with different optimisation settings, using clinically-relevant metrics including the HTQ, Target Coverage (TC) and HT temperature parameters. Results demonstrate that the proposed algorithm provides an improvement over the current clinically-used PSO at the hyperthermia unit of Erasmus MC, by more frequently and consistently locating the global optimum for all studied patients.

The purpose of Chapter 4 is to investigate the potential of time-multiplexed hyperthermia, i.e. application of multiple SAR patterns in a time-multiplexed way to improve the temperature pattern. A multi-objective genetic algorithm is used to find the time-multiplexed antenna settings, aimed at diversity between the SAR distributions. Two antenna settings derived by MOGA are applied sequentially within the time-multiplexed thermal simulations to evaluate the performance of the proposed method. The time-multiplexed patterns are compared to a single optimal
static pattern found by minimising $\text{HTQ}$ using the $\text{PSO}$ algorithm. Firstly, the $\text{SAR}$ assessment is carried out, followed by thermal evaluation.

Chapter 5 establishes the robustness of time-multiplexed hyperthermia to thermal tissue properties variation. Time-multiplexed performance using constant thermal model parameters and thermal-dependent perfusion model are compared for five patients. The results show that varying the blood perfusion value for fat, muscle and tumour tissue has no significant impact on focusing the tumour heating and suppressing the hotspot when time-multiplexed steering is applied; furthermore an increase in temperature is observed in the target region when the static solution is obtained with the temperature dependent perfusion model.

The final chapter summaries the main contributions presented throughout this thesis and conclusions are discussed. Some suggestions for future work are also provided.
2

Background and Literature Review

2.1 Introduction

In this chapter an overview of different aspects of H&N cancer is given. The biological aspects of microwave hyperthermia are discussed together with the technology required to apply different types of hyperthermia. A description of clinical experiences follows. The procedure of the hyperthermia treatment planning at the Erasmus MC is described and relevant optimisation strategies and objective functions present in literature are reviewed. Finally, the metrics used to evaluate the performance of the optimisation algorithms and, more generally, to quantify the quality of hyperthermia treatment are outlined.

2.2 Head and Neck Cancer

Head and neck cancers originate in different regions and by definition exclude tumours that occurs in the eyes, in the brain and in the skin. H&N cancers generally begin in the squamous cells that delineate the mucosal surfaces inside the head and neck. These squamous cell cancers are usually named squamous cell carcinomas of the head and neck. Often H&N cancer occurs in the oral cavity and the larynx, while cancers in the salivary glands are relatively uncommon. H&N cancers are categorized as illustrated in Figure 2.1.
Figure 2.1: Head and neck cancer regions. Image from www.cancer.gov. (For the National Cancer Institute © 2012 Terese Winslow LLC, U.S. Govt. has certain rights)

1. Oral cavity: comprises the front two-thirds of the tongue, the lining inside the cheeks and lips, the gums, the lips, the bottom of the mouth under the tongue, the area of the gum behind the wisdom teeth and the hard palate;

2. Pharynx: the pharynx is a tube that starts behind the nose and leads to the esophagus. It includes nasopharynx, the upper part of the pharynx, behind the nose; the hypopharynx, the lower part of the pharynx, and the oropharynx, the middle part of the pharynx that includes the soft palate, the base of the tongue, and the tonsils;

3. Paranasal sinuses and nasal cavity: the paranasal sinuses are small hollow spaces in the bones of the head which surrounds the nose. The nasal cavity is the hollow space inside the nose.

4. Larynx: short hallway formed by cartilage below the pharynx in the neck. It contains the vocal cords and the epiglottis which is used to prevent food from getting into the air passages.

5. Salivary glands: located near the jawbone and the floor of the mouth.

In the H&N region, treatment of advanced tumours and the control of tumours in localised areas, i.e. loco-regional control, are complex aspects [4], [29]. When treated
with conventional therapies, surviving patients suffer significant side effects, such as impaired speech, hearing loss, difficulty in chewing, swallowing and breathing. Chemotherapy and radiotherapy are associated with high levels of toxicity and often fail for locally advanced or recurrent tumors. Recent research has focused on alternative or adjunct therapies, where the burden of treatment is less severe on patients. Hyperthermia has demonstrated a substantial benefit when administered in combination with radio- and chemotherapy, improving the control of the tumor locally without increasing toxicity [1].

2.3 Hyperthermia

2.3.1 Definition

Hyperthermia is a therapeutic treatment that involves increasing the temperature of the body or a specific region of it to supraphysiologic levels between 40 °C and 44 °C. It is administered as a multimodal oncological strategy; clinical studies have demonstrated hyperthermia to be a powerful therapy for the treatment of the cancer when implemented in combination with radio- and chemotherapy [1]. Hyperthermia increases the concentration of oxygen in the tumor region enhancing the effectiveness of radiotherapy, and increases the blood flow leading to an increase in perfusion which improves the drug absorption in cells for chemotherapy.

2.3.2 Thermal Biology of Hyperthermia

While much research has been conducted, and hyperthermia has successfully been used in clinical application, the biological rationale for the use of hyperthermia is not completely established. According to Kampinga et al. [30], the principal target of hyperthermia is proteins, but little knowledge is available about the mechanisms of cell killing. Heat-induced protein denaturation occurs randomly throughout the cell. It damages the Deoxyribonucleic acid (DNA) repair systems and leads to alterations in molecular structures and changes in enzyme complexes for DNA synthesis; nuclear proteins seem to be most sensitive and aggregation occurs in the nuclear environment, with a high heat sensitivity observed in various nuclear processes.
The amount of cell death after heat shock is dependent on cell type and heat dose. Some cells may die quickly due to apoptosis if the initiation and execution phases are not inactivated by high heat dose. If the heat damage is too significant, apoptosis defective cells will not proliferate, and they may lose their proliferative capacity via permanent cell cycle arrest, by necrosis or secondary apoptosis after S-phase or mitotic failure [30].

Elevation of temperatures transiently stimulates the production of a family of proteins, called Heat Shock Proteins (HSPs) which are produced by cells under exposure to stressful conditions, such as heating. An autoregulatory loop is responsible for the heat shock response. HSP levels increase after heating and decrease after prolonged stress free periods. This regulation of HSPs is associated with a resistant phase of cells towards a subsequent second heat shock. The resistance phase is called thermotolerance. The higher the initial temperature, the larger the effect of thermotolerance induced in surviving cells. Thermotolerance decreases towards baseline thermosensitivity after a few days [30]. However, the inhibition of DNA repair can happen at temperatures of 40 °C which is a temperature where thermotolerance is not induced during or after heating [31]. This has been subject of discussion for combining hyperthermia with radiotherapy sessions.

Other biological effects occur over the temperature range used in clinical practice, such as changes in perfusion, re-oxygenation, induction of heat shock response and immunological simulation. During hyperthermia, the tissue metabolism increases the blood flow to counteract the temperature rise. When healthy tissue is heated, the blood vessels can enlarge to facilitate an increased blood flow which produces a temperature reduction. In contrast to healthy tissue, tumour tissues present a chaotic vascular structure with regions of low pH, hypoxia and lack of perfusion. In these circumstances, the capacity of tumour blood flow to increase upon heating is limited compared to the normal tissue blood flow; therefore, the heat dissipation is slower and the temperature of the tumour tends to rise higher than normal tissue during heating. The temperature in the healthy tissue does not increase as much and the perfusion and oxygenation enhancement in the tumour regions potentiate drug
Figure 2.2: (a) Survival rate of Chinese hamster ovary cells (CHO-10B cell) (b) Survival rate of human melanoma cells (HTB-66) heated over time. Measurements were made *invitro*. (Reprinted from [33], Copyright 1991, with permission from Elsevier)

and molecular uptake and radio-sensitivity [32]. As temperature increases further, the tumour cells die, or the tumour may reduce in size, facilitating surgical removal.

All these aspects can be considered to improve tumour response to radio- and chemotherapy, though the effect of hyperthermia on tumour environment related to the clinical temperature range, is still a matter of research. The rate of cell death during hyperthermia is dependent on the time and temperature of exposure. Experimental studies *in vitro* were described in [33], which used human and rodent cells propagated under the same growth conditions. The cells were contained in flask which were immersed into racks, in precision temperature-controlled water baths regulated to ± 0.05°C. Irradiation was performed with an x-ray machine operating at 300 kVp. The time-temperature relationship to the rate of cell death found in [33] is shown in Figure 2.2.

Three clear aspects of cell behavior under heating have been exploited for the thermal therapy. First of all, the rate of cell survival depends on the temperature exposure. Figure 2.2a shows a high rate of death of CHO-10B cells when heated at 42.5 °C compared to heating to 42 °C for 5 hours. Secondly, after a certain period of heating, each cell type develops a thermal resistance which is indicated
by the change of slope of the curves. For example, the HTB-66 cell shows the reduction in the slope after 3 hours of heating at 42.5 °C and 43 °C, while the CHO-10B shows thermal resistance at 42.5 °C after 4 hours of heating. Ultimately, the thermo-sensitivity varies between cell type. The CHO-10B cell exhibits a lower surviving fraction (0.001) for 5 hours of heating at 42.5 °C compared to the HTB-66 cell (0.03). Hence, CHO-10B cell is more sensitive to heat than HTB-66.

A typical break temperature of 43 °C has been chosen for several cell types [34]; this is the temperature at which thermal damage, i.e cell death due to heat, starts to occur. HSPs and apoptosis may occur before the temperature of 43°C. The thermal enhancement of the treatment depends on the temperature rise in the tumour and the duration of the heating, and treatment may have a duration up to 90 minutes depending on patient tolerance. The break temperature is cell dependent and is estimated by plotting the rate of cell killing against 1/temperature (K). The rate of cell death is defined as 1/Do, where Do is the period required to reduce survival by 63%. The Arrhenius plots used to calculate the break temperature related to rodent and human cells are illustrated in Figure 2.3. The break temperature occurs at the change in the slope of the Arrhenius plot.

**Figure 2.3:** Arrhenius plots for a number of human and rodent cell lines. (Reprinted from [33], Copyright 1991, with permission from Elsevier)
2.4 Hyperthermia Treatments and Systems

Depending on the target volume, hyperthermia can be classified as local, regional or whole-body hyperthermia [35]. Heating can be delivered using EM energy, mostly in the RF or microwave range. EM applicators can be categorized into two types: interstitial and external. Interstitial heating requires the insertion of tiny antennas into the tumour. During external heating the tumour can be heated by a conformal multi-element antenna phase array or applicators, emitting microwaves or radiowaves, to transfer the EM energy into the tissue. A Water Bolus (WB) is used to fill the space between the applicator and the patient to ensure good EM coupling and to limit hotspots at the skin. A 3D temperature distribution can be obtained by a temperature measurement system. The entire system usually has a computer-controlled feedback loop in combination with a graphical user interface for operator control. The general configuration of a microwave hyperthermia system is given in Figure 2.4.

2.4.1 Local Hyperthermia

Superficial tumours, such as lymph-node metastases of H&N tumours, chest wall recurrence, breast cancer or cutaneous metastases can be heated by waveguide
antennas or horn, spiral, compact applicators \[36\]. The applicators have a typical frequency of 150-430 MHz with therapeutic depths not more than 3 cm \[36\]. Figure 2.5 shows the components of such a hyperthermia system. The water bolus ensures the EM coupling of the applicator to the tissue. For the treatment of deep seated tumours, multisensory probes are placed interstitially into the tumour by inserting catheters. In the case of superficial tumours, the probes are placed on the surface of the tumour region under the water bolus. The temperature can be controlled by positioning the applicator or by controlling the output of the power generator.

The type of the applicator determines how the energy is distributed in the treated area. One of the most widely-used applicators is the waveguide applicator which is made from a section of waveguide transmission line, open at one end. A short extension of loop antenna or coaxial feed line provides the excitation. These types of applicator are usually filled with distilled water \[37\]. The horn applicators produce a more uniform temperature field than classical waveguides and utilise a flared opening to spread the radiated field. Another type of applicator is the microstrip antenna applicator, consisting of a resonant metallic arrangement on a continuous metallic
2. Background and Literature Review

Figure 2.6: A 2x3 Lucite Cone Applicator (LCA) array and Water Bolus (WB). (Reprinted from [40], www.tandfonline.com)

The area of the heating patterns in local hyperthermia treatments can be shaped and enlarged by adding the antenna elements of the specific applicator.

An example of waveguide applicator is the Lucite Cone Applicator (LCA) illustrated in Figure 2.6. The LCA has been designed and clinically used at Erasmus MC to treat breast carcinoma, melanoma, mesothelioma, and lymph node metastasis of H&N squamous cell carcinoma by superficial hyperthermia, using a 433 MHz signal. The LCA antennas are fed by power amplifiers with non-coherent sources [38], [39]. The antenna array configuration is determined by the size of the hyperthermia volume (depth of up 4 cm) and the shape of the anatomy, which encompasses the re-irradiation field. Several water bolus, to couple the electromagnetic waves into the patient and to cool the skin, are available according to the different LCA array configurations.

2.4.2 Interstitial and Intracavitary Hyperthermia

Rectal, prostate, vaginal, cervical or oesophageal cancers can be treated by intracavitary hyperthermia, while prostate, breast cancer, some head and neck tumours can be treated by interstitial hyperthermia. For interstitial treatments, the antennas are placed within the tumour; for intracavitary hyperthermia the antennas are inserted in natural openings such as rectum or, urethra in proximity to the tumour. These
types of treatments are applicable for tumours less than 3 cm in diameter and the
treatment is done in combination with brachytherapy. Interstitial techniques are also
used for another cancer therapy, thermoablation, which involves invasive applicators
and radiofrequency. During thermoablation, the temperature in the tumour is raised
over 50 °C, causing cellular coagulation and tissue necrosis. Small focal tumour
located within liver, kidney, lung or bones can be treated by thermal ablation [41].

2.4.3 Regional Hyperthermia

Regional hyperthermia can be applied to large parts of the body such as the
limbs, the abdominal cavity, liver, stomach, bladder, prostate, or ovaries. Arrays
of antennas can be used to treat deep-seated tumours. The goal is to focus the
heating to the tumour while keeping the energy deposition in the surrounding
healthy tissue under control. Multi-antenna phased array systems are normally
used in such systems [17], [18], [42]–[45]. The principle of the phased array is
to generate a desired electric field distribution by combining the fields of all the
individual antennas. For this reason, these systems are designed in such a way
that the antennas produce collinear polarizations and the total electric field can be
calculated as the sum of the \( \text{EM} \) signals generated by each antenna. Focusing into
the target area can be obtained by constructive interference of the \( \text{EM} \) fields that
are radiated by the system. The \( \text{EM} \) wave interference can be controlled by selecting
the appropriate antenna amplitude and phase settings of each RF-signal [46]. The
block scheme of a regional hyperthermia system is represented in Figure 2.7.

The typical frequency used with regional hyperthermia ranges from 70 to 200
MHz for pelvic region [17], [42]–[44], and 434 MHz for H&N region [18], [45].
Examples of regional hyperthermia systems are the BSD 2000 systems (Pyrexar
Medical, Salt Lake City, USA)\(^1\) and the HYPERcollar systems shown in Figure 2.8
and 2.9. The BSD 2000 system is used at Erasmus MC for the treatment of cancer
in the pelvic regions. There are two kinds of applicators: BSD Sigma 60 applicator,
a cylinder-shaped applicator consisting of a ring of 8 dipole antennas that are

\(^1\)http://pyrexar.com/hyperthermia/bsd-2000
coupled in 4 channels of two antennas each, with an operating frequency of 77 MHz; and BSD Sigma Eye, an elliptical-shaped applicator with 24 dipole elements and 12 channels, which works at 100 MHz.

Over the last decade, two phased array applicators have been developed at the Erasmus MC for the treatment of H&N cancer. The first generation of H&N applicator is the HYPERcollar system (Figure 2.8), developed to treat regions such as thyroid, oropharynx and nasal cavity [18], [45], [47], [48]. The applicator consists of a ring-shaped phased array of twelve patch antennas, equally divided over two rings, operating at a frequency of 434 MHz. The water bolus is used to fill the space between the ring and the patient with water, whose shape is influenced by positioning and gravity. Recently a re-designed version of the HYPERcollar system, HYPERcollar3D [45], [49] (Figure 2.9), has been developed and introduced in current clinical practice, with improved antenna arrangement, twenty patch antennas over three rings, and a better configuration of the water bolus, i.e. flat margins corresponding to the antenna ring boundaries, rather than a water bolus bulging out at the antenna ring boundaries.
2.4.4 Whole-body Hyperthermia

Carcinomas with distant metastases, i.e. cancer that has expanded from the primary tumour to distant lymph nodes or organs, can be treated by whole-body hyperthermia. Example of cancer suitable for this type of treatment are soft tissue sarcomas, melanomas or leukaemia. Various methods such as extracorporeal induction, electromagnetic induction and thermal conduction can be used to induce whole-body heating. Two systems are clinically used by employing microwave and infrared radiation with a heating time equal to 60-90 minutes [36].
2.4.5 Clinical Treatment Procedure

By way of example, this section outlines the typical procedure used in a clinical setting in Erasmus MC to treat different types of cancer. The number of hyperthermia treatment sessions depends on the patient’s clinical conditions. At Erasmus MC, superficial breast hyperthermia to treat areas close to the surface is typically applied for 60 minutes, once a week, for a period of several weeks. There is an initial heat-up phase, during which the power level applied is gradually increased in order to heat the target volume up to the therapeutic temperature of 44°C, or until the patient indicates discomfort. The power steering actions are based on the interpretation of measured temperatures and patient feedback by the clinician.

The duration of H&N hyperthermia treatment is usually 90 minutes per session and the number of hyperthermia sessions varies depending on the specifics of the patients. The treatment procedure consists of different phases. The patient is positioned on a bed and the tumour is placed centrally within the applicator, adjusting the height of head and shoulders according to the positions fixed during the treatment planning phase. The water bolus is filled with demineralized water at a temperature of 20-30°C. Firstly, a power level of 200 W is applied, using the optimised phase and amplitudes settings from the HTP phase and is subsequently increased in steps of 30 W every 30 seconds [51]. The patient is asked to indicate if they feel any discomfort. If the patient feels burning sensations or pressure, the power is reduced. In this case, a SAR based re-optimisation is applied setting new phase and amplitude and aiming to reduce power limiting hotspots. After 15 minutes of treatment, defined as the start of the plateau phase, RF power increase is in steps of 15 W [51].

2.5 Clinical Trials of Hyperthermia

Clinical trials have demonstrated the benefits of using hyperthermia combined with chemotherapy and/or radiotherapy in the treatment of solid tumours, such as breast [14], carcinoma of the head and neck [12, 52], pelvic tumours [13], brain [53].
2. Background and Literature Review

and superficial tumours [54], [55]. Head and neck cancers are treated with surgery, radiotherapy, chemotherapy or a combination of these.

The three meta-analyses study conducted by Pignon et al. [29] showed that the combination of chemotherapy and radiotherapy results in an 8% increase of the overall 2-years survival rate and a more recent study [56], involving 87 trials, demonstrated a 4.5% benefit at 5 years. However, improvement is needed since 80% of patients experience severe toxicity associated with conventional therapies.

Four prospective randomised phase III trials prove the effectiveness of hyperthermia in H&N cancers. Table 2.1 summarises the results for these studies. In the study carried out by Valdagni et al. [12], [52] metastatic lymph nodes from H&N were randomised to receive radiotherapy or radiotherapy combined with hyperthermia and improvement in the complete response (i.e. complete regression or no evidence of tumour) rate of 45.5% was observed with the combined treatment versus radiotherapy alone.

The randomised study of [57] included sixty-five patients to test the efficacy of local hyperthermia together with radiotherapy and showed improvement in terms of better control after combined treatment in patients with advanced disease.

In [58] fifty six patients with cancers of the hypopharynx, oral cavity and oropharynx showed a complete response of 42.4% with radiotherapy alone compared to 78.6% in the hyperthermia group.

The study of [59] included 180 patients with nasopharyngeal cancer randomised to receive chemoradiotherapy with or without hyperthermia. The study showed significant improvement in complete response when applying chemoradiotherapy together with hyperthermia; also, five years local control and progression free survival were significant but overall survival was not significant.

The study by Zhao et al. [60] showed improvements in terms of survival rate and quality of life domains (swallowing, speech, dry mouth, social eating) for 83 patients with nasopharyngeal cancer when receiving chemoradiotherapy with hyperthermia. These clinical trials provide evidence that hyperthermia improves the effect of chemo- and radiotherapy in head and neck cancer treatments.
Table 2.1: Results of randomised phase III trials on Hyperthermia (HT) for H&N. RT: radiotherapy, CRT: chemo-radiotherapy, N: total number of included patient in the study, -HT: results without HT, +HT: results with HT, LC: local control, CR: complete response, PFS: progression free survival, OC: oral cavity, OP: oropharynx, HP: hypopharynx, NP: nasopharynx, QoL: quality of life. Results significant at the 5%-level are shown in bold. (After [61]).

<table>
<thead>
<tr>
<th>Reference</th>
<th>Tumour</th>
<th>Combi</th>
<th>N</th>
<th>Endpoint(s)</th>
<th>-HT</th>
<th>+HT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valdagni et al. 1988 &amp; 1994</td>
<td>Neck Nodes</td>
<td>RT</td>
<td>44</td>
<td>CR</td>
<td>41%</td>
<td>83%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5 years LC</td>
<td>24%</td>
<td>69%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5 years OS</td>
<td>0%</td>
<td>50%</td>
</tr>
<tr>
<td>Datta et al. 1990</td>
<td>OC, OP</td>
<td>RT</td>
<td>65</td>
<td>CR</td>
<td>31%</td>
<td>55%</td>
</tr>
<tr>
<td>Huilgol et al. 2010</td>
<td>OC, OP, HP</td>
<td>RT</td>
<td>54</td>
<td>CR</td>
<td>42%</td>
<td>79%</td>
</tr>
<tr>
<td>Hua et al. 2011</td>
<td>NP</td>
<td>CRT</td>
<td>180</td>
<td>5 years LC</td>
<td>79%</td>
<td>91%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5 years PFS</td>
<td>63%</td>
<td>73%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5 years OS</td>
<td>70%</td>
<td>78%</td>
</tr>
<tr>
<td>Zhao et al. 2014</td>
<td>NP</td>
<td>CRT</td>
<td>83</td>
<td>3 years OS (QoL)</td>
<td>54%</td>
<td>73%</td>
</tr>
</tbody>
</table>

2.6 Hyperthermia Treatment Planning

A hyperthermia treatment planning procedure is run for each patient before HT treatment. Appropriate amplitude and phase settings for individual antennas are used to calculate SAR and simulate the temperature distribution. The resulting temperature distribution in the tissue is monitored during HTP and modified as needed. Hence, the major benefit of HTP is to assess the SAR distribution and the temperature prior to the treatment and to guide optimisation during the treatment itself. Different focusing strategies have been studied to optimise the SAR and the temperature distribution in hyperthermia systems, and several optimisation algorithms and objective functions will be discussed in this sections. The general procedure for HTP can be divided into four steps [62]:

1. Generation of the patient model;
2. Modelling of treatment set up;
3. Calculation of the power deposition in the tissue;
4. Calculation of the temperature distribution.

The HTP procedure at Erasmus MC can be described as follows. The HTP process starts by acquiring radiotherapy-planning Computerised Tomography (CT) scan, with the patient in the same position as planned for the hyperthermia treatment. The 3D patient specific model is created using an automatic segmentation routine followed by small manual correction using the iSeg software tool (Zurich Medtech, Zurich, Switzerland). The 3D patient model is afterwards combined with the applicator model in SEMCAD X (version 14.8.6 SPEAG, Zurich, Switzerland), which is an electromagnetic computation software package based on the Finite Difference-Time Domain (FDTD) method. Following this process, a 1-V sinusoidal signal with frequency 434 MHz with zero phase delay between all antennas is applied to each antenna in turn, and the resulting EM field distribution and CT scan are imported into the Visualisation Tool for Electromagnetic Dosimetry and Optimisation (VEDO) developed at Erasmus MC. The data stored in VEDO include EM field distributions generated from each individual antenna, density and electrical conductivity of each voxel, antenna locations, target regions and the patient’s tissue profile.

VEDO is based on the particle swarm optimisation algorithm, followed by a line search method, and is used to adjust the combination of amplitudes and phases of the individual antennas to achieve the optimal SAR distribution. The SAR \((W \cdot Kg^{-1})\) is expressed as:

\[
SAR = \frac{(\sigma_{eff}(r)) |E(r)|^2}{2\rho(r)} \quad (2.1)
\]

where \(\sigma_{eff} (S\cdot m^{-1})\) is the effective conductivity, \(\rho (Kg\cdot m^{-3})\) is the mass density, \(E (V \cdot m^{-1})\) the combined electric field, calculated as the sum of the fields generated by each antenna of the system, \(E_j (V \cdot m^{-1})\), where \(j\) is antenna index and \(r\) refers to the axis directions \((x, y, z)\) of the EM propagation. The total electric field \(E\) is expressed as:

\[
E (r, t) = \sum_{j=1}^{N} a_j e^{-i\theta_j} E_j (r, t) \quad (2.2)
\]
where antenna $j$ has amplitude $a_j$ and phase delay $\theta_j$, and $N$ is the number of antennas. The technique aims to optimise $a_j$ and $\theta_j$ of the EM field phasor applied to each antenna. The phasors are summed by equation 2.2 and the resultant SAR is calculated by equation 2.1. The objective (or fitness) function, the hotspot-target quotient $HTQ$, is the quotient of the hotspot SAR and the average tumour SAR:

$$HTQ = \frac{SAR_a(V1)}{SAR_a(target)}$$  \hspace{1cm} (2.3)

The hotspot $SAR$, referred to as $SAR_a(V1)$, is defined as the average SAR in the volume represented by $V1$, which is defined as the top 1% of healthy tissue volume with the highest SAR in the total patient model. $SAR_a(target)$ is defined as the mean SAR in the target itself [51], [64]. Therefore, the optimisation of the fitness function aims to maximise the EM energy in the target area, while reducing the hotspots in the healthy tissue.
2.6.1 Objective Functions in Hyperthermia

Several HT studies have been carried out to synthesize the pattern of power deposition and to achieve the desired SAR and temperature distributions in the target body. Several quality indicator metrics and objective functions have been used for HTP optimisation [26], [65]. This section provides an overview of the relevant studies.

Different objective functions for both power and temperature optimisation have been considered by Wust et al. [66]. Their study concerns the optimisation of deep (pelvic region) electromagnetic heating based on 3D patient-specific geometry, showing the possibilities to improve the treatment by increasing the number and orientation of the hyperthermia system antennas. Related works on EM heating of the pelvis have been conducted in [67] where a single objective function has been used to minimise hotspots in healthy tissue, focusing the EM energy on the tumour position.

A further study [27] examined a variety of objective functions using a generalised mathematical formulation. Temperature-based optimisation has been applied in [28] in combination with HTP to improve treatment outcome in patients with esophageal cancer.

Canters et al. [26] carried out a survey of several quality indicators for SAR followed by an evaluation based on heuristic criteria and proposed modifications of existing indicators or proposed new indicators. The correlation of the SAR indicators with the corresponding predicted temperature was evaluated and each SAR indicator was used as the target function for SAR optimisation. The quality of treatment depends on the balance between SAR in the target volume and SAR in the healthy tissue. Hence, during HTP the SAR distribution is optimised to maximise SAR in the tumour and minimise the energy in the hotspots. Many indicators have been proposed over the years and a set of criteria have been developed to allow evaluation to determine the most appropriate indicators. The criteria should enable comparison between sessions, patients, systems and institutes. The definition of the set of heuristics is described as follows:
1. Characterisation of SAR distributions: \(\text{SAR}_{\text{max}}\) independence. Inaccuracies in tissue segmentation can lead to SAR peaks that do not represent the real situation. To overcome this problem, volume-average SAR is preferred to \(\text{SAR}_{\text{max}}\) which may be affected by local details of the model.

2. Characterisation of SAR distributions: target-related criteria. Three criteria are associated with the target. The first one is the deposition of SAR in the target in absolute values (\(W/Kg\)), the second one is the quantification of SAR in the target in relation to the whole body average SAR and the third one is the homogeneity of the target, i.e. SAR or temperature homogeneity. The latter requires knowledge of perfusion in the target.

3. Characterisation of SAR distributions: hotspot-related criteria. Quantification of the absolute SAR level in hotspots, and relative to the target.

4. Optimisation criteria for SAR objective functions. Optimisation of a specific objective function which restricts hotspot SAR and maximises SAR in the target area.

To evaluate the suitability of the quality indicators, the correlation of the median temperature in the target, \(T_{50}\), with each indicator has been investigated. The higher the correlation is, the higher the temperature is in the target. To assess the predictive value of the quality indicators, electromagnetic and temperature distributions for 36 patient models with cervical cancer were calculated using 30 different amplitude and phase settings each when heated with the BSD 2000 Sigma 60 applicator [26]. Each indicator has been used as objective function for SAR optimisation. Table 2.2 reports the quality indicators found in [26] described as follows:

1. \(P_{\text{targ}}\): the power absorbed in the target [27].

2. \(P_{\text{ratio}}\): ratio between target power and total power absorbed in the patient [66]. [68], [69].
Table 2.2: Quality criteria from literature. (After [26])

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Formula</th>
<th>Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>$P_{\text{targ}}$</td>
<td>$W$</td>
</tr>
<tr>
<td>2</td>
<td>$P_{\text{ratio1}} = \frac{P_{\text{targ}}}{P_{\text{tot}}}$</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>$P_{\text{ratio2}} = \frac{P_{\text{targ}}}{\sum_{i=1}^{10} SAR_{\text{max},i}}$</td>
<td>$kg$</td>
</tr>
<tr>
<td>4</td>
<td>$P_{\text{ratio3}} = \frac{P_{\text{targ}}}{\left[\int_{V_{\text{targ}}} SAR^2 dV\right]^2}$</td>
<td>$kg \cdot m^{-1.5}$</td>
</tr>
<tr>
<td>5</td>
<td>$P_{\text{ratio4}} = \frac{P_{\text{targ}}}{\left[\int_{V_{\text{targ}}} \left(\frac{SAR}{wb}\right)^2 dV\right]^2}$</td>
<td>$kg \cdot m^{-4.5} \cdot s^{-1}$</td>
</tr>
<tr>
<td>6</td>
<td>$P_{\text{ratio5}} = \frac{P_{\text{targ}}}{\sum_{i=1}^{10} \left(\frac{SAR}{wb}\right)_{\text{max},i}}$</td>
<td>$m_3 \cdot s^{-1}$</td>
</tr>
<tr>
<td>7</td>
<td>$P_{\text{square-ratio}} = \frac{P_{\text{targ}}^2}{P_{\text{tot}}}$</td>
<td>$W$</td>
</tr>
<tr>
<td>8</td>
<td>$STH_{\text{ratio}} = \frac{SAR_{\text{targ}}^2}{SAR_{\text{hotspot}}}$</td>
<td>$W/kg$</td>
</tr>
<tr>
<td>9</td>
<td>$SAR_{\text{targ}}$</td>
<td>$W/kg$</td>
</tr>
<tr>
<td>10</td>
<td>$SAR_{\text{ratio}} = \frac{SAR_{\text{targ}}}{SAR_{\text{tot}}}$</td>
<td>-</td>
</tr>
<tr>
<td>11</td>
<td>$10gSAR_{\text{max}}$</td>
<td>$W/kg$</td>
</tr>
<tr>
<td>12</td>
<td>$10gSAR_{\text{max-ratio}} = \frac{10gSAR_{\text{targ}}}{SAR_{\text{tot}}}$</td>
<td>-</td>
</tr>
<tr>
<td>13</td>
<td>$x%SAR_{\text{max-coverage}} = \frac{V_{x%SAR_{\text{max}}}}{V_{\text{targ}}}$</td>
<td>-</td>
</tr>
<tr>
<td>14</td>
<td>$HC = \frac{V_{75%SAR_{\text{targ}}}}{V_{25%SAR_{\text{targ}}}}$</td>
<td>-</td>
</tr>
<tr>
<td>15</td>
<td>$SAR_{\text{10max}} = \sum_{i=1}^{10} SAR_{\text{max},i}$</td>
<td>$W/kg$</td>
</tr>
<tr>
<td>16</td>
<td>$SAR_{\text{hs-targetratio}} = \frac{SAR_{\text{region}}}{SAR_{\text{hotspot}}}$</td>
<td>-</td>
</tr>
</tbody>
</table>

3. $P_{\text{ratio2}}$: target power divided by the sum of the $\text{SARs}$ at the 10 $\text{SAR}$ peak locations [68].

4. $P_{\text{ratio3}}$: ratio of target power and to the volume integral over the squared $\text{SAR}$ perfusion quotient in healthy tissue, which minimises high $\text{SAR}$ peaks [68].

5. $P_{\text{ratio4}}$: target power divided by the volume integral over the squared $\text{SAR}$ in
2. Background and Literature Review

healthy tissue. **SAR** perfusion quotient is used to account for bias between **SAR** and temperature [68].

6. $P_{ratio}$: target power divided by the sum of the 10 maximum **SAR** perfusion quotients [68].

7. $P_{square-ratio}$: ratio of the squared target power and the total power in healthy tissue [69].

8. $STH_{ratio}$: squared volume averaged **SAR** in the target divided by **SAR** in the hotspot [69].

9. $SAR_{target}$: target volume averaged **SAR** used as objective function in [67]. In Sandrini et al. [70], this indicator is generally defined as the ratio of the power absorbed in a region and to the region volume.

10. $SAR_{ratio}$: averaged **SAR** in the target divided by the average **SAR** in the patient. Generally defined as the average **SAR** in a region divided by the average **SAR** in the patient [71].

11. 10g$SAR_{max}$: maximum average **SAR** over 1 or 10g of tissue, defined in IEEE-1529 [72].

12. 10g$SAR_{maxratio}$: ratio of maximum average **SAR** in 1 or 10g to average **SAR** in the patient, as described in Bernardi et al. [73].

13. $x\%SAR_{maxcoverage}$: part of the volume enclosed by $x\% SAR_{max}$. Used to evaluate the quality of the treatment [18], [74], [75].

14. $HC$: homogeneity coefficient defined by the volume enclosed by the 75% $SAR_{targmax}$ isoSAR divided by the volume enclosed by 25% $SAR_{targmax}$ [76].

15. $SAR_{10max}$: sum of the 10 highest **SAR** spots [69].

16. $SAR_{hs-targetratio}$: ratio of the **SAR** exceeded in 1% of a region’s volume and the median target **SAR** [76].
Canters et al. \cite{26} evaluated the indicators based on the heuristic criteria. They found that $SAR_{\text{targ}}$ (9) and $SAR_{\text{ratio}}$ (10) were the most appropriate indicators for target-related characterisation of SAR distributions, while modifications of $x\%SAR_{\text{max coverage}}$ (13) and $HC$ (14) were needed to remove dependency on the maximum SAR. For hotspot-related characterisation of SAR distributions, $SAR_{hs-target ratio}$ (16) was considered a good indicator that related SAR in the target to the hotspot SAR. The hotspot prediction from a SAR indicator is difficult because of several factors such as the perfusion, the thermodynamics of the surrounding healthy tissue and the exposed volume. However, if the energy is low, it will not cause overheating in well perfused healthy tissue. Most of the indicators were suitable for objective function optimisation; however some of them as $P_{\text{ratio2}}$ (3), $P_{\text{ratio5}}$ (6) and $STH_{\text{ratio}}$ (8) depend on $SAR_{\text{max}}$. An indicator that related SAR in the hotspot and SAR in the target was $SAR_{hs-target ratio}$ (16), which was also found to be independent of maximum SAR in the patient. The literature survey led to the conclusion that most indicators met the criteria for target characterisation, considering the disadvantage of $SAR_{\text{max}}$ dependency; some new indicators were also proposed for hotspot characterisation.

Table 2.3 reports the additional indicators and objective functions suggested by \cite{26}, numbered according to the criterion in Table 2.2 on which they are based.

13-m. $SAR_{5\text{tot coverage}}$: this indicator was introduced to remove the dependency on $SAR_{\text{max}}$ of $x\%SAR_{\text{max coverage}}$. The modified indicator is defined as the part of the target where the SAR exceeds $SAR_{5\text{tot}}$, which is the SAR exceeded in 5% of the total volume.

14-m. $HC_{\text{new}}$: a modified homogeneity coefficient that provides the same information as $HC$ defined above but is less sensitive to the maximum SAR in the target.

16-m. $SAR_{hs-target ratio new}$: this indicator is similar to $SAR_{hs-target ratio}$, the ratio between hotspot SAR and target SAR with the only difference of using averages instead of medians.
Table 2.3: Modified and new quality indicators for characterisation and SAR. (After [26])

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Formula</th>
<th>Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>13-m $SAR_{5\text{tot coverage}}$</td>
<td>$V_{\text{targ}}(SAR &gt; SAR_{5\text{tot}})/V_{\text{targ}}$</td>
<td>-</td>
</tr>
<tr>
<td>14-m $HC_{\text{new}}$</td>
<td>$SAR_{75\text{targ}}/SAR_{25\text{targ}}$</td>
<td>-</td>
</tr>
<tr>
<td>16-m $SAR_{hs-targrationew}$</td>
<td>$SAR_{1}\cdot V_{\text{targ}}$</td>
<td>-</td>
</tr>
<tr>
<td>17a $\rho_{hs} (\vec{x})$</td>
<td>$\frac{1}{4\pi \cdot 0.05^2} \cdot \int_{</td>
<td>\vec{y}-\vec{x}</td>
</tr>
<tr>
<td>17b $I_{hs} (\vec{x})$</td>
<td>$SAR_{hs} (\vec{x}) \cdot \rho_{hs} (\vec{x})$</td>
<td>W/kg</td>
</tr>
<tr>
<td>17c $I_{hs-region}$</td>
<td>$\sum_{\text{region}} I_{hs(n)} V(n)/V_{\text{region}}$</td>
<td>W/kg</td>
</tr>
<tr>
<td>17 $I_{hs-ratio-region}$</td>
<td>$I_{hs-region}/SAR_{\text{targ}}$</td>
<td>-</td>
</tr>
<tr>
<td>18 $SAR_{targ-compl-ratio}$</td>
<td>$SAR_{\text{targ}} - SAR_{\text{compl-region}}/SAR_{\text{tot}}$</td>
<td>-</td>
</tr>
</tbody>
</table>

17a. $\rho_{hs}$: hotspot density at a specific point in the patient volume is used to estimate the hotspot volume in a sphere of 5 cm radius around that point. It was introduced to identify multiple hotspot close together.

17b. $I_{hs}$: hotspot intensity, which is the product of the absolute SAR level and $\rho_{hs}$.

17c. $I_{hs-region}$: local average hotspot intensity.

17. $I_{hs-ratio-region}$: ratio between $I_{hs-region}$ and average $SAR$ in the patient.

18. $SAR_{targ-compl-ratio}$: objective function to optimise SAR. It is similar to $SAR_{ratio}$ but the target is represented by the complaint region.

The evaluation metric used for both characterisation and optimisation was the median temperature in the target, $T_{50\text{targ}}$. Caners et al. [26] found that $SAR_{targ}$ (9), $SAR_{ratio}$ (10), $SAR_{hs-targ-ratio}$ (16-m), and $HC_{\text{new}}$ (14-m) were useful indicators for target SAR analysis; while $SAR_{hs-targ-ratio}$ (16-m) was the most suitable indicator for hotspot analysis. The most suitable objective function for SAR optimisation was the hotspot-target SAR quotient (16-m) which is balanced minimising the hotspots in the healthy tissue with maximising SAR in the target.
This indicator correlated best with the temperature with respect to other SAR indicators; however, it has been noted in the literature that further investigations are needed to prove that it is the best optimisation coefficient to improve the temperature pattern. Nonetheless, it has proven to be a useful metric in clinical practice and therefore is used in this thesis as a baseline.

2.6.2 Overview of the Optimisation Techniques in Hyperthermia

Various optimisation techniques have been described in the literature to achieve optimal tumour heating by setting antenna amplitudes and phases. Among these, the eigenvector problem has been investigated by Bardati et al. [77] to optimise the SAR in a phased array radiofrequency system, selecting two types of targets, those to be heated and those to be protected from EM radiation. The eigenvector problem is characterised by a positive definite Hermitian matrix defined for the specific target. The solution was represented by the antenna amplitudes and phases, and the optimal solution was found as a tradeoff between the best antenna settings for individual targets. A gradient-search feedback algorithm was implemented by Fenn et al. [78] to control the channel amplitudes and phases of an adaptive phased array radiofrequency hyperthermia system. A homogeneous saline phantom target and a ring phased-array system of four controlled RF transmitters channels operating at a frequency of 100 MHz were used for the hyperthermia experiments. The amplitudes and phases of each transmitter channel were controlled by a gradient-search feedback algorithm which implemented the method of steepest ascent for adaptive focusing, hence for power maximisation and the method of steepest descent for adaptive nulling, for power minimisation. Invasive electric field probes were placed at one or more positions to provide necessary feedback information. The power delivered to the tumour by the transmitter was constrained to maintain constant total transmit amount, $P_T$, in such a way that:

$$\sum_{n=1}^{N} |\omega_n|^2 = P_T$$ (2.4)
where $\omega_n$ is the power transmitted for the $n^{th}$ adaptive channel. An iterative scheme was then used to maximise the electric field at the tumour site while minimising the electric field elsewhere. The gradient-search algorithm could control the transmit weights, amplitudes and phases. Hence, the hyperthermia phased-array antenna transmitted an RF signal that generates RF power that was measured in receive field probe antennas. For any antenna configuration, the amplitudes and phases were adjusted by a small negative or positive amount and the received powers at the electric-field probes were used to calculate the total received probe array power and update the transmit weight settings. Fenn et al. showed a potential improvement in hyperthermia thermal dose by adaptive techniques. However, the need for invasive measurements of the electric field inside the body makes this technique difficult to employ for deep-seated tumours.

Kohler et al. [23] presented a fast algorithm for optimal control of multi-antenna applicators in regional hyperthermia. The study analysed functions to compute hyperthermia treatment plans to heat deep tumours. Efficient numerical methods were used to maximise the ratio of integral absorbed power inside the tumour and a weighted energy norm outside the tumour. Real patient data were used to test these fast routines and results were compared to global optimisation techniques. Kohler et al. developed techniques for online optimisation in a hybrid system using global optimisation methods to optimise objective functions by search algorithms as used in [66]. The study generalised the eigenvalue problem proposed by Bardati et al. [77] using 3D models, including temperature distribution, time dependences and weighting functions. The inverse optimisation problem was posed as follows:

$$\max_{p \in \mathbb{C}^n} T_{90} \quad \text{subject to} \quad T(x) \leq T_c(x) \quad \forall \ x \in G$$

where $p = (p_1, ..., p_N) \in \mathbb{C}^n$ are complex numbers describing amplitudes and phases of the emitted radiowaves, $x$ is the tissue point of the volume of interest $G$, $T_c(x)$ are the critical temperatures for each point $x$ (defined on a clinical basis), and $T_{90}$ is the temperature exceeded by 90% of $x$. This functional requires the solution of a high-dimensional, nonlinear optimisation problem. Kohler et al. found
simplifications of this functional following the optimisation criterion formulated in [79] and used a generalisation of the eigenvalue problem proposed by Bardati et al. [77] to maximise efficiency. Moreover, Kohler et al. developed efficient functionals for optimising temperature distribution, incorporating the temperature solution of the bioheat equation in a Hilbert space functional and introducing adapted weight functions. They found a computation time of less than 80 s for an updated optimisation of the Sigma-Eye applicator. This led to the flexibility in customising the antenna parameters to adapt for changes in perfusion, electrical conductivity, and individual complaints of the patient.

Zastrow et al. [80] used a non-invasive transmit beamforming algorithm to target microwave energy at the tumour site in breasts. Four numerical breast phantoms with different breast tissue densities, including fatty scattered fibrograndular, heterogeneously dense, and extremely dense, were used to evaluate the focusing and selective heating efficacy. Transmit beamforming consisted of passing microwave signals through a set of filters, in such a way the signal emitted from each antenna adds coherently at the target location and incoherently in the healthy tissue. The beamformer signal set is designed by using a patient-specific propagation model. The model is obtained from 3D FDTD EM simulations of the numerical phantom.

Then, thermal FDTD simulations were used to calculate heating potential and steady state temperature distributions in the breast. The beamformer consisted of a Finite Impulse Response (FIR) filter in each antenna channel. By adjusting the frequency-dependent amplitude and phase of the signals, the filters focused microwave energy at the target location. Hence, the objective was to maximise the fraction of the total transmitted power delivered to the target region \( r_f \):

\[
\max_{H_n(\omega)} \frac{\int \left| \sum_{n=1}^{N} H_n(\omega) T_n(\omega, r_f) \right|^2 d\omega}{\int \sum_{n=1}^{N} |H_n(\omega)|^2 d\omega} \tag{2.6}
\]

where \( H_n(\omega), n = 1, \ldots, N, \) is the frequency response of the FIR filter for the \( n \)th channel, and \( T_n(\omega, r_f) \) represents the frequency response of the one-way propagation path from the \( n \)th source to the target location \( r_f \). The selective heating efficacy of transmit beamforming was quantified using the following metrics:
• $V_{43}$ ($cm^3$): the volume of breast tissue with temperature greater than 43°C.

• $r$ (mm): the radial distance from $r_f$ to the location of peak breast interior temperature.

• $t_{\text{skin}}$ (°C): peak skin temperature.

• $t_{\text{breast}}$ (°C): peak breast interior temperature.

The performance of the beamforming algorithm was evaluated as a function of operating frequency and results showed there was an optimal frequency at which the narrowband beamformer reached a predicted outcome. This frequency depended on the tissue composition and the physical structure of the breast. The beamforming proved to be a robust method to focus microwave energy at the tumour location in breasts with different volume and breast tissue density.

Schenk et al. [81] proposed a parallel scalable Partial Differential Equations (PDE) constrained optimisation based on a parallel iterative linear solver on distributed-memory architectures. The objective function to be minimised is formulated as in [82] and the Pennes’ bio-heat equation [83] is used as a constraint as follows:

$$F = \int_{x \in \Omega_t} (T_{\text{ther}} - T)^2 \, d\Omega + \int_{x \notin \Omega_t, T > T_{\text{health}}} (T - T_{\text{health}})^2 \, d\Omega$$  \hspace{1cm} (2.7)

subject to

$$- \nabla \cdot (k \nabla T) + \rho_b \rho \omega (T - T_b) = \frac{\rho \sigma}{2} \left| \sum_j u_j E_j \right|^2 \text{ in } \Omega$$  \hspace{1cm} (2.8)

$$k \theta T_n = q_{\text{const}}$$  \hspace{1cm} (2.9)

where $T$ is the temperature and $T_b$ the arterial blood temperature, $k$ the thermal conductivity, $\rho$ the density, $\rho_b$ the blood density, $\omega$ the perfusion rate, $\sigma$ the electrical conductivity and $\Omega$ is the patient’s volume of interest. The temperature is $T_{\text{ther}} = 43^\circ\text{C}$, $T_{\text{health}} = 42^\circ\text{C}$, $T_{\text{lim}} = 44^\circ\text{C}$, the control of the antenna is represented by $u_j = a_j e^{-i \alpha_j}$ and $E_j$, where $a_j$ and $\alpha_j$ are respectively the antenna amplitude and phase.
and $E_j$ is the electric field generated by each antenna. The PDE-constrained interior-point algorithm makes use of a global convergent optimisation method and a scalable linear solver, implemented to scale-up to thousands of computing cores.

Iero et al. proposed a computationally effective approach to focus the heating during hyperthermia, the Optimal Constraint Power Focusing (OCPF) method. The goal was to determine the excitations of the sources in order to produce maximum focusing of the field within the target region and maintain low heating elsewhere. The method required computationally intensive global procedures based on convex programming. Two-dimensional numerical phantoms were extracted from Magnetic Resonance Imaging (MRI) images of the breast obtained from researchers at University of Wisconsin-Madison and used to test the feasibility of the approach with tumours in different locations, and at different operating frequencies. A circular array of radius 20 cm was used as applicator and the synthesis procedure was performed at 2 GHz and 2.25 GHz. The proposed method was a generalisation of the 'pencil beams' synthesis method through fixed geometry arrays. The optimal focusing of scalar fields for the hyperthermia problem was posed as follows:

$$\text{maximise } |E(r_{tumour})|^2$$

while

$$|E(r)|^2 \leq UB(r) \quad r \in \Omega$$

where $r_{tumour}$ is the tumour location, $\Omega$ represents the healthy tissue which does not include cancer, $UB(r)$ is the upper bound mask, i.e. a non-negative function which corresponds to field amplitudes leading to sub-critical temperature increases into healthy tissue. The method assumes that the field in the direction of the tumour is purely real, hence Equation was considered as the maximisation of the real part of the field. Therefore, the problem was formulated to determine the real and imaginary parts of the excitation coefficients $\Re(I_n), \Im(I_n), (n = 1, ..., N)$ such that:

$$\Psi(I) = -\Re[E(r_{tumour})] \text{ is minimum}$$
subject to:

\[ \Im\{E(r_{\text{tumour}})\} = 0 \quad (2.13) \]

\[ |E(r_t)|^2 \leq UB(r_t) \quad \forall t = 1, 2, \ldots, M \quad (2.14) \]

where \( I = I_1, \ldots, I_N \) is the vector of the excitation coefficients and \( r_1, \ldots, r_T \) is a discretization of the domain \( \Omega \), \( |E(r_t)|^2 \) is a positive semidefinite quadratic form with \( (t = 1, \ldots, M) \) where \( M \) represents the number of elements into which the space is discretized, the constraints 2.13 and 2.14 define convex sets in the space of the unknowns [86]. Since the term \( \Re\{E(r_{\text{tumour}})\} \) in 2.12 is a linear function of the real and imaginary parts of the excitation coefficients, the problem was formulated as the minimisation of the linear function in a convex set [87]. The study showed the capability of the method to reach a focused \( \text{SAR} \) deposition in the region of interest; however thermal analysis was needed for a complete assessment and to confirm the potential of the method in clinical use.

In 2004, Converse et al. [88] investigated the feasibility of using Ultrawide Band (UWB) microwave techniques to localise heating for breast cancer hyperthermia. The UWB pulses were transmitted simultaneously into the breast from a set of antennas and passed through a space-time beamformer whose filters were designed to compensate for dispersive propagation in the tissue, in such a way that the pulses added coherently at the treatment location and incoherently elsewhere. The design of the space-time beamformer was implemented using a frequency domain approach, computationally faster than the time-domain approach. Realistic numerical breast phantoms derived from magnetic resonance images of patients were used in this study.

The power density absorbed by the breast was calculated by FDTD simulations. The method was evaluated by varying the breast density and heterogeneity. The same propagation model was used for tumour localisation and for transmit-focusing beamformer design, to allow accounting for errors in estimated tumour location. The temperature distribution was also calculated by using a two-dimensional (2D) FDTD thermal model based on the bio-heat equation. The robustness of the
approach was evaluated by varying the dielectric properties of breast tissue and two metrics were used to quantify the focused heating:

$$\frac{Q_{\text{ave}}(\text{breast})}{Q_{\text{ave}}(\text{tumour})}$$

(2.15)

$$\frac{Q_{\text{ave}}(\text{surface})}{Q_{\text{ave}}(\text{tumour})}$$

(2.16)

where $Q_{\text{ave}}(\text{tumour})$, $Q_{\text{ave}}(\text{breast})$, $Q_{\text{ave}}(\text{surface})$, are respectively the average heating potential of the tumour, breast and surface. The value of $Q_{\text{ave}}(\text{breast})$ was calculated from tissue in the region within a 1 cm radius of the center of the tumour, $Q_{\text{ave}}(\text{surface})$ was determined from data in a 0.5 cm thick layer beneath the skin/breast interface. Results showed that the method was able to reach high temperatures in proximity of small tumours while maintaining temperatures under critical values in healthy tissue.

Converse et al. [21] also carried out a computational study of narrowband microwave hyperthermia for the breast cancer treatment as an alternative to their earlier ultra-wideband study [88]. The evaluation was performed based on EM power density and temperature profiles using three different breast phantoms with heterogeneous tissue composition and with a small tumour of 2 mm diameter. The study showed that ultra-wideband allows better focusing and greater reduction of the hotspots compared to the narrowband method.

In 2008, Cheng et al. [89] proposed a method for fast temperature optimisation of a multi-source hyperthermia applicator using a subset of source configurations, i.e. a subset of antennas which were called virtual sources. The sources were characterised by specific amplitudes and phases calculated based on the patient model and the tumour. The method was tested on a patient upper-leg tumour model, with and without a temperature perfusion model, and the applicator was simulated as mini-annular-phased array of ten dipole antennas. The study showed that the temperature distributions obtained from the pre-defined virtual sources were comparable to those calculated using all antennas, and hence provide a sufficiently good solution.

Bardati and Tognolatti [20] investigated three optimisation strategies under the constraint to not exceed a maximal power per channel. The first optimisation
technique optimises the power-to-target; the second optimisation method maximises the ratio of power-to-tumour to the power delivered to the healthy tissue volume in order to investigate the tumour-heating selectivity; the third method maximises the ratio of power-to-tumour to the total array power to investigate the heating efficiency. The numerical analysis was done using an array of eight dipoles placed on two lines around a head/neck. They found that the EM power following the power-to-target optimisation was the largest one delivered to the tumour.

In 2005, Guo et al. \[90\] proposed a time reversal based ultra-wideband microwave method for the treatment of breast hyperthermia. Time reversal and the Capon beamformer were adopted. The technique was evaluated on two 2D breast models which included a small tumour. The first step of the method consisted of transmitting a lower-power pulsed microwave signal from one antenna and the backscattered signals were received by all the antennas and then time-gated. Capon beamforming was performed based on the time-gated signals in order to calculate the beamforming weights to focus the energy into the tumour. The time-gated signals were retransmitted into the breast from each antenna at the same time with a certain pulse repetition frequency to control the average EM power. The study was based on 2D numerical simulations and showed the ability to achieve better EM focusing compared to the space-time beamforming method.

Iero et al. \[91\] investigated the relationship between thermal and electromagnetic power focusing using the OCPF method developed in \[22\]. The study exploited a Green’s function method to solve the Bioheat equation and carried out a quantitative assessment of the robustness of the OCPF technique against two kinds of inaccuracies; EM parameter uncertainty, i.e. incorrect values of permittivity and conductivity; and errors derived from incorrect morphology of the fibroglandular region of the breast. Two-dimensional numerical phantoms, obtained from realistic images of four breast topologies were used to carry out the evaluation. The phantoms were characterised by fatty, fibrograndular, heterogeneously dense, and very dense compositions taken from the University of Wisconsin-Madison repository. Results
showed good focusing of the temperature in the target area and temperatures below critical values, i.e. 40.8 °C in the healthy tissue.

In 2016, Iero et al. [92] extended two techniques originally developed for 2D scenarios to a 3D scenario. The study showed how to focus vector fields for hyperthermia treatments. An improved version of the Time Reversal method, the Optimised Time Reversal [93], and Optimal Constrained Power Focusing [94] were compared in two conditions, a lossless scenario surrounded by a spherical array, and a hemispherical antenna applicator. Results showed that the Optimal Constrained Power Focusing provided better focusing performance at the cost of computation time.

The work of Bellizzi et al. [95] concerned an optimal multi-frequency approach based on convex programming to focus the SAR distribution at a certain point in the tumour, while maintaining low SAR distribution elsewhere. The method followed the theory of the OCPF already adopted by Iero et al. [91] and exploited a multi-frequency applicator, i.e. different excitations used at different frequencies. The method was called Independent Multi-Frequency OCPF (i-mf-OCPF) and based on the Multi-Frequency Optimal Constraint Power Focusing (mf-OCPF) algorithm described in [96]. The idea of the multi-frequency approach was first introduced by Zastrow et al. [97]. Two-dimensional breast phantoms derived from realistic 3D phantoms provided by the Wisconsin repository were used in this study.

The effectiveness of the i-mf-OCPF approach was compared to the OCPF and mf-OCPF methods confirming the optimality of SAR distribution, though still subject to undesired SAR peaks. A thermal analysis was also carried out and showed that all the methods were able to focus the temperature in the target point. However, the performance of the technique was also subject to the type of the tissue, frequencies, number of antennas and can be worse for more challenging scenarios.

In previous studies of microwave hyperthermia, the array has been constructed from simple point sources [21], [25], [90], [91] or multilayers of antenna elements around the breast model [80], while Nguyen et al. [24] introduced the differential
beam-steering subarray approach to pre-steer each subarray separately, instead of controlling the array at the level of individual elements.

A recent study by Nguyen et al. [24] proposed particle swarm optimisation to optimise amplitudes and phases of the antennas to maximise power, and hence temperature at the tumour location, while preventing hotspots in healthy tissue. The proposed strategy was implemented using a 3D antenna array of 4 x 6 unidirectional antenna elements. The system was tested using a very dense 3D breast models with tumours in different locations and a frequency of 4.2 GHz which represented a compromise between the required signal penetration and focusing. Results showed the ability of the method in focusing the heating at the tumour volume.

Wiersma et al. [98] developed a flexible optimisation tool for hyperthermia treatments with RF phased array systems. The goal was to optimise the SAR distribution taking into considerations constraints at regions in the healthy tissue. The quantitative metric to define the optimal target volume focusing was the ratio between the SAR in the target volume and SAR in the whole tissue volume. The method was tested with a real patient case using a phased array applicator with four rectangular waveguides.

Trefna et al. [25] proposed a time-reversal focusing algorithm for microwave hyperthermia to treat deep-seated tumours. The method was based on the time-reversal cavity principle described by Cassereau and Fink [99] and it was applicable for both continuous and pulsed waves. An artificial EM source was placed in a model of the patient. Trefna et al. calculated the antenna amplitudes and phases from simulation of wave transmission and not from measured data, in contrast to other UWB approaches [88], [90], and the antenna was placed in the tumour model.

The beamforming algorithm was implemented using a FDTD algorithm. Two realistic 2D models of head and neck, and breast, were used for the study and the assessment of the technique was done based on the power absorption distributions.

To quantify the relative amount of energy that is absorbed in the tumour and to evaluate the effectiveness of the method, Trefna et al. calculated the ratio between
the average power per voxel in the tumour volume and the average power per voxel in the healthy tissue [100]. The average power absorption ratio is defined as:

$$aPA = \frac{1}{N_{V_{tum}}} \sum^{V_{tum}} P_{A_{\text{norm}}} (x, y) \times \frac{1}{N_{V_{rt}}} \sum^{V_{rt}} P_{A_{\text{norm}}} (x, y)$$  (2.17)

where $V_{tum}$ and $V_{rt}$ represent the tumour and non-tumour tissue volume, while $N_{V_{tum}}$ and $N_{V_{rt}}$ are the total numbers of volume elements of the tumour tissue and non-tumour tissue. The remaining tissue maximum index is defined as:

$$RTM_i = \frac{P_{A_{50}} (\text{remaining tissue})}{P_{A_{50}} (\text{tumour})}$$  (2.18)

where $P_{A_{50}}$ is the median PA in the tumour and $P_{A_1}$ indicates the highest percentile of the PA distribution in the remaining tissue. Moreover a statistical analysis was performed to calculate the maximum power absorbed in all tissues, and a quantitative evaluation of ultrawideband and narrowband beamforming was carried out on the breast model. Finally, minimisation of organ at risks was not taken into consideration in this method.

Zastrow et al. [97] investigated time-multiplexed beamforming for noninvasive microwave brain hyperthermia treatment by using a numerical head phantom from the Virtual Family (IT’S Foundation) 2. To test the effectiveness of the sequence of multiple beamformers, three target locations were chosen in different regions of the brain volume. The objective of the beamformer was to maximise the ratio of the power dissipation per unit volume at the target location and the power dissipation per unit volume at location outside the target volume with temperatures exceeding 41 °C. Thermal simulations using a time-varying heating element as source were performed to evaluate the performance of the technique. Results demonstrated the potential of the approach to minimise overheating regions of healthy tissue while maintaining the therapeutic temperature in the tumour.

In 2006, Kok et al. [28] carried out a treatment planning combined with high resolution temperature based optimisation to treat esophageal cancer by loco-regional hyperthermia. The study adopted a quasi-static zooming method to

2http://itis.swiss/virtual-population
calculate the power density at high resolution combined with a temperature-based optimisation technique to accomplish high resolution optimisation. The method was implemented according to the method described by Das et al. [101].

2.6.3 Discussion of Optimisation Techniques

In HTP optimisation techniques based on SAR are often used to obtain the optimal antenna settings to focus the tumour heating. However, there does not seem to be clear agreement on whether SAR or temperature is most appropriate for optimisation. The work by Canters et al. [65] showed that the improvement from thermal optimisation may be difficult to discern in the presence of modelling uncertainties, such as tissue perfusion uncertainty and that SAR was a better predictor for the median temperature. Contrarily, a previous study [102] found that temperature-based optimisation was superior to SAR-based optimisation under the assumption of constant perfusion at hyperthermic levels. However, Lee et al. [103] showed that SAR-based metric $TC_{25}$ also correlates with clinical outcome. In addition, thermal uncertainties can even negate the benefit from thermal optimisations.

At Erasmus MC, SAR coverage is currently used for treatment guidance in clinical practice and thermal simulations are performed to evaluate the quality of the treatment. In the recent study of Drizdal et al. [104] two different temperature models were used to investigate the differences in hyperthermia treatment quality when using different hyperthermia systems for sub-superficial tumours in H&N regions. One thermal model was studied with constant values of conductivity and perfusion optimised by [105] and a second model with a temperature-dependent blood perfusion. The study found the same CTV coverage in terms of SAR ($TC_{25}$) and temperature ($T_{50}$) when comparing the performance of the Lucite Cone and the HYPERcollar applicators by using the thermal model with constant values of conductivity and perfusion values. At the same time, temperature differences up to 3 °C were found between the two thermal models, suggesting the need for further research on the most accurate thermal model. In this thesis, SAR-based
optimisation techniques have been investigated to focus the heating into the tumour
without impairing the healthy tissue, and thermal simulations are used as the most
appropriate criterion to assess the expected benefit in the clinic.

2.7 Treatment Quality Quantifiers

The clinical metrics used to evaluate the performance of the algorithms in this
thesis and to assess hyperthermia treatment quality can be divided in two groups.

2.7.1 SAR Target Coverage Indicators

Treatment quantifiers such as the Target Coverage 25% $TC_{25}$, Target Coverage 50% $TC_{50}$
were used in [HTP] [45], where these are defined as:

$$TC_{25} = V_{\text{target}} (cfSAR > 0.25 \times \max (cfSAR))$$

i.e. Target Coverage $TC_{25}$ and $TC_{50}$ indicate the percentage of the volume of the
tumour, $V_{\text{target}}$, that is enclosed by the iso-contour of 25% and 50% respectively
of the maximum Cubic Filtered Specific Absorption Rate (cfSAR) in the patient.
Cubic filtering of SAR is a smoothing method to average the SAR over a cubic space
of $1 \text{ cm}^3$ of tissue [51]. The larger the TC percentage, the better the treatment
quality.

2.7.2 Bio-heat Equation and Temperature Indicators

Previous work has demonstrated that the hotspot-target quotient, [HTQ] is correlated
with the simulated temperature distributions for deep [HT] [26]. The Pennes’ bio-heat
equation is employed to describe heat transfer inside biological tissue [83], and
is used in this thesis as the thermal model to predict temperature distribution
in the patient model:

$$\rho c \frac{\partial T}{\partial t} = \nabla \cdot (k \nabla T) + \rho Q + \rho S - \rho_b c_b \rho \omega (T - T_b)$$

(2.20)
where $T$ ($^\circ$C) is the temperature, $t$ (s) is the time, $\rho$ ($kg \cdot m^{-3}$) is the volume density of mass, $c$ ($J \cdot kg^{-1} \cdot ^\circ C^{-1}$) is the specific heat capacity, $k$ ($W \cdot m^{-1} \cdot ^\circ C^{-1}$) is the thermal conductivity, $\omega$ ($m^3 \cdot s^{-1} \cdot kg^{-1}$) is the volumetric blood perfusion rate, $Q$ ($W \cdot kg^{-1}$) is the metabolic heat generation rate, $S$ ($W \cdot kg^{-1}$) is the SAR and the subscript $b$ indicates a blood property. Moreover, a mix of convective and Neumann boundary conditions are used to account for temperature losses [105].

Thermal indicators, as $T_{90}$, $T_{50}$, $T_{10}$, are computed to quantify the temperature in the target tumour ($T_x$) which is exceeded by $X$ percent of all temperature values [106]. Larger values of $T_x$ reflect the higher temperatures in the tumour, hence better treatment quality.

### 2.8 Discussion and Conclusions

This chapter has given an overview of the different areas of H&N cancer. The biological mechanisms of hyperthermia and the different types of hyperthermia treatments and systems were presented. A discussion of the hyperthermia treatment planning carried out at the Erasmus MC and the requirement to ensure a good treatment quality was provided, together with the clinic evaluation metrics. A detailed discussion of objective functions and optimization techniques was also presented.

While research has been carried out to achieve sufficient heating for the tumours while avoiding the surrounding healthy tissue, optimising the antenna settings of the hyperthermia applicator remains a difficult task. This thesis aims to improve the heating delivery for H&N hyperthermia treatments by proposing novel optimisation algorithms and assessing their effectiveness on patient models provided by the Erasmus MC.

Different numerical techniques for SAR and temperature optimisation have been described in the literature. Optimisation algorithms based on SAR are more widely applied than temperature-based methods. Important factors as perfusion, thermal conduction and bolus cooling are not taken into account in SAR-based optimisation strategies. One of the limitation of SAR optimisation is that SAR and temperature in the hotspot might not always coincide. For example, the effect of bolus cooling on
superficial high $\text{SAR}$ values might affect the temperature values, and therefore high $\text{SAR}$ does not always imply high temperatures. Moreover, moderate $\text{SAR}$ values in poorly perfused media can result in high temperatures. All these factors led to investigation of temperature-based optimisation methods. However, whether $\text{SAR}$ or temperature optimisation is more appropriate is still not clear. Radiofrequency hyperthermia treatments induce a plethora of effects of which some, but not all, are temperature related. Hyperthermia is defined by the increase in temperature, but this treatment also modulates, increases and decreases perfusion. Sometimes only low temperatures are obtained in the clinic in very healthy patients due to very responsive thermoregulation. Regions with high $\text{SAR}$ are then cooled by high perfusion. In these patients, the treatment effect can be best explained by the fact that this perfusion itself has a strong impact on treatment outcome. Hence, whether the relation between $\text{SAR}$ and outcome is less strong than the relation between temperature and outcome is still unknown.

The reminder of this thesis presents novel $\text{SAR}$-based optimisation algorithms whose performance is evaluated by thermal simulations and a $\text{SAR}$-temperature correlation is calculated to determine the most appropriate method for hotspot selection. Thermal modeling in general is strongly affected by uncertainties; the simulations carried out in this research use tissue cooling values for fat, muscle and tumour tissue that have been specifically optimised using temperature measured during hyperthermia treatments at Erasmus MC. In this regard, the robustness of the time-multiplexed hyperthermia method is also demonstrated against thermal tissue properties variation.

Objective functions reported in the literature have been described and the correlation of the $\text{SAR}$ indicator with the corresponding predicted temperature was evaluated; each $\text{SAR}$ indicator was used as the objective function for $\text{SAR}$ optimisation. $\text{HTQ}$ was found to be the best objective function for hotspot reduction and optimisation procedures, being able to minimise the hotspots in the healthy tissue while maximising $\text{SAR}$ in the target. The optimisation methods developed in this research aim to minimise $\text{HTQ}$ and a novel objective function
is formulated to find the optimal antenna settings to heat the tumor region and suppress pre-defined hotspots.

The next chapter discusses the optimisation method clinically employed at the Erasmus MC for the treatment of pelvic and head and neck cancer and introduces a novel optimisation algorithm to enhance heat focusing.
3.1 Introduction

As noted in Chapter 2 while significant advances have been made in hyperthermia treatment, challenges remain in selecting system parameters in order to optimise SAR and temperature distributions, in particular through reducing the incidence of hotspots.

In this chapter, a Differential Evolution (DE) algorithm is proposed for improving H&N HTP. Data for six patients treated by the HYPERcollar applicator developed at the Erasmus MC Cancer Institute have been used in order to compare the proposed DE algorithm to the Particle Swarm Optimisation (PSO) technique that is currently in use in clinical practice. These two techniques have been evaluated through different optimisation settings, clinical metrics including the Hotspot-Target SAR Quotient (HTQ), Target Coverage (TC) and HT temperature parameters. The work described in this chapter has been published in Cappiello et al., “Differential evolution optimisation of the SAR distribution for head and neck Hyperthermia,” IEEE Transactions on Biomedical Engineering, Vol. 64, Issue 8, August 2016 (© [2016] IEEE. Reprinted with permission).
3. Hyperthermia Treatment Planning via Differential Evolution Optimisation

The remainder of this chapter is organised as follows. In Section 3.2 the\textcolor{red}{PSO} and \textcolor{red}{DE} algorithms are introduced. The performance of the proposed technique compared to the \textcolor{red}{PSO} method is presented in Section 3.3. Finally, conclusions are given in Section 3.5.

3.2 Methodology

This section describes the \textcolor{red}{PSO} and \textcolor{red}{DE} algorithms and illustrates the experimental testbed, and the set of optimisation parameters chosen for the two algorithms. Details of the temperature simulations are also given.

3.2.1 PSO Optimisation of SAR Distribution

\textcolor{red}{PSO} is a population-based stochastic technique inspired by social behavior principles \cite{108}. \textcolor{red}{PSO} adapts the trajectories of a particle population in a search problem space, according to the evaluation of a fitness function. The particles represent the candidate solutions to the problem and have their own positions and velocities, and are organised into clusters. The best particle in a cluster is called $p_{\text{best}}$ and the global best in the population is defined as $g_{\text{best}}$. Generation after generation, each particle changes its velocity toward the $p_{\text{best}}$ and $g_{\text{best}}$ locations according to Equations 3.1 and 3.2

\begin{equation}
 v_t^i = w * v_{t-1}^i + c_1 * \text{rand} * (p_{\text{best}}_{t-1}^i - x_{t-1}^i) + c_2 * \text{rand} * (g_{\text{best}}_{t-1}^i - x_{t-1}^i) \tag{3.1}
\end{equation}

\begin{equation}
 x_t^i = x_{t-1}^i + v_t^i \tag{3.2}
\end{equation}

where $v_t^i$ and $x_t^i$ are the velocity and position at iteration $t$ with $i = 1, \ldots, n$, where $n$ is the number of particles; $c_1$ and $c_2$ are the attraction weights of local optimum and global optimum of the particles, respectively, while $w$ gives the proportion of the velocity in the previous step $t-1$ that contributes in the new step $t$. At each iteration, the best particle in the cluster is updated and, then the best particle in the population. Hence, the optimal solution is represented by $g_{\text{best}}$. An applicator
3. Hyperthermia Treatment Planning via Differential Evolution Optimisation

Table 3.1: Pseudocode of the PSO algorithm.

<table>
<thead>
<tr>
<th>Pseudocode of PSO</th>
</tr>
</thead>
<tbody>
<tr>
<td>For each particle (i)</td>
</tr>
<tr>
<td>Initialise particle with random position and velocity</td>
</tr>
<tr>
<td>End</td>
</tr>
<tr>
<td>Do</td>
</tr>
<tr>
<td>For each particle (i)</td>
</tr>
<tr>
<td>Evaluate fitness function</td>
</tr>
<tr>
<td>If the current fitness function value is better than pbest</td>
</tr>
<tr>
<td>set current value as the new pbest</td>
</tr>
<tr>
<td>If the current fitness value is better than the global best of the population, set current value as the new gbest</td>
</tr>
<tr>
<td>End</td>
</tr>
<tr>
<td>For each particle (i)</td>
</tr>
<tr>
<td>Calculate particle velocity according to Equation 3.1</td>
</tr>
<tr>
<td>Update particle position according to Equation 3.2</td>
</tr>
<tr>
<td>End</td>
</tr>
<tr>
<td>While (iterations &lt; maximum number of generations) or (defined minimum fitness value not achieved).</td>
</tr>
</tbody>
</table>

antenna configuration consisting of amplitude and phase values is represented by a particle in the PSO algorithm. The PSO toolbox developed by Chen [109] has been implemented in the software tool VEDO developed by the hyperthermia group at Erasmus MC and its pseudocode is given in Table 3.1.

3.2.2 DE Optimisation of SAR Distribution

The differential evolution algorithm, originally developed by Storn and Price [110], is a heuristic search and optimisation technique which belongs to the class of evolutionary optimisation algorithms. Similar to PSO, DE is initialized by a population of random solutions, called individuals. Genetically-inspired operations of crossover, mutation and selection are applied to the population in order to minimise an objective function over the course of consecutive generations (iterations). The relationship between the hyperthermia parameters to be optimised and the DE candidate solutions is proposed as follows: the chromosomes of the individual are represented by antenna amplitudes and phases, individually called genes (Table 3.2). Then, each chromosome is characterized by its corresponding complex
3. Hyperthermia Treatment Planning via Differential Evolution Optimisation

Table 3.2: DE Hyperthermia Parameters Relation.

<table>
<thead>
<tr>
<th>DE Parameter</th>
<th>Antenna Array Parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene</td>
<td>Amplitude or Phase</td>
</tr>
<tr>
<td>Chromosome</td>
<td>Amplitude and phase pair</td>
</tr>
<tr>
<td>Individual</td>
<td>One antenna array configuration</td>
</tr>
<tr>
<td>Population</td>
<td>Several arrays</td>
</tr>
</tbody>
</table>

phasor notation $P$:

$$P = a \cdot e^{-i\Theta}$$ \hspace{1cm} (3.3)

where $a$ and $\Theta$ indicate the antenna amplitude and phase.

After randomly initializing the population, each individual is evaluated by a fitness function. At each generation, a new population is created from the current population. The individuals are named $x_i$, ($i = 1, \ldots, I$), where $i$ identifies the individuals that form the population and $I$ is the number of individuals in the population. Firstly, for each target individual $x_i$, DE applies a differential mutation operator. An initial offspring $y_i$, is created by randomly choosing three members of the population, $x_{r0}$, $x_{r1}$, $x_{r2}$, and $y_i$ is generated as:

$$y_i = x_{r0} + F \cdot (x_{r1} - x_{r2})$$ \hspace{1cm} (3.4)

where $F$ is the differential weighting factor. Following mutation, the crossover operator is applied with a Crossover Probability (CP). The crossover probability determines the fraction of chromosomes that are copied from the mutant offspring to the new offspring. These newly created individuals are referred to as trial members. Each trial member is then compared to the target individual by evaluating the objective function. If the new offspring yields a superior fitness value, the trial individual will be inserted into the next generation, otherwise the old individual is retained. The procedure above is repeated until the stopping criterion (either a certain fitness value or a maximum number of iterations) is satisfied, returning the best solution from the current population. DE was implemented as described in [111].
Table 3.3: Patient and treatment characteristics: Patient identification number, location and type of the tumour, treatment number.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Tumour location</th>
<th>Type of the tumour</th>
<th>Treatment no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>Oropharynx</td>
<td>Recurrent tumour</td>
<td>1</td>
</tr>
<tr>
<td>P2</td>
<td>Nasopharynx</td>
<td>Recurrent tumour</td>
<td>1</td>
</tr>
<tr>
<td>P3</td>
<td>Oral cavity</td>
<td>Primary tumour</td>
<td>1</td>
</tr>
<tr>
<td>P4-T1</td>
<td>Oral cavity</td>
<td>Primary tumour</td>
<td>1</td>
</tr>
<tr>
<td>P4-T2</td>
<td>Oral cavity</td>
<td>Primary tumour</td>
<td>2</td>
</tr>
<tr>
<td>P5</td>
<td>Retroauricular</td>
<td>Primary tumour</td>
<td>1</td>
</tr>
</tbody>
</table>

3.2.3 Experimental Dataset

The experimental dataset to test the performance of DE and PSO is detailed in this section. Six anonymised clinical records, related to the treatment of H&N cancer using the Erasmus MC HYPERcollar system, have been used to test the proposed DE implementation and compare it with the PSO algorithm. The patient clinical characteristics are listed in Table 3.3 and include patient identification numbers, tumour type, location and treatment number. The data related to the patients identified by P4-T1 and P4-T2 represent the first and second hyperthermia treatments on the same patient.

Figure 2.8 illustrates the HYPERcollar applicator, developed at Erasmus MC to heat deep H&N regions, such as thyroid, oropharynx and nasal cavity [18], [45], [47], [48]. As noted in Chapter 2, the applicator consists of a ring-shaped phased array of twelve patch antennas, equally divided over two rings, operating at a frequency of 434 MHz. However, Erasmus researchers have observed that in practice, four dorsal antennas often did not contribute to the heating during treatment due to issues of their practical location [45]. Therefore, only eight antennas were used for HTP.

3.2.4 Optimisation Parameters

The PSO and DE approaches have been employed to minimise the HTQ metric and obtain the optimal antenna settings (consisting of 8 amplitudes and 8 phases). The application of PSO and DE to the hyperthermia problem requires the selection
Table 3.4: Optimisation technique parameters (common to PSO and DE).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>PSO and DE</th>
</tr>
</thead>
<tbody>
<tr>
<td>amplitude boundaries</td>
<td>[0,1]</td>
</tr>
<tr>
<td>phase boundaries</td>
<td>[-180,180]</td>
</tr>
<tr>
<td>number of individuals</td>
<td>$I_a = 60$, $I_b = 60$, $I_c = 100$, $I_d = 200$</td>
</tr>
<tr>
<td>number of iterations</td>
<td>$G_a = 200$, $G_b = 400$, $G_c = 200$, $G_d = 200$</td>
</tr>
</tbody>
</table>

Table 3.5: Specific optimisation technique parameters of PSO and DE.

<table>
<thead>
<tr>
<th>PSO Parameter</th>
<th>value</th>
<th>DE Parameter</th>
<th>value</th>
</tr>
</thead>
<tbody>
<tr>
<td>$c_1$</td>
<td>0.5</td>
<td>F</td>
<td>0.85</td>
</tr>
<tr>
<td>$c_2$</td>
<td>1.25</td>
<td>CP</td>
<td>1</td>
</tr>
<tr>
<td>$w$</td>
<td>0.9</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

of adjustable parameters such as: the boundary range of the antenna and phase parameters, the number of individuals per population, and the number of iterations per method; these parameters common to both optimisation algorithms are reported in Table 3.4. Four different settings of the two latter parameters have been considered to compare the PSO and DE performances; these are identified by subscripts $a$, $b$, $c$, and $d$ in Table 3.4. Additional parameters specific to each technique are given in Table 3.5 and were selected from initial experimentation on the data.

Furthermore, the parameters in Tables 3.4 and 3.5 have been chosen empirically to provide a balance between the breadth of the search and the computation time. For PSO, the weight of local and global optimum of the particles, $c_1$ and $c_2$, and the weight $\omega$ in Equation 3.1 are given, while for the DE, the differential factor $F$ and the crossover probability CP are given.

### 3.2.5 Temperature Simulations

To evaluate the performance of DE and PSO algorithms, temperature simulations were carried out in SEMCAD X (version 14.8.6 Speag, Zurich, Switzerland) using the Pennes’ bio-heat equation expressed by Equation 2.20 in Section 2.7. Transient thermal simulations were calculated by SEMCAD X using the tissue-specific thermal properties (conduction and perfusion) used in [105], with an applicator efficiency.
factor of 40% for the HYPERcollar system. The applicator efficiency of the system is the percentage of the power from the antenna connectors delivered into the patient. Dielectric and thermal properties indicated in Table 3.6 were used in this study. The waterbolus temperature was fixed at 20 °C and the input total power, was tuned to reach the maximum target temperature of 44 °C in healthy tissue and 40 °C in critical organs (i.e. brain, eye and spinal cord) for all configurations. Heat dissipation represents a major factor in the clinical application of hyperthermia.

The study conducted by Verhaart et al. [105] shows that iterative tuning of the tissue-specific conduction and perfusion terms for matching the Pennes’ bio-heat equation simulations to temperature measurements data of sixteen patients treated with the HYPERcollar leads to a substantial improvement in simulation accuracy.

This approach has been shown to provide accurate predictions for the overall temperature distribution, e.g. the median temperature in the target region. Hence, in this thesis, the optimised values for muscle, fat and tumour tissue found in [105] have been used to estimate the temperature distribution improvement for various optimisation settings. A mix of convective and Neumann boundary conditions was applied such that [105]:

$$k \frac{\partial T}{\partial n} = h (T - T_{\text{outside}})$$  \hspace{1cm} (3.5)$$

where $T_{\text{outside}}$ (°C) is the temperature outside the boundary, $n$ (m) is the direction normal to the surface, $h$ (W·m$^{-2}$·°C$^{-1}$) is the heat transfer coefficient due to convective and radiative losses. The waterbolus temperature was set to 30 °C and the initial tissue temperature to 37 °C. The temperature of external air and headrest were set to 20 °C and $h = 8W \cdot m^{-2} \cdot °C^{-1}$ [105] was used for the boundary conditions. The interfaces at tissue-internal air, tissue-lung and tissue-metal implants were modelled using $h = 50W \cdot m^{-2} \cdot °C^{-1}$ [105], while $h = 292W \cdot m^{-2} \cdot °C^{-1}$ was applied for the tissue-waterbolus interface.
Table 3.6: EM tissue properties at 434 MHz and thermal tissue properties for temperature simulations at 37 °C \cite{112} and *thermal properties in \cite{105}.

<table>
<thead>
<tr>
<th>Tissue</th>
<th>$\varepsilon_r$</th>
<th>$\sigma_{eff}$</th>
<th>$\rho$</th>
<th>$c$</th>
<th>$Q$</th>
<th>$k$</th>
<th>$\omega$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Internal air</td>
<td>1.0</td>
<td>0.0</td>
<td>1.2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lung</td>
<td>23.6</td>
<td>0.38</td>
<td>394</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Muscle</td>
<td>56.9</td>
<td>0.81</td>
<td>1090</td>
<td>3421</td>
<td>0.96</td>
<td>0.4*</td>
<td>442.8*</td>
</tr>
<tr>
<td>Fat</td>
<td>11.6</td>
<td>0.08</td>
<td>911</td>
<td>2348</td>
<td>0.51</td>
<td>0.5*</td>
<td>255*</td>
</tr>
<tr>
<td>Bone</td>
<td>13.1</td>
<td>0.09</td>
<td>1908</td>
<td>1313</td>
<td>0.15</td>
<td>0.32</td>
<td>10.0</td>
</tr>
<tr>
<td>Cerebrum</td>
<td>56.8</td>
<td>0.75</td>
<td>1045</td>
<td>3696</td>
<td>15.5</td>
<td>0.55</td>
<td>763.3</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>55.1</td>
<td>1.05</td>
<td>1045</td>
<td>3653</td>
<td>15.7</td>
<td>0.51</td>
<td>770.0</td>
</tr>
<tr>
<td>Brainsteam</td>
<td>41.7</td>
<td>0.45</td>
<td>1046</td>
<td>3630</td>
<td>11.4</td>
<td>0.51</td>
<td>558.6</td>
</tr>
<tr>
<td>Spinal cord (myelum)</td>
<td>35.0</td>
<td>0.46</td>
<td>1075</td>
<td>3630</td>
<td>2.48</td>
<td>0.51</td>
<td>160.3</td>
</tr>
<tr>
<td>Sclera</td>
<td>57.4</td>
<td>1.01</td>
<td>1032</td>
<td>4200</td>
<td>5.89</td>
<td>0.58</td>
<td>380.3</td>
</tr>
<tr>
<td>Lens</td>
<td>37.3</td>
<td>0.38</td>
<td>1076</td>
<td>3133</td>
<td>-</td>
<td>0.43</td>
<td>-</td>
</tr>
<tr>
<td>Vitreous humour</td>
<td>69.0</td>
<td>1.53</td>
<td>1005</td>
<td>4047</td>
<td>-</td>
<td>0.59</td>
<td>-</td>
</tr>
<tr>
<td>Optical nerve</td>
<td>35.0</td>
<td>0.46</td>
<td>1075</td>
<td>3613</td>
<td>2.48</td>
<td>0.49</td>
<td>160.3</td>
</tr>
<tr>
<td>Cartilage</td>
<td>45.1</td>
<td>0.60</td>
<td>1100</td>
<td>3568</td>
<td>0.54</td>
<td>0.49</td>
<td>35.0</td>
</tr>
<tr>
<td>Thyroid</td>
<td>61.3</td>
<td>0.89</td>
<td>1050</td>
<td>3609</td>
<td>87.1</td>
<td>0.52</td>
<td>5624.3</td>
</tr>
<tr>
<td>GTV</td>
<td>59.0</td>
<td>0.89</td>
<td>1050</td>
<td>3950</td>
<td>-</td>
<td>1.5*</td>
<td>848*</td>
</tr>
</tbody>
</table>

3.3 Results

Experimental results obtained by \textbf{PSO} and \textbf{DE} are given in this section. More specifically, Section 3.3.1 presents an analysis of the two algorithms. Section 3.3.2 discusses the performance of \textbf{PSO} and \textbf{DE} with clinical settings, evaluating TC parameters, and SAR distributions. Section 3.3.3 analyses the temperature measurements.

3.3.1 Performance of PSO versus DE as a Function of the Objective Function

3.3.1.1 Mean and Standard Deviation of HTQ

To obtain the fitness values, \textbf{DE} and \textbf{PSO} have been run 50 times using four different optimisation algorithm settings (through varying the number of individuals and iterations), reported in Table 3.4. The results of these experiments are illustrated...
in Table 3.7 and in Figure 3.1. The best performance, achieved by **PSO** and **DE** across all parameter configurations is reported in the second row of Table 3.7. The best performance corresponds to the lowest **HTQ** value. Both algorithms achieve the best fitness score at least once out of the 50 runs for all configurations.

Table 3.7 also includes the highest (worst) **HTQ** value, together with **HTQ** average and standard deviation for each algorithm configuration and for each patient. The percentage variation in standard deviation between the **PSO** and **DE** algorithms is also highlighted in bold for each algorithm configuration.

Substantial performance differences can be observed between **DE** and **PSO** for all settings investigated. **DE** exhibits **HTQ** standard deviation lower than **PSO** by between 40.1% and 96.8%, which means that **DE** locates the global optimum more frequently and consistently than **PSO**. It is also interesting to note that no particular parameter configuration for either of the optimisation algorithms consistently outperforms the others.

This finding suggests that the optimisation algorithms are not particularly parameter sensitive. The improvement of **DE** over **PSO** is graphically illustrated in Figure 3.1 where mean **HTQ** and standard deviation are represented. In all graphs (corresponding to the six different patient records), **DE** reaches a lower mean **HTQ** over 50 runs compared to **PSO** and lower standard deviation value in each algorithm configuration considered. Hence, **DE** is consistently superior compared to **PSO** both for accuracy and robustness results. These results mean that using **DE** reduces the risk of non-optimal solutions being selected during the hyperthermia optimisation process.
Table 3.7: Best and maximum HTQ mean and standard deviation values over 50 runs. Relative percent standard deviation improvements of DE over PSO are presented.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>P1</th>
<th>P2</th>
<th>P3</th>
<th>P4-T1</th>
<th>P4-T2</th>
<th>P5</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSO and DE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Best HTQ</td>
<td>1.3269</td>
<td>3.399</td>
<td>1.034</td>
<td>2.1207</td>
<td>1.0343</td>
<td>1.1056</td>
</tr>
<tr>
<td>Max PSO</td>
<td>1.4447</td>
<td>3.8776</td>
<td>1.2366</td>
<td>2.5844</td>
<td>1.2269</td>
<td>1.1523</td>
</tr>
<tr>
<td>Avg. PSO</td>
<td>1.336</td>
<td>3.4226</td>
<td>1.0426</td>
<td>2.1376</td>
<td>1.0437</td>
<td>1.1175</td>
</tr>
<tr>
<td>Std. PSO</td>
<td>0.0237</td>
<td>0.0772</td>
<td>0.0303</td>
<td>0.0669</td>
<td>0.0292</td>
<td>0.0128</td>
</tr>
<tr>
<td>Max DE</td>
<td>1.3584</td>
<td>3.4505</td>
<td>1.0695</td>
<td>2.2264</td>
<td>1.0836</td>
<td>1.1282</td>
</tr>
<tr>
<td>Avg. DE</td>
<td>1.3292</td>
<td>3.4029</td>
<td>1.036</td>
<td>2.1257</td>
<td>1.0378</td>
<td>1.1077</td>
</tr>
<tr>
<td>Std. DE</td>
<td>0.0063</td>
<td>0.0101</td>
<td>0.0055</td>
<td>0.0161</td>
<td>0.0099</td>
<td>0.0042</td>
</tr>
<tr>
<td>DE Percent improvement over PSO</td>
<td>73.4</td>
<td>87</td>
<td>81.9</td>
<td>75.9</td>
<td>65.9</td>
<td>67</td>
</tr>
</tbody>
</table>

---

60 individuals, 200 iterations \((PSO_{60-200}, \ DE_{60-200})\)

<table>
<thead>
<tr>
<th>PSO</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Max</td>
<td>1.3788</td>
<td>3.6918</td>
<td>1.1554</td>
<td>2.3157</td>
<td>1.3049</td>
<td>1.1491</td>
</tr>
<tr>
<td>Avg.</td>
<td>1.3327</td>
<td>3.4128</td>
<td>1.0391</td>
<td>2.1387</td>
<td>1.0466</td>
<td>1.1123</td>
</tr>
<tr>
<td>Std.</td>
<td>0.0119</td>
<td>0.0522</td>
<td>0.0188</td>
<td>0.0426</td>
<td>0.042</td>
<td>0.0102</td>
</tr>
<tr>
<td>DE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Max</td>
<td>1.3343</td>
<td>3.4505</td>
<td>1.0377</td>
<td>2.2243</td>
<td>1.0696</td>
<td>1.1135</td>
</tr>
<tr>
<td>Avg.</td>
<td>1.3279</td>
<td>3.4032</td>
<td>1.0344</td>
<td>2.125</td>
<td>1.0368</td>
<td>1.1062</td>
</tr>
<tr>
<td>Std.</td>
<td>0.0018</td>
<td>0.0108</td>
<td>0.0006</td>
<td>0.0154</td>
<td>0.0085</td>
<td>0.0016</td>
</tr>
<tr>
<td>DE Percent improvement over PSO</td>
<td>84.9</td>
<td>79.3</td>
<td>96.8</td>
<td>63.9</td>
<td>79.8</td>
<td>83.9</td>
</tr>
</tbody>
</table>

---

60 individuals, 400 iterations \((PSO_{60-400}, \ DE_{60-400})\)

<table>
<thead>
<tr>
<th>PSO</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Max</td>
<td>1.3757</td>
<td>3.8452</td>
<td>1.0892</td>
<td>2.2872</td>
<td>1.084</td>
<td>1.2467</td>
</tr>
<tr>
<td>Avg.</td>
<td>1.3308</td>
<td>3.4286</td>
<td>1.038</td>
<td>2.1329</td>
<td>1.0391</td>
<td>1.114</td>
</tr>
<tr>
<td>Std.</td>
<td>0.0108</td>
<td>0.0907</td>
<td>0.0117</td>
<td>0.0371</td>
<td>0.0118</td>
<td>0.0207</td>
</tr>
<tr>
<td>DE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Max</td>
<td>1.3546</td>
<td>3.6253</td>
<td>1.0466</td>
<td>2.152</td>
<td>1.0466</td>
<td>1.1133</td>
</tr>
<tr>
<td>Avg.</td>
<td>1.3282</td>
<td>3.4069</td>
<td>1.0346</td>
<td>2.1221</td>
<td>1.0353</td>
<td>1.1063</td>
</tr>
<tr>
<td>Std.</td>
<td>0.0047</td>
<td>0.0332</td>
<td>0.0018</td>
<td>0.0048</td>
<td>0.003</td>
<td>0.0015</td>
</tr>
<tr>
<td>DE Percent improvement over PSO</td>
<td>55.8</td>
<td>63.3</td>
<td>84.8</td>
<td>87</td>
<td>74.4</td>
<td>92.5</td>
</tr>
</tbody>
</table>

---

100 individuals, 200 iterations \((PSO_{100-200}, \ DE_{100-200})\)

<table>
<thead>
<tr>
<th>PSO</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Max</td>
<td>1.4016</td>
<td>3.5392</td>
<td>1.096</td>
<td>2.2687</td>
<td>1.0809</td>
<td>1.1375</td>
</tr>
<tr>
<td>Avg.</td>
<td>1.3297</td>
<td>3.4069</td>
<td>1.0374</td>
<td>2.126</td>
<td>1.036</td>
<td>1.1123</td>
</tr>
<tr>
<td>Std.</td>
<td>0.0118</td>
<td>0.0285</td>
<td>0.0122</td>
<td>0.0212</td>
<td>0.0081</td>
<td>0.0091</td>
</tr>
<tr>
<td>DE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Max</td>
<td>1.3641</td>
<td>3.4247</td>
<td>1.0466</td>
<td>2.152</td>
<td>1.0374</td>
<td>1.1212</td>
</tr>
<tr>
<td>Avg.</td>
<td>1.3294</td>
<td>3.4009</td>
<td>1.0347</td>
<td>2.1218</td>
<td>1.0343</td>
<td>1.1064</td>
</tr>
<tr>
<td>Std.</td>
<td>0.0071</td>
<td>0.0052</td>
<td>0.0018</td>
<td>0.0047</td>
<td>0.0004</td>
<td>0.0029</td>
</tr>
<tr>
<td>DE Percent improvement over PSO</td>
<td>40.1</td>
<td>81.8</td>
<td>85</td>
<td>77.9</td>
<td>94.6</td>
<td>68.3</td>
</tr>
</tbody>
</table>
3.3.1.2 HTQ Metric in Clinical Settings

In this section, PSO and DE HTQ results are compared using a single parameter configuration from the previous results (selected among the four algorithm configurations). Since, as discussed in the previous section, the selection of optimisation parameters does not significantly affect algorithm performance, the setting of 60 individuals and 400 iterations was selected to compare with the VEDO software configuration in clinical use [51]. The PSO algorithm implemented in VEDO is referred to as $PSO_{CS}$ while the chosen DE configuration is referred to as $DE_{CS}$.

The maximum percent errors between best and worst optimisation obtained by $PSO_{CS}$ and $DE_{CS}$ are shown in Table 3.8 and calculated as follows:
\[ \text{Max Percentage Error} = \left| \frac{HTQ_{\text{worst}} - HTQ_{\text{best}}}{HTQ_{\text{best}}} \right| \times 100 \] (3.6)

Table 3.8 reveals that the maximum percentage error between the best and worst fitness solutions of PSO\(_{\text{CS}}\) varies from 3.9\% to 26.2\%, whereas the maximum error of DE\(_{\text{CS}}\) ranges from 0.3 to 4.9\%. Moreover, as illustrated in bold font in Table 3.8, the mean HTQ maximum error across all records is 10.6\% and 1.9\% for PSO\(_{\text{CS}}\) and DE\(_{\text{CS}}\) respectively. In agreement with the results presented in Table 3.7, these findings demonstrate that a more targeted and consistent heat focusing is achieved by DE\(_{\text{CS}}\) compared to the clinically-deployed algorithm.

**Table 3.8:** HTQ Maximum percentage errors for the PSO\(_{\text{CS}}\) and DE\(_{\text{CS}}\) optimisation strategies.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>P1</th>
<th>P2</th>
<th>P3</th>
<th>P4-T1</th>
<th>P4-T2</th>
<th>P5</th>
<th>Error average (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSO(_{\text{CS}}) max. percent error</td>
<td>3.9</td>
<td>8.6</td>
<td>11.7</td>
<td>9.2</td>
<td>26.2</td>
<td>3.9</td>
<td>10.6</td>
</tr>
<tr>
<td>DE(_{\text{CS}}) max percent error</td>
<td>0.5</td>
<td>1.5</td>
<td>0.3</td>
<td>4.9</td>
<td>3.4</td>
<td>0.7</td>
<td>1.9</td>
</tr>
</tbody>
</table>

### 3.3.1.3 HTQ Convergence Time

Convergence time to achieve the best HTQ has been calculated for PSO and DE. In general, DE exhibits faster convergence than PSO over the 50 runs. Table 3.9 lists the number of iterations required for both DE and PSO to reach the best value achieved by PSO\(_{\text{CS}}\), this value is chosen as a common optimisation goal for the number of iterations for ease of comparison. DE converges faster than PSO for all configurations analysed, except for the PSO\(_{200-200}\) setting, where PSO converges faster than DE in three out of the six patients (highlighted in bold in Table 3.9).

However, although PSO converges faster in these cases, DE still outperforms PSO when results at the stopping criterion are considered. Along with HTQ results, the computation time for a standard CPU (Intex X86) implementation of DE and PSO was investigated. Since PSO\(_{\text{CS}}\) and DE\(_{\text{CS}}\) evaluate an identical number of candidate solutions, the execution time of both optimisation approaches is similar. The required optimisation time for one patient for PSO\(_{\text{CS}}\) is 79 s on average across all records, while DE\(_{\text{CS}}\) computation time is 94 s. Computation time on a
Table 3.9: Convergence rate for four PSO and DE individual and iteration configurations. Each result represents the number of iterations required for DE and PSO to reach PSO’s best solution.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>P1</th>
<th>P2</th>
<th>P3</th>
<th>P4-T1</th>
<th>P4-T2</th>
<th>P5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iteration no.</td>
<td>60</td>
<td>200</td>
<td>165</td>
<td>129</td>
<td>150</td>
<td>147</td>
</tr>
<tr>
<td>PSO</td>
<td>60</td>
<td>200</td>
<td>76</td>
<td>72</td>
<td>70</td>
<td>84</td>
</tr>
<tr>
<td>DE</td>
<td>60</td>
<td>200</td>
<td>130</td>
<td>153</td>
<td>144</td>
<td>218</td>
</tr>
<tr>
<td>PSO</td>
<td>100</td>
<td>200</td>
<td>89</td>
<td>94</td>
<td>75</td>
<td>79</td>
</tr>
<tr>
<td>DE</td>
<td>100</td>
<td>200</td>
<td>132</td>
<td>120</td>
<td>116</td>
<td>164</td>
</tr>
<tr>
<td>PSO</td>
<td>200</td>
<td>200</td>
<td>100</td>
<td>165</td>
<td>65</td>
<td>127</td>
</tr>
<tr>
<td>DE</td>
<td>200</td>
<td>200</td>
<td>138</td>
<td>94</td>
<td>82</td>
<td>98</td>
</tr>
</tbody>
</table>

CPU points to the possibility of using a Graphical Processing Unit (GPU) accelerator as a useful computational platform. Initial GPU experiments, conducted as part of this research, suggest a speed-up factor of between 4 and 5 is achievable.

3.3.2 Performance of PSO versus DE as a Function of the SAR-Treatment Quantifiers

3.3.2.1 Mean and Standard Deviation of HTQ

The amplitudes and phases of the best solution achieved by the two optimisation methods using VEDO clinical settings, PSOCS and DECS, are reported in Table 3.10.

3.3.2.2 SAR Treatment Quantifiers

The treatment quantifiers previously discussed in Section 2.7 have been used to evaluate the treatment quality and the performance of each HTQ optimisation algorithm. Tables 3.11 and 3.12 present TC25 and TC50 results. All antenna amplitudes are normalised between 0 and 1 in order to calculate the SAR for 1W total input power.

The variation between the best and worst case of the hyperthermia TC indicators, ΔTC, is reported in Tables 3.11 and 3.12. While PSOCS reaches a range of ΔTC25 equal to 0-11%, across all the six records, the DECS ΔTC25 is smaller and equal
Table 3.10: Antenna amplitudes and phases of the best solution achieved by PSO and DE optimisations.

<table>
<thead>
<tr>
<th></th>
<th>P1</th>
<th>P2</th>
<th>P3</th>
<th>P4-T1</th>
<th>P4-T2</th>
<th>P5</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSO</td>
<td>0.1</td>
<td>0.15</td>
<td>0.2</td>
<td>0.6</td>
<td>0.65</td>
<td>0.45</td>
</tr>
<tr>
<td>DE</td>
<td>-40°</td>
<td>82.2°</td>
<td>-4.6°</td>
<td>-180°</td>
<td>-146.2°</td>
<td>-49.6°</td>
</tr>
<tr>
<td>PSO</td>
<td>0.06</td>
<td>0.74</td>
<td>0.97</td>
<td>0.6</td>
<td>0.64</td>
<td>0.73</td>
</tr>
<tr>
<td>DE</td>
<td>-125°</td>
<td>-2.3°</td>
<td>132.6°</td>
<td>-43°</td>
<td>-66.4°</td>
<td>30.2°</td>
</tr>
<tr>
<td>PSO</td>
<td>0.08</td>
<td>0.04</td>
<td>0.05</td>
<td>0.47</td>
<td>0.51</td>
<td>0.35</td>
</tr>
<tr>
<td>DE</td>
<td>0.08</td>
<td>0.04</td>
<td>0.05</td>
<td>0.47</td>
<td>0.51</td>
<td>0.35</td>
</tr>
<tr>
<td>PSO</td>
<td>0.08</td>
<td>0.04</td>
<td>0.05</td>
<td>0.47</td>
<td>0.51</td>
<td>0.35</td>
</tr>
<tr>
<td>DE</td>
<td>0.08</td>
<td>0.04</td>
<td>0.05</td>
<td>0.47</td>
<td>0.51</td>
<td>0.35</td>
</tr>
<tr>
<td>PSO</td>
<td>0.08</td>
<td>0.04</td>
<td>0.05</td>
<td>0.47</td>
<td>0.51</td>
<td>0.35</td>
</tr>
<tr>
<td>DE</td>
<td>0.08</td>
<td>0.04</td>
<td>0.05</td>
<td>0.47</td>
<td>0.51</td>
<td>0.35</td>
</tr>
</tbody>
</table>

To 0-4% for five patients. This means that DE can provide greater tumour SAR coverage and more uniform heating during the patient treatment. Moreover, \( TC_{50} \) varies from 0% to 11% in five patients for \( PSO_{CS} \) and from 0% to 3% in four out of the six patient records for \( DE_{CS} \). Furthermore, in some cases (highlighted in bold) the worst solutions show a larger target coverage than the ones corresponding to the best fitness values. One reason for this is that \( HTQ \) accounts for energy deposited both in the tumour and in healthy tissue, while the TC metrics only consider the tumour region (without any regard to the healthy tissue). For this reason, \( HTQ \) performance can be improved with a small loss in \( TC \) in a small number of cases.
Table 3.11: $TC_{25}$ Performance metric tested on six clinical records for the PSO and DE optimisation strategies. Percentage variation between best and worst cases are also given.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>$TC_{25}$ PSO</th>
<th>$TC_{25}$ DE</th>
<th>$TC_{25}$ PSO</th>
<th>$TC_{25}$ DE</th>
<th>$\Delta TC_{25}$ PSO (Best-worst case variation)</th>
<th>$\Delta TC_{25}$ DE (Best-worst case variation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>88</td>
<td>77</td>
<td>84</td>
<td>11</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>P2</td>
<td>17</td>
<td>10</td>
<td><strong>19</strong></td>
<td>7</td>
<td><strong>-2</strong></td>
<td></td>
</tr>
<tr>
<td>P3</td>
<td>89</td>
<td>85</td>
<td>88</td>
<td>4</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>P4-T1</td>
<td>96</td>
<td>85</td>
<td>89</td>
<td>11</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>P4-T2</td>
<td>89</td>
<td><strong>89</strong></td>
<td>85</td>
<td>0</td>
<td><strong>-4</strong></td>
<td></td>
</tr>
<tr>
<td>P5</td>
<td>38</td>
<td>37</td>
<td>38</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>$\Delta TC_{25}$ average (%)</strong></td>
<td><strong>5.6</strong></td>
<td><strong>2.3</strong></td>
<td><strong>5.6</strong></td>
<td><strong>2.3</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3.12: $TC_{50}$ Performance metric tested on six clinical records for the PSO and DE optimisation strategies. Percentage variation between best and worst cases are also given.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>$TC_{50}$ PSO</th>
<th>$TC_{50}$ DE</th>
<th>$TC_{50}$ PSO</th>
<th>$TC_{50}$ DE</th>
<th>$\Delta TC_{50}$ PSO (Best-worst case variation)</th>
<th>$\Delta TC_{50}$ DE (Best-worst case variation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>25</td>
<td>16</td>
<td>22</td>
<td>9</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>P2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>P3</td>
<td>32</td>
<td><strong>35</strong></td>
<td><strong>33</strong></td>
<td>-3</td>
<td><strong>-1</strong></td>
<td></td>
</tr>
<tr>
<td>P4-T1</td>
<td>29</td>
<td>18</td>
<td>27</td>
<td>11</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>P4-T2</td>
<td>32</td>
<td>28</td>
<td>29</td>
<td>4</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>P5</td>
<td>8</td>
<td>8</td>
<td><strong>9</strong></td>
<td>0</td>
<td><strong>-1</strong></td>
<td></td>
</tr>
<tr>
<td><strong>$\Delta TC_{50}$ average (%)</strong></td>
<td><strong>3.5</strong></td>
<td><strong>0.5</strong></td>
<td><strong>3.5</strong></td>
<td><strong>0.5</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
3.3.2.3 SAR Distributions

For each patient, the cubic filtered SAR distribution was plotted. While the HTQ results for all patients are presented in Section 3.3.1, the SAR distributions of only three patients are presented here in the interest of brevity. The SAR maps related to the two methods are presented in Figures 3.2-3.7. The SAR distribution is visualised by varying the \( z \) coordinate on the transversal plane, where the direction of \( z \) is from the neck to the top of the head. For each patient, the coordinates specified in Figures 3.2-3.7 have been chosen according to the location of the tumour in the 3D patient model. The tumour is delineated in black in each map.

The SAR distributions in Figures 3.2-3.7 demonstrate that the PSO and DE hyperthermia optimisations are comparable in the best case optimisation, since both algorithms successfully locate the minimum of HTQ solution. However, in the worst case, DE better focuses the energy in the target area, compared to PSO.

Figures 3.2, 3.3 illustrate how for Patient 2, DE better focuses the heat more consistently in the target area over PSO, achieving respectively a maximum percentage error of 1.5% and 8.6% (as described in Table 3.8). Further, DE results in a greater \( T_{C_{25}} \) in the worst case compared to the best one. This is because although there is a lower \( T_{C_{25}} \) coverage in the tumour in the best case, the performance is compensated by the reduction in energy being transmitted to healthy tissue.

Also for Patient 4-T1 (first treatment) in Figures 3.4, 3.5 the DE optimisation results in a smaller HTQ value than PSO in the worst case. Maximum errors of 4.9% and 9.2% between the HTQ best and worst cases are observed with DE and PSO respectively. The DE \( \Delta T_{C_{25}} \) and \( \Delta T_{C_{50}} \) are also smaller than those of PSO. Patient 4-T2 (Figures 3.6, 3.7), refers to the second treatment of Patient 4. A substantial error of 26.2% is observed between the PSO best and worst scenarios, against a 3.4% error provided by DE. In the worst case optimisation, PSO presents a \( T_{C_{25}} \) equivalent to that of the best case, with hotspots in the healthy tissue. This is not the case for DE which shows better focusing in the worst case compared to PSO, despite of greater \( \Delta T_{C_{25}} \).
Figure 3.2: Cubic filtered SAR distributions in a transversal cut through the target location ($z = 58$ mm), using the optimised antenna and phase settings resulting from PSOCS best (a) and worst optimisation (b) in patient P2.
Figure 3.3: Cubic filtered \text{SAR} distributions in a transversal cut through the target location \((z = 58\,\text{mm})\), using the optimised antenna and phase settings resulting from \text{DE}_{CS} best (a) and worst optimisation (b) in patient P2.
Figure 3.4: Cubic filtered SAR distributions in a transversal cut through the target location (z = 20 mm), using the optimised antenna and phase settings resulting from PSOCS best (a) and worst optimisation (b) in patient P4-T1.
Figure 3.5: Cubic filtered SAR distributions in a transversal cut through the target location ($z = 20$ mm), using the optimised antenna and phase settings resulting from $DE_{CS}$ best (a) and worst optimisation (b) in patient P4-T1.
Figure 3.6: Cubic filtered SAR distributions in a transversal cut through the target location \((z = 20 \text{ mm})\), using the optimised antenna and phase settings resulting from PSO\(_{CS}\) best (a) and worst optimisation (b) in patient P4-T2.
Figure 3.7: Cubic filtered SAR distributions in a transversal cut through the target location \((z = 20 \text{ mm})\), using the optimised antenna and phase settings resulting from \(DE_{CS}\) best (a) and worst optimisation (b) in patient P4-T2.
3.3.3 Thermal Performance

Thermal modeling, which converts 3D SAR distribution to a 3D temperature field, has been performed to evaluate whether a therapeutic temperature of 40 °C is reached inside the tumour, while maintaining the temperature of the healthy tissue in a specific range. Cumulative Temperature-Volume (T-V) histograms and temperature indices were computed for PSO CS and DE CS in the best and worst cases for the six patients. The absorbed energy from the EM field simulation was used for the thermal calculations.

The cumulative T-V histograms related to the best and worst PSO CS and DE CS optimisations of three patients are illustrated in Figure 3.8. Temperature results for all records are reported in Table 3.13. The histograms show a tumour temperature difference between PSO CS best (solid red) and worst (dash-dot red) case is observable in at least three out of the six records.

The corresponding temperature parameters, $T_{90}$, $T_{50}$, $T_{10}$, together with the maximum temperature, $T_{\text{max}}$, achieved in the tumour area, are listed in Table 3.13. The variations ($\Delta T$) arising from best and worst PSO CS and DE CS optimisations are also reported in bold. In the worst case, PSO CS shows an average $\Delta T_{\text{max}}$ of 0.9 °C (range 0.1 - 2.3 °C) over the best case and across all patients; in contrast, an average $\Delta T_{\text{max}}$ of 0.2 °C (range 0 - 1.1 °C) is measured between DE CS best and worst optimisations. Also, the average variation of the temperature indices ($\Delta T_x$) between best to worst was found to be higher for PSO compared to DE. An average $\Delta T_{10}$ equal to 0.7 °C and 0.2 °C is observed for PSO CS and DE CS, whose values range respectively from 0 °C to 2 °C and from 0 °C to 0.2 °C. Furthermore, PSO and DE report an average $\Delta T_{C_{50}}$ equal to 0.5 °C (range 0 - 1.1 °C) and 0.1 °C (range -0.1 - 0.6 °C) across all the six data; whereas an average $\Delta T_{90}$ of 0.5 °C (range 0.2 – 1 °C) and 0.2 °C (range 0.1 - 0.6 °C) are measured for PSO CS and DE CS. The histograms also indicate that the temperature pattern in the healthy tissue remains the same for the best and worst optimisations both for PSO and DE. The median temperatures, $T_{50}$, in the healthy tissue range between 37 °C and 37.3 °C across all patients.
Table 3.13: $T_{max}$ and temperature indices $T_x$ that are exceeded by $x$ percent of all temperature readings in the tumour target. $T_{max}$ and $T_x$ best and worst optimisation results arising from PSOC and DE are given with their variation.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>$T_{max}$ ($°C$)</th>
<th>$T_{10}$ ($°C$)</th>
<th>$T_{50}$ ($°C$)</th>
<th>$T_{90}$ ($°C$)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PSO</td>
<td>DE</td>
<td>PSO</td>
<td>DE</td>
</tr>
<tr>
<td>P1 Best</td>
<td>43.8</td>
<td>43.8</td>
<td>41.7</td>
<td>41.7</td>
</tr>
<tr>
<td>P1 Worst</td>
<td>43.7</td>
<td>43.8</td>
<td>41.7</td>
<td>41.7</td>
</tr>
<tr>
<td>$\Delta T$ ($°C$)</td>
<td>0.1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>P2 Best</td>
<td>40.6</td>
<td>40.6</td>
<td>38.7</td>
<td>38.7</td>
</tr>
<tr>
<td>P2 Worst</td>
<td>39.5</td>
<td>40.6</td>
<td>38.4</td>
<td>38.6</td>
</tr>
<tr>
<td>$\Delta T$ ($°C$)</td>
<td>1.1</td>
<td>0</td>
<td>0.3</td>
<td>0.1</td>
</tr>
<tr>
<td>P3 Best</td>
<td>40.3</td>
<td>40.3</td>
<td>39.7</td>
<td>39.7</td>
</tr>
<tr>
<td>P3 Worst</td>
<td>39.6</td>
<td>40.3</td>
<td>39</td>
<td>39.7</td>
</tr>
<tr>
<td>$\Delta T$ ($°C$)</td>
<td>0.7</td>
<td>0</td>
<td>0.7</td>
<td>0</td>
</tr>
<tr>
<td>P4-T1 Best</td>
<td>43</td>
<td>43</td>
<td>41.2</td>
<td>41.2</td>
</tr>
<tr>
<td>P4-T1 Worst</td>
<td>40.7</td>
<td>41.9</td>
<td>39.2</td>
<td>40.2</td>
</tr>
<tr>
<td>$\Delta T$ ($°C$)</td>
<td>2.3</td>
<td>1.1</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>P4-T2 Best</td>
<td>43.4</td>
<td>43.4</td>
<td>41.9</td>
<td>41.9</td>
</tr>
<tr>
<td>P4-T2 Worst</td>
<td>43.3</td>
<td>43.3</td>
<td>41.5</td>
<td>41.7</td>
</tr>
<tr>
<td>$\Delta T$ ($°C$)</td>
<td>0.1</td>
<td>0</td>
<td>0.4</td>
<td>0.2</td>
</tr>
<tr>
<td>P5 Best</td>
<td>43.5</td>
<td>43.5</td>
<td>39.9</td>
<td>39.7</td>
</tr>
<tr>
<td>P5 Worst</td>
<td>42.4</td>
<td>43.4</td>
<td>39.2</td>
<td>39.7</td>
</tr>
<tr>
<td>$\Delta T$ ($°C$)</td>
<td>1.1</td>
<td>0.1</td>
<td>0.7</td>
<td>0</td>
</tr>
</tbody>
</table>

Overall, the temperature measurements data support the better performance of the DE algorithm, where smaller differences were found between the best and the worst optimisations.
Figure 3.8: Cumulative Temperature-Volume (T-V) histograms representing the 3-D temperature distribution within the tumour and healthy tissue for patient 3 (a), 4-T1 (b), and 5 (c). Best (solid line) and worst cases (dash-dot line) for PSOCS and DECS are illustrated.
3.4 Discussion

The success of microwave hyperthermia in H&N cancer treatment is strongly dependent on the power levels of the RF signals used for each antenna of the applicator. The DE optimisation algorithm proposed in this chapter provides improvements over the clinically used PSO in terms of SAR coverage and thermal performance. Although both algorithms achieve the same optimal SAR distribution, i.e. the minimum value of the objective function HTQ over 50 runs, DE outperforms PSO in the worst optimisation. This translates into a better focus of the energy in the target and minimisation of energy in the hotspots. This is confirmed by temperature results, which indicate smaller temperature differences between best and worst optimisation. More specifically, average temperature variation of 0.5 °C and 0.1 °C were observed in $T_{50}$ for PSO and DE respectively. According to [113], differences on the order of 0.3 °C in CTV temperature are relevant in clinical practice. DE optimisation leads to higher CTV temperatures in the worst case compared to PSO and hence a better treatment outcome. Therefore, thermal results show a significant clinical benefit of the DE optimisation.

There has been substantial research on the most appropriate measure to use for optimisation in HTP. As mentioned above, the optimisation algorithms presented in this work minimise HTQ and the treatment is evaluated through a set of treatment quality indicators. In fact, the study by Canter et al. [26] found that HTQ was a good SAR optimisation function and correlated best with the temperature compared to other SAR indicators. The parameters $TC_{25}$ and $TC_{50}$ were also used to assess the quality of the treatment in terms of SAR results and the temperature-based quality parameters. For H&N hyperthermia, Verhaart et al. [105] demonstrated that $T_{50}$ can be predicted with a median accuracy of 0.8 °C, even when neglecting the temperature dependence of tissue cooling. Thermal modeling is highly affected by uncertainties; however, the thermal properties of tissues used in this work were validated using temperatures measured by thermometer probes which were placed interstitially [45].
3.5 Conclusions

In this chapter, a DE optimisation method for SAR distribution for H&N hyperthermia treatment was presented. DE generates a set of parameters which allows for the application of an optimal HT SAR distribution in the target treatment area of the patient. The SAR distribution was investigated in a set of data from patients treated by the HYPERcollar system in the clinic of Erasmus MC. The optimum amplitude and phase of each applicator’s antenna are found by minimising an objective function, in order to focus the energy in the tumour while reducing hotspots in the surrounding healthy area.

DE is compared to the PSO optimisation technique across four algorithm parameter settings. While results illustrate that both algorithms are capable of finding an optimal power distribution, the proposed DE algorithm provides an improvement over the PSO algorithm used at the hyperthermia unit of Erasmus MC, by more frequently and consistently locating the global optimum for all studied patients. DE performs better in terms of HTQ average and standard deviation, gaining HTQ average and standard deviation improvements of 0.02-0.94% and 40.1-96.8% respectively across all patients. The clinically-employed version of PSO, PSOC, was compared to DE and the best and worst optimisations produced by the two algorithms were analysed in terms of HTQ, TC and temperature performance metrics. The best and worst DECS optimisations exhibit an average HTQ error of 1.9% compared to the 10.6% average error obtained by PSOC. Similar trends are found for TC and thermal variations.

The computation time for a standard desktop computer implementation of DE and PSO was also determined. The convergence rate for PSO and DE configurations was found to be similar, with average values of 79 s and 94 s respectively across all patients. The DE algorithm was not entirely optimised for speed purposes and was slightly slower than PSO though there is scope for further optimization for efficiency.

Despite the improvements obtained with DE, there is scope for improvement. In the following chapter, the development and application of time-multiplexed hyperthermia will be described, in order to further improve the tradeoff between
tumour heating and the generation of hotspots. A multi-objective genetic algorithm is introduced together with the formulation of a novel objective function to obtain multiple optimal heating patterns applied sequentially.
4

Time-Multiplexed Steering in Phased Array Microwave Hyperthermia for Head and Neck Cancer Treatment

4.1 Introduction

In the previous chapter, a Differential Evolution (DE) optimisation algorithm was proposed in order to improve the SAR and heating of the target region while reducing hotspots. The efficacy of the proposed algorithm was demonstrated by testing with a H&N cancer patient dataset from Erasmus MC. DE resulted in enhanced focus of microwave energy absorption to the target region during hyperthermia treatment. In particular, DE offered improved performance over the current clinically-used Particle Swarm Optimisation (PSO), by more frequently and consistently locating the global optimum for all patients in the data set. These results were confirmed by thermal simulations.

In this chapter, sequential, i.e. “time-multiplexed”, application of multiple optimal heating patterns is presented to further improve the tradeoff between increased tumour heating and reduced hotspots. A Multi-Objective Genetic Algorithm (MOGA) is introduced to balance two objectives that both focus SAR delivered to the target region but differ in the suppressing of pre-defined hotspots.
This step leads to two optimal solutions for antenna settings. These antenna settings are then applied sequentially and thermal simulations are used to evaluate the effectiveness of the time-multiplexed steering.

The proposed technique is tested using treatment planning data of a representative dataset of five H&N cancer patients for the HYPERcollar3D system, provided by the Erasmus MC hyperthermia group. Steering dynamics are analysed and the time-multiplexed steering is compared to the current static solution used in the clinic, i.e. HTQ optimisation using PSO. The results demonstrate the ability to enhance target heating while reducing hotspots and provides a better time-averaged treatment quality. The work described in this chapter is published in Cappiello et al., “The potential of time-multiplexed steering in phased array microwave hyperthermia for head and neck cancer treatment,” Physics in Medicine and Biology, Vol. 63, Issue 13, July 2018 [115] (© Institution of Physics and Engineering in Medicine. Reproduced with permission. All rights reserved. DOI: 10.1088/1361-6560/aaca10).

The reminder of this chapter is organised as follows: Section 4.2 describes the methodology used to implement time-multiplexed steering in the phased array hyperthermia applicator, and the method used for performance analysis and the dataset used in this work. The MOGA implementation, the formulation of the novel objective function and the thermal model are also described in this section. Section 4.3 reports SAR and thermal results from the performance evaluation. Finally, the conclusions are presented in Section 4.5.

4.2 Methodology

This section introduces the time-multiplexed steering for H&N hyperthermia. Firstly, the basic principle of the multi-objective genetic algorithm is described; then, a novel objective function to suppress a pre-defined hotspot is formulated, after which the thermal model employed to carry out the thermal evaluation is discussed. Lastly, the time-multiplexed steering procedure for H&N hyperthermia is presented.
4.2.1 Multi-Objective GA Optimisation

Multi-Objective Genetic Algorithms (MOGAs) [116] apply a heuristic search and optimisation technique that can solve multi-objective problems while promoting diversity within the solutions. In most instances, there will not be a solution which is best (globally maximum or minimum) over all objectives. A MOGA generates a set of Pareto optimal solutions which may favor one objective at the expense of the others. The Pareto optimal solutions are defined as those solutions that dominate other solutions in the search space when all objectives are considered. Hence, an optimal solution can be selected based on tradeoffs between all objectives. Mathematically, the Pareto-optimality problem [117] can be posed as follows:

\[
\text{minimise } \ f(x) = f_1(x), f_2(x), \ldots, f_n(x) \tag{4.1}
\]

where \( n \) is the number of the objective functions, and \( x \) is a vector of \( m \) decision variables: \( x = x_1, x_2, \ldots, x_m \) in the solution space \( X \). In a minimisation problem, given two vectors \( x \) and \( y \), a solution \( x \) dominates another solution \( y \) if:

\[
f_i(x) \leq f_i(y) \quad \text{for } i = \{1, \ldots, n\} \tag{4.2}
\]

\[
f_j(x) < f_j(y) \quad \text{for at least } j = \{1, \ldots, n\} \tag{4.3}
\]

i.e. solution \( x \) dominates solution \( y \) if \( x \) is no worse than \( y \) in all objectives and \( x \) is strictly better than \( y \) in at least one objective. A solution is called non-dominated if none of the objective functions can be improved in value without worsening one or more objective functions. The set of all non-dominated solutions in \( X \) represents the Pareto optimal set and the plot of the objective functions is referred to as the Pareto Front [118], [119].

The MOGA used in this study is a variant of the fast Non-dominated Sorting Genetic Algorithm (NSGA-II) [116], [118]. NSGA-II starts by initializing a population of random candidate solutions, called individuals. The population is sorted in two groups (known as fronts), a first non-dominant front and a second front dominated by the individuals in the first front. The individuals in both fronts are
ranked based on a quality measure called the “fitness value”, which indicates how close a given solution is to the optimum solution for the specific problem. Next, the distance between each individual and the other individuals in the front is calculated. This distance is known as the crowding distance and it is used to promote diversity whereby a larger crowding distance will encourage greater diversity in the population. The distance between individuals is calculated as the Euclidean distance between their respective solution vectors ($x_1$ and $x_2$). A new population is created by selecting “parents” based on the crowding distance and the fitness value. Crossover and mutation operators are applied to form the new “offspring”. Then, the offspring population is compared with the current population to ensure that only individuals that are superior to their parents (either by fitness value or crowding distance) progress to the next generation. This process is known as elitism.

The algorithm proposed in this work follows the same implementation as NSGA-II except that the elitism mechanism is slightly different. NSGA-II favors individuals with strictly better fitness value, while the proposed MOGA uses a version of elitism which improves both the fitness and the diversity of the population by examining both in the selection process.

The relation between MOGA solutions and the hyperthermia parameters to be optimised is similar to that described in Section 3.2.2 where each candidate solution is represented by the antenna array amplitude and phase configurations. Although the HYPERcollar3D consists of 20 antennas, only 12 amplitudes and phases are optimised in HTP since the number of operational channels is currently constrained by the number of available power amplifiers in the system [120]. The 12 antennas selected for the treatment are those that individually achieve the highest mean SAR in the target region [45]. This set of 12 antennas is fixed throughout all simulation experiments.

4.2.2 Hotspot Specific Objective Function

In this section, a novel objective function, the total Hotspot-Target SAR Quotient for a specific HotSpot ($HTQ_{HS}$) is formulated to suppress a specific hotspot that
occurs in the healthy tissue. The $HTQ_{HS}$ is defined as:

$$HTQ_{HS} = \frac{SAR_a(V_{HS})}{SAR_a(target)}$$  (4.4)

where $SAR_a(V_{HS}) \ (W \cdot kg^{-1})$ is the mean SAR in the hotspot volume $V_{HS}$. $V_{HS}$ represents the region of the healthy tissue volume outside the CTV with the highest SAR in the H&N patient model. Therefore, MOGA minimises the two objective functions, $HTQ$ and $HTQ_{HS}$ and gives rise to a set of Pareto optimal antenna parameters that individually provide different SAR levels in the CTV and in the hotspots.

4.2.3 Temperature Simulations

To evaluate the performance of time-multiplexed hyperthermia, temperature simulations were carried out in SEMCAD X using the Pennes’ bio-heat equation described in Section 2.7. As in previous research reported in Chapter 3, transient thermal simulations were carried out using the dielectric and thermal properties indicated in Table 3.6. Constant values of thermal conductivity and blood perfusion for muscle, fat and tumour tissue used in [105] have been used in this study. The total input power was tuned to reach the maximum temperature of 44 °C in the healthy tissue outside the CTV and/or 40 °C in critical organs (eyes, brains and spinal cord). A mix of convective and Neumann boundary conditions was applied as in Section 3.2.5.

4.2.4 Time-Multiplexed Steering Procedure

In this section, the methodology adopted to implement time-multiplexed steering for H&N hyperthermia is described. The methodology can be divided into three parts.

4.2.4.1 SAR-Temperature Correlation

For each patient, PSO optimisation was performed to get the best amplitude and phase settings that minimise $HTQ$; as noted before, these settings are referred to as StaticS. Then, the EM distributions of individual antenna were combined and the cubic filtered SAR (cfSAR) was calculated. The resulting absorbed energy was used to obtain the 3D temperature distribution. Finally, the coefficient of
determination, $R^2$, was calculated to measure how well the highest simulated cfSAR values approximate the simulated temperatures above 40 °C in the healthy tissue, and to determine the most appropriate method for hotspot selection. $R^2$ was calculated based on the difference between the temperature values for HTQ optimised antenna settings and the predicted temperature values and is defined as:

$$R^2 = 1 - \frac{\sum_{i}^{n} (y_i - f_i)^2}{\sum_{i}^{n} (y_i - y_{av})^2}$$ (4.5)

where $n$ is number of voxels in the hotspot volume, $y_i$ are the observed temperature values, $f_i$ are the predicted temperature values from the fit, $y_{av}$ is the mean of the observed temperature data. $R^2$ is a measure of how well the regression line agrees with the observed temperature values. The smaller the second term is, the closer to the fit the observed data are, hence the closer the value of $R^2$ is to 1 [121].

### 4.2.4.2 SAR Optimisation

A multi-objective optimisation was performed to find the best time-multiplexed antenna settings. In a single application of the method, MOGA is able to find Pareto optimal antenna settings that yield multiple SAR distributions. The SAR fields differ in the amount of energy absorbed in the target and in the hotspot. For each patient, one Pareto Optimal Solution (PoptS) was identified to supply a balance between establishing sufficient SAR in the target and SAR reduction in the hotspot. Then, two antenna settings, StaticS and PoptS were sequentially combined to form the time-multiplexed configuration.

### 4.2.4.3 Thermal Evaluation

In order to assess the effectiveness of time-multiplexed hyperthermia the static and the time-multiplexed thermal performance were compared. A resolution of 2 mm was used for the thermal solver. First, the thermal simulations with StaticS and PoptS were run individually to obtain the total input power required for each static configuration. Then, the thermal simulation for time-multiplexed steering was run applying two antenna settings in the sequence StaticS followed by PoptS and the total input power of the combined steering settings was tuned. As noted
above, total power was tuned to achieve the maximum temperature of 44 °C in
the healthy tissue and/or 40 °C in critical organs. The sequence was repeated
throughout the simulation period which was set to 1200 s. This value was found
empirically to be sufficient to reach steady-state conditions.

The overall methodology is given in Figure 4.1. The steering rate was also
investigated and defined as the time duration for which each antenna setting has to
be applied to guarantee stable hotspot suppression and enhance heat delivery
to the tumour.

4.2.5 Experimental Dataset and Evaluation Parameters
4.2.5.1 Patient models

Patient models treated using the HYPERcollar3D system in Erasmus MC have
also been used in this study. The HYPERcollar3D system [49], [122] has been
developed at Erasmus MC for hyperthermia treatment of deep-seated tumours in the head and neck region. The applicator is a re-designed version of the HYPERcollar system \cite{18, 47} and consists of 20 patch antennas operating at a frequency of 434 MHz and arranged in three antenna rings (Figure 2.9).

From the group of the patients subject to treatment using the HYPERcollar3D at Erasmus MC, five patient models were selected, fully anonymised and used in this study (henceforth referred to as Patient 1 to Patient 5). The patient group selection was based on the prevalence of hotspots in the optimal SAR distribution, i.e. worst case scenarios were chosen for the StaticS cases. The hotspot occurrence was also verified in the thermal pattern. The patient group included two oropharynx tumours, one neck node metastasis, one parotid gland and one oral cavity tumour in four males and one female with mean age of 62.6 years.

4.2.5.2 Evaluation Parameters

As noted before, quantifying the quality of hyperthermia treatment is challenging. Applicators are usually compared in terms of their ability to focus the SAR. In the clinic, the temperature rise or cumulative equivalent minutes at 43 °C are used \cite{123–125} but thermal simulations are affected significantly by uncertainties in thermal tissue parameters. For H\&N cancer, these tissue properties were recently examined and it was shown that $T_{50}$ can be predicted with good accuracy \cite{105}. Hence, since time-multiplexed hyperthermia exploits the relatively large time constant of tissue cooling for averaging different SAR patterns that are applied in a sufficiently fast sequence, its performance was analysed both in terms of SAR and temperature simulation based quantifiers described in Section 2.7.

4.3 Results

In this section the results obtained by applying time-multiplexed hyperthermia are discussed. Firstly, the SAR-temperature correlation is analysed to select the hotspots. Then, PSO and MOGA are compared in terms of SAR indicators and
SAR distributions. Finally, thermal performance of static and time-multiplexed configuration is discussed.

4.3.1 SAR-Temperature Correlation

The hotspots were accurately defined before performing MOGA. An analysis was conducted to decide if the hotspots should be defined based on SAR or temperature. Figure 4.2 plots cfSAR values against temperature using the static settings for Patient 1 and shows the fitted regression line. The prediction model (red linear fit) does not fit the observed data well, and very low correlation was found ($R^2 = 0.13$). The observed temperature values lie in the 95% confidence interval of [40.8 °C, 43.7 °C]. $R^2$ values for all other patient models were in the range of 0.2 and 0.6. Hence, hotspot selection was based on the temperature distribution and the region with the highest temperature (i.e. 44°C) was delineated.

Figure 4.2: Simulated cubic filtered SAR and corresponding temperature values (after 20 minutes of simulation) for HTQ optimised antenna settings. Linear fits and $R^2$ values are shown for Patient 1.
4.3.2 SAR Performance of MOGA against PSO

In order to find the best solution from the set produced by MOGA solutions were compared with the static solution, in terms of energy reduction in the hotspot, HTQ and TC metrics. The cfSAR distributions were also obtained for each patient. Thus, SAR results are presented in three parts.

4.3.2.1 Pareto Optimal Solutions

For each patient model, the MOGA optimisation was run to select the Pareto solution (PoptS) that maintained adequate focusing in the target region, i.e. \( TC_{25} \geq 75\% \) \[^{51}\] and provided substantial hotspot energy reduction, i.e. 30-60% SAR reduction compared to the HTQ optimised distribution for all patients. Figure 4.3 shows the set of solutions returned by MOGA when HTQ and HTQ\(_{HS}\) are minimised for Patient 1, together with the chosen PoptS solution for that patient.

![Figure 4.3: Simulated cfSAR and corresponding temperature values (after 20 minutes of simulation) for HTQ optimised antenna settings. Linear fits and \( R^2 \) values are shown for Patient 1.](image-url)
4.3.2.2 SAR Quantifiers

Tables 4.1 and 4.2 report SAR performance quantifiers calculated using static and Pareto settings applied individually. Results show higher HTQ values for the Pareto solutions compared to the static solution, meaning a non-optimal ratio between the energy in the healthy tissue and in the target. However, this is counteracted by much lower HTQ_{HS} values, i.e. reduction of 59-71%, and hence more effective suppression of the energy in a specific area by the PoptS. The Pareto solutions reach a range of improvement over the static solution equal to 8-17% for TC_{25} (3/5 patients) and 3-25% for TC_{50} (4/5 patients). For two patient models, no TC_{25} improvement or reduction was found compared to the static results and TC_{50} was reduced by 15% for one patient.

Table 4.1: HTQ performance metric for static and Pareto solutions and percentage variation tested on 5 patient models.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>HTQ</th>
<th>HTQ_{HS}</th>
<th>ΔHTQ</th>
<th>ΔHTQ_{HS}</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Static</td>
<td>PoptS</td>
<td>PoptS - Static (%)</td>
<td>Static</td>
</tr>
<tr>
<td>P1</td>
<td>0.57</td>
<td>0.85</td>
<td>+49.1</td>
<td>0.45</td>
</tr>
<tr>
<td>P2</td>
<td>0.45</td>
<td>0.54</td>
<td>+20</td>
<td>0.22</td>
</tr>
<tr>
<td>P3</td>
<td>0.29</td>
<td>0.39</td>
<td>+34.5</td>
<td>0.42</td>
</tr>
<tr>
<td>P4</td>
<td>0.46</td>
<td>0.80</td>
<td>+74</td>
<td>0.78</td>
</tr>
<tr>
<td>P5</td>
<td>0.39</td>
<td>0.52</td>
<td>+33.3</td>
<td>0.78</td>
</tr>
</tbody>
</table>

Table 4.2: TC_{25} and TC_{50} performance metrics for static and Pareto solutions and percentage variation tested on 5 patient models.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>TC_{25} (%)</th>
<th>ΔTC_{25}</th>
<th>TC_{50} (%)</th>
<th>ΔTC_{50}</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Static</td>
<td>PoptS</td>
<td>PoptS - Static (%)</td>
<td>Static</td>
</tr>
<tr>
<td>P1</td>
<td>82</td>
<td>82</td>
<td>0</td>
<td>65</td>
</tr>
<tr>
<td>P2</td>
<td>99</td>
<td>99</td>
<td>0</td>
<td>81</td>
</tr>
<tr>
<td>P3</td>
<td>73</td>
<td>90</td>
<td>+17</td>
<td>32</td>
</tr>
<tr>
<td>P4</td>
<td>89</td>
<td>97</td>
<td>+8</td>
<td>25</td>
</tr>
<tr>
<td>P5</td>
<td>73</td>
<td>90</td>
<td>+17</td>
<td>30</td>
</tr>
</tbody>
</table>
Figure 4.4: Normalised cfSAR distributions for 1W input power in the transversal cut at $z = 35$ mm through the target location obtained by the StaticS (a) and PoptS antenna settings (b) for Patient 1.
Figure 4.5: Normalised cfSAR distributions for 1W input power in the transversal cut at $z = 31$ mm through the target location obtained by the StaticS (a) and PoptS antenna settings (b) for Patient 2.
Figure 4.6: Normalised cfSAR distributions for 1W input power in the transversal cut at \( z = 32 \) mm obtained by the StaticS (a) and PoptS antenna settings (b) for Patient 3.
Figure 4.7: Normalised cfSAR distributions for 1W input power in the transversal cut at $z = 40$ mm through the target location obtained by the StaticS (a) and PoptS antenna settings (b) for Patient 4.
Figure 4.8: Normalised cfSAR distributions for 1W input power in the transversal cut at $z = 43$ mm through the target location obtained by the StaticS (a) and PoptS antenna settings (b) for Patient 5.
4.3.2.3 \textbf{SAR} Distribution

Figures 4.4a, 4.4b show two cross sections of normalised energy profile in the 3D model of Patient 1, obtained by the StaticS and PoptS settings. The CTV region is delineated in black and the most prominent hotspot (Hotspot 1) in red. While the hotspot is evident in the cfSAR map in Figure 4.4a for the StaticS case, the cfSAR map for PoptS in Figure 4.4b clearly shows the suppression of energy in the primary hotspot, still maintaining a good SAR coverage in the target when using MOGA. However, other hotspots arise in the healthy tissue in Figure 4.4b; the significance of these new hotspots is assessed by the thermal simulation and discussed later in this chapter. In general, the same behavior was observed with Patients 2, 3, 4 and 5. For example, the suppression of Hotspot 1 is also observed as shown in Figures 4.5-4.6-4.7-4.8.

4.3.3 Thermal Performance of Static and Time-multiplexed Configurations

4.3.3.1 Time-Multiplexed Steering Speed

Thermal simulations were carried out using SEMCAD X, wherein a point sensor was placed in the hotspot and in the CTV to track the temperature over time during the thermal simulation. Figure 4.9a illustrates the temperature of the tumour as a function of time, while Figure 4.9b shows the temperature of the hotspot recorded in Patient 1. The figures show the temperature evolution for the static settings (StaticS and PoptS), as well as temperatures applying the time-multiplexed settings at a total cycle time of 10, 40 and 120 s (i.e. where each individual solution is applied for 5, 20 or 60 s). Time-multiplexing periods of 10 s (red curve) or 40 s (green curve) ensured a stable temperature in the CTV within 0.04 °C and 0.2 °C respectively, and prevented high peak temperatures. Total cycle time of 120 s resulted in a temperature ripple of 0.4 °C. Further, the simulation period of 1200 s was found to be sufficient to attain steady-state temperature in the five patient models. Figure 4.9 also shows the benefit of the time-multiplexed steering approach.
in the target region for Patient 1, with the temperature increased by 0.3 °C in the CTV and reduced by 1.4 °C in the hotspot.

The overall power for time-multiplexed steering was tuned to reach maximum temperature of 44 °C in the healthy tissue and allow fair comparison with the static solutions. This power tuning also compensates for the decrease in temperature observed in the CTV for the $P_{optS}$ solution as shown in Figure 4.9a. This results in suppression of a specific hotspot, an increase in the temperature to 44 °C at a different location of the healthy tissue volume, and further, a temperature increment in the CTV. The results for time-multiplexed steering using a 10 second period will be discussed in more detail in the next section.

4.3.3.2 Cumulative Temperature-Volume histograms and thermal quantifiers

Static and time-multiplexed hyperthermia performance were compared for all five patients using cumulative T-V histograms. The temperature in the CTV and in the most prominent hotspot, Hotspot 1, was calculated based on the static temperature distribution. Temperatures of additional hotspots arising during time-multiplexed steering were also estimated. Thermal indicators for all clinical records are reported in Table 4.3, together with the variation ($\Delta T$) arising from static and time-multiplexed methods. Examples of cumulative T-V histograms are shown in Figure 4.10. Consideration of the behaviour for each patient now follows.

Patient 1. The time-multiplexed steering technique provides a temperature increase equal to 0.3 °C in the CTV compared to the static method, while decreasing the temperature in Hotspot 1 from 44 °C to 42.9 °C, as indicated in Table 4.3. However, total input power was tuned to achieve a maximum temperature of 44 °C in the healthy tissue in the thermal simulation. Therefore, additional hotspots can occur in the healthy tissue during time-multiplexed steering and reach equal or higher maximum temperature compared to the maximum temperature in Hotspot 1 achieved by the static method. In fact, $T_{\text{max}}$ of Hotspots 2 and 3 shows increases of 0.8 °C and 1.5 °C, although their median values are maintained below the CTV temperatures.
4. Time-Multiplexed Steering in Phased Array Microwave Hyperthermia for Head and Neck Cancer Treatment

Figure 4.9: Point temperature (degrees Celsius) in the CTV (a) and in Hotspot 1 (b) over the simulation period of 1200 s (axis is labelled in kiloseconds as produced by SEMCAD X). Static (magenta), Pareto optimal (yellow) and time-multiplexed thermal performance are compared varying the steering rate of five (red), twenty (green) and sixty (blue) seconds.

Patient 2. A target temperature gain equal to 1 °C was observed when time-multiplexed steering is applied. The temperature of Hotspot 1 drops by 1.5 °C. Hence, a second hotspot is heated without exceeding the target median values. The temperature difference between static (solid) and time-multiplexed (dash-dot) configurations for Patient 2 is shown in Figure 4.10a.

Patient 3. Similarly, Patient 3 reports a CTV temperature improvement of...
0.5 °C, a reduction of 1.5 °C in Hotspot 1 and a maximum temperature rise of 0.9 °C in a different healthy region.

*Patient 4 and 5.* The time-multiplexed approach increases the target temperature of 1.2 °C and 0.8 °C while suppressing Hotspot 1 by 0.6 °C and 1 °C and raising Hotspot 2 temperatures by 0.1 °C and 1.9 °C, respectively for Patients 4 and 5.

Across all patients studied, time-multiplexed hyperthermia provides a reduction in the hotspot average maximum temperature of 1.2 °C, at the expense of raising the maximum temperatures in other hotspots, although maintaining their median values below the CTV temperatures. The proposed method also provides a benefit through an average improvement of $T_{50}$ in CTV about 0.8 °C.

**Table 4.3:** Thermal quantifiers $T_x$ that are exceeded by $x$ percent of all temperature readings in the CTV for a selection of worst cases treated with the HYPERcollar3D and $T_{max}$ in the hotspots. Temperature changes from StaticS (single SAR steering) to TMS (time-multiplexed steering) are given in bold.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Antenna settings</th>
<th>CTV $T_{50}$(°C)</th>
<th>Hotspot 1 $T_{max}$(°C)</th>
<th>Hotspot 2 $T_{max}$(°C)</th>
<th>Hotspot 3 $T_{max}$(°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>StaticS</td>
<td>40.4</td>
<td>44</td>
<td>43.1</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>TMS</td>
<td>40.7</td>
<td>42.9</td>
<td>43.9</td>
<td>43.5</td>
</tr>
<tr>
<td></td>
<td>$\Delta_{TMS-StaticS}(°C)$</td>
<td>+0.3</td>
<td>-1.4</td>
<td>+0.8</td>
<td>+1.5</td>
</tr>
<tr>
<td>P2</td>
<td>StaticS</td>
<td>41.7</td>
<td>43.7</td>
<td>41.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TMS</td>
<td>42.7</td>
<td>42.2</td>
<td>43.7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$\Delta_{TMS-StaticS}(°C)$</td>
<td>+1</td>
<td>-1.5</td>
<td>+2.4</td>
<td></td>
</tr>
<tr>
<td>P3</td>
<td>StaticS</td>
<td>40.2</td>
<td>42.9</td>
<td>42.7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TMS</td>
<td>40.7</td>
<td>41.4</td>
<td>43.6</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$\Delta_{TMS-StaticS}(°C)$</td>
<td>+0.5</td>
<td>-1.5</td>
<td>+0.9</td>
<td></td>
</tr>
<tr>
<td>P4</td>
<td>StaticS</td>
<td>40.3</td>
<td>43.7</td>
<td>43.6</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TMS</td>
<td>41.5</td>
<td>43.1</td>
<td>43.7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$\Delta_{TMS-StaticS}(°C)$</td>
<td>+1.2</td>
<td>-0.6</td>
<td>+0.1</td>
<td></td>
</tr>
<tr>
<td>P5</td>
<td>StaticS</td>
<td>39.9</td>
<td>43.7</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TMS</td>
<td>40.7</td>
<td>42.7</td>
<td>43.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$\Delta_{TMS-StaticS}(°C)$</td>
<td>+0.8</td>
<td>-1</td>
<td>+1.9</td>
<td></td>
</tr>
</tbody>
</table>
Figure 4.10: Cumulative Temperature-Volume (T-V) histograms representing the 3D temperature distribution within CTV (red), healthy tissue (blue), Hotspot 1 (violet), Hotspot 2 (green) for Patient 2 (a) and Patient 4 (b). The static (solid line) and the time-multiplexed (dash-dot line) thermal performances are compared. Hotspots 2 (green) arising in Patient 2 during time-multiplexed steering is also illustrated in (a).
Figure 4.11: Patient 1. Simulated 3D temperature distribution (range of 42-44.1 °C) on a coronal view obtained through the static (a), selected Pareto (b) and time-multiplexed (c) settings. Figures were produced by SEMCAD X software. CTV and Hotspot 1 are indicated in (a). Hotspot 1 suppression is evident in (b). Hotspot 1 reduction and the Hotspot 2 appearance are shown in (c) while a $T_{50}$ gain of 0.3 °C is achieved in the target region.
4.3.3.3 Temperature Distributions

Figure 4.11 shows the temperature patterns (range of 42-44.1 °C) after 20 minutes of irradiation predicted by SEMCAD X for Patient 1 when using static, the selected Pareto solution by itself, and time-multiplexed settings. The CTV and Hotspot 1 are highlighted in the static distribution (Figure 4.11a). In Figure 4.11b, it can clearly be seen that Hotspot 1 is totally suppressed, while a second region is being heated. Then, the temperatures of the new hotspot increases when time-multiplexed steering is applied until the occurrence of Hotspot 2; however, Hotspot 1 remains at a lower temperature than in the static temperature pattern (Figure 4.11c).

4.4 Discussion

For time-multiplexed hyperthermia treatment, the characteristics of the applicator system are important. One of the great difficulties in hyperthermia systems in maintaining amplitude and phase stability during the whole hyperthermia treatment are well known problems. However, the work of [48] showed excellent phase (±5°) and amplitude (5%) stability of the Erasmus MC custom-made amplifier system. Furthermore, the progress in RF amplifier technology has made possible devices with improved efficiency that absorb less power and hence have even greater stability. These developments point to the feasibility of the techniques described in this chapter.

An important aspect addressed in this work concerned the correlation between SAR and temperature. Previous research has also examined the correlation between SAR and temperature, with varying conclusions.

Several studies [126–129] show a good correlation between SAR and temperature. For example, Hirata and Fujiwara [126] studied the correlation in head models using a generic dipole antenna, and found SAR averaged over 10 g correlated well with local temperature increase for frequencies from 3 to 6 GHz. Razmadze et al. [128] studied the mass-averaged SAR and the correlation with temperature elevation using a full-body numerical model exposed to plane waves in the frequency range.
range between 30 MHz and 800 MHz. Results showed that better correlation with temperature was obtained with an averaging mass of 10 g.

On the other hand, other studies have also found a weak correlation between SAR and temperature, in common with the investigations in this thesis. For example, Hirata et al. [130] investigated the correlation between peak spatial-average SAR and maximum temperature increase for different averaging schemes and masses. The correlation was obtained by using two head models and a dipole antenna was used as a wave source at different frequencies. Results showed a weak correlation in the brain tissue when using 1 g and 10 g averaged SAR. Samaras et al. [131] investigated the uncertainty in the temperature calculations due to tissue composition and thermal properties in the head of mobile phone users. Frequencies of 900 MHz and 1800 MHz were examined. They found that the maximum temperature rise in the brain was not correlated to maximum 10 g averaged SAR in the head.

Most of the aforementioned studies reported that the average SAR over 10 g correlates well with the temperature rise when models are exposed to high frequencies from a dipole antenna. However, our scenario is different in that a lower frequency was used (434 MHz vs ≥ 800 MHz), a phased array was applied and heating was done to maximum tolerance (max 44°C vs max 38°C). In our simulations, steady state was reached within 20 minutes while other studies report longer periods to reach steady state. Further, the cooling effect by the water bolus in H&N hyperthermia can also affect the SAR temperature correlation particularly in the hotspots near to the skin. Therefore, a direct comparison between previous studies and our specific scenario is difficult. Our analysis indicates that the correlation between SAR and temperature is low and SAR cannot be readily used to assess hotspot location and intensity during H&N hyperthermia.

Further research is needed to establish the true correlation for this specific scenario. However, overall, the results obtained in this chapter indicate the clinical potential of this approach.
4. Time-Multiplexed Steering in Phased Array Microwave Hyperthermia for Head and Neck Cancer Treatment

4.5 Conclusions

In this chapter, time-multiplexed hyperthermia was proposed for the treatment of H&N cancers and compared with the static method clinically deployed at Erasmus MC, using 3D models derived from five patients treated by HYPERcollar3D.

Sequentially applied SAR patterns were used as the source for thermal simulations. MOGA was used for the optimisation of HTQ and HTQ_HS to find the time-multiplexed setting of amplitudes and phases, the so called Pareto optimal solutions, whereas PSO of HTQ was used to optimise the static settings. SAR results obtained by MOGA indicate the feasibility of applying time-multiplexed hyperthermia.

Time-multiplexed hyperthermia for H&N cancers showed improved performance over the static method clinically deployed at Erasmus MC. A substantial gain of the CTV temperatures is observed, which indicates that more effective heat focusing to the target volume is possible for these five patients. The temperature simulations predict a reduction in the average maximum temperature (-1.2 °C) and hence a clinically relevant average improvement in target temperatures, i.e. 0.8 °C in T50. SAR results obtained by MOGA i.e. TC25 values greater than 75% and hotspot energy suppression indicate the potential of time-multiplexed steering via MOGA optimisation. From this analysis, a steering period of ten seconds is found to be sufficient to ensure a stable temperature increment in the target (< 0.1 °C).

In the following chapter, the robustness of time-multiplexed hyperthermia will be tested against thermal tissue properties variation by using a thermal dependent perfusion model.
Robustness of Time-multiplexed Hyperthermia to Temperature Dependent Thermal Tissue Properties

5.1 Introduction

As discussed previously, the principal need in hyperthermia treatments is to optimally focus the heating into the target while protecting the surrounding healthy tissue. Patient-specific treatment planning is done to optimise the specific absorption rate and the resulting temperature distribution. Uncertainties related to the thermal model used for temperature simulations present another important challenge. For example, uncertainty exists as to the exact thermal properties of tissues and as to whether SAR or temperature simulations are a better basis for optimisation. Additionally, neither the mechanism for heat dissipation in tissues, nor changes in perfusion with respect to temperature, are fully understood.

The previous chapter proposed a time-multiplexed steering procedure and evaluated its performance using several sets of real patient data. The procedure was found to result in better performance than a static procedure based on a single solution. The previous chapter assumed constant thermal properties. In this chapter, the benefits of time-multiplexed hyperthermia are further evaluated using
5. Robustness of Time-multiplexed Hyperthermia to Temperature Dependent Thermal Tissue Properties

The work evaluates the robustness of the time-multiplexed hyperthermia algorithm from Chapter 4 using the thermal dependent perfusion model developed in [132].

The remainder of this chapter is organised as follows: Section 5.2 describes the methods, including the different sets of thermal properties used for evaluation. Section 5.3 presents the results and compares the temperature distributions achieved using constant and temperature-dependent perfusion properties. Finally, Section 5.5 concludes the chapter.

5.2 Methodology

In this section, the time-multiplexed steering, previously introduced in Chapter 4 is reviewed, together with the thermal models employed to perform the thermal evaluation. The criteria adopted to test the robustness of the method are also described.

5.2.1 Temperature Properties

To assess the robustness of time-multiplexed hyperthermia, temperature simulations were performed in SEMCAD X using the Pennes’ bio-heat equation [83] where a Scaling Factor (SF) is used to implement a temperature dependent blood perfusion model [132, 133]:

$$\rho c \frac{\partial T}{\partial t} = \nabla \cdot (k \nabla T) + \rho Q + \rho S - SF \rho_b c_b \omega (T - T_b)$$

(5.1)

where $T$ (°C) is the temperature, $t$ (s) is the time, $\rho$ (kg·m$^{-3}$) is the volume density of mass, $c$ (J·kg$^{-1}$·°C$^{-1}$) is the specific heat capacity, $k$ (W·m$^{-1}$·°C$^{-1}$) is the thermal conductivity, $\omega$ (m$^3$·s$^{-1}$·kg$^{-1}$) is the volumetric blood perfusion rate, $Q$ (W·kg$^{-1}$) is the metabolic heat generation rate, $S$ (W·kg$^{-1}$) is the SAR and the subscript $b$ indicates a blood property. Transient thermal simulations were done using the tissue dielectric and thermal properties reported as detailed in Chapter 3 (3.6). Previous research has shown that the response of vasculature in tissues to heat stress depends on the temperature [133]. In this chapter, two different cases are considered:
• Constant values of blood perfusion and thermal conductivity for muscle, fat and tumor tissue were optimised in [105]. This is referred to as the Constant Thermal Model (CTM).

• Temperature dependent perfusion [104]: blood perfusion for muscle was piecewise linearly scaled by a factor of 8.9, for fat by a factor of 2 and for tumor by a factor of 0.5 between temperatures of 37 °C and 45 °C as indicated in Figure 5.1. Temperature-dependent perfusion was modelled only for muscle, fat and tumour; for other tissues, the scaling factor is equal to 1 [104]. This is referred to as the Thermal Dependent Perfusion Model (TDPM).

The manner in which the thermal properties vary with temperature is taken into account in the thermal behaviour of the tissue by the inclusion of the scaling factor SF in equation 5.1. Figure 5.1 shows the linear temperature dependent perfusion scaling factors for fat, muscle and tumor. The blood perfusion increases between 37 °C and 45 °C for fat and muscle. This is described by sigmoidal curves consisting of a Gaussian profile followed by a plateau for temperatures above 45 °C. In contrast, the blood perfusion in the tumor decreases with temperature.

![Figure 5.1: Linear temperature dependent perfusion scaling factors for fat, muscle and tumor](image-url)
5. Robustness of Time-multiplexed Hyperthermia to Temperature Dependent Thermal Tissue Properties

To evaluate the robustness of time-multiplexed hyperthermia, results obtained using the [CTM] and the [TDPM] have been compared. The same procedure that was used in Chapter 4 was applied with both thermal models (CTM and TDPM), and is summarised here for completeness:

- Individual StaticS thermal simulations were run for 1200 s to obtain the total input power required to reach the maximum temperature of 44 °C in the healthy tissue and/or 40 °C in critical organs (eyes, brains and spinal cord).

- The hotspot was selected on the StaticS temperature distribution delineating the area with the highest temperature (44 °C). The hotspot volume varies over a range between 0.5 and 0.2 % of the healthy tissue among all patients. After finding the PoptS settings by MOGA, individual PoptS thermal simulations were run to reach the maximum temperature of 44 °C in the healthy tissue and/or 40 °C in critical organs.

- Thermal simulations for time-multiplexed steering were run applying StaticS and PoptS antenna settings in a sequence over a simulation period of 1200 s and using a steering interval of 10 s. The steering interval is the time length for which each antenna setting is applied.

5.2.2 Hotspot Delineation and Localisation

As described in Section 5.2.1, the selection of the primary hotspot (Hotspot 1) was done on the static temperature distribution and the region with the highest temperature was delineated. In Chapter 4 it was found that additional hotspots occurred in the healthy tissue during time-multiplexed steering, hence a second hotspot (Hotspot 2) was selected based on the time-multiplexed temperature distribution obtained by using the constant thermal model.

To evaluate the robustness of static and time-multiplexed hyperthermia, the highest temperature was identified from the static TDPM distribution. Hence, Hotspot 1 related to [CTM] (Hotspot 1-CTM) and Hotspot 1 related to [TDPM] (Hotspot 1-TDPM) were found.
To verify whether Hotspot 1-TDPM occurred in the same or a nearby location as Hotspot 1-CTM, the Euclidean distance was calculated between the two hotspots, using the highest temperatures in the CTM and TDPM distributions as comparison points. Lastly, the time-multiplexed steering was run using TDPM.

5.2.3 Experimental Dataset and Evaluation Parameters

The five patient models selected in Section 4.2.5 were also used in this study. The patient group included one neck node metastasis, one oral cavity, one parotid gland and two oropharynx tumors. All patients were treated with the HYPERcollar3D at Erasmus MC Cancer Institute.

The StaticS and the PoptS solutions were evaluated based on SAR performance metrics as described in 4.2.5. In particular, Target Coverage by 25% iso-SAR ($TC_{25}$) and Target Coverage 50% ($TC_{50}$) were used to select the best Pareto solution which supplied a balance between providing sufficient SAR in the target and SAR reduction in the healthy tissue and these results were discussed in Section 4.3.

The thermal performance of the StaticS and the PoptS configurations and the robustness of the time-multiplexed steering to temperature dependent thermal tissue properties was evaluated using cumulative Temperature-Volume (T-V) histograms and thermal indices such as the median temperature, $T_{50}$ in the CTV, and the maximum temperature $T_{max}$ in the hotspot, to quantify the hotspot suppression.

5.3 Results

Experimental results obtained by running the time-multiplexed steering using constant and thermal dependent perfusion model are presented in this section. Firstly, the hotspots based on the TDPM distributions are identified. Then, static and time-multiplexed thermal performances are compared and discussed.

5.3.1 Hotspot location: CTM and TDPM Distributions

The StaticS and PoptS settings used to run the CTM thermal simulation were the ones selected in Chapter 4 for five patient models. PoptS was selected by ensuring
adequate focusing in the target area, i.e. $TC_{25} \geq 75\%$ \cite{51} and suppression of the hotspot energy, i.e. 30-60\% SAR reduction compared to the HTQ-optimised distribution for each patient. Static temperature distributions for Patient 5 for CTM and TDPM are given in Figure 5.2a and 5.2b respectively.

The location of the highest temperature in the static TDPM temperature distribution was identified as shown in Figure 5.2b and it was found that the maximum Euclidean distance between the highest temperatures in CTM and TDPM was 5.4 mm, and was generally much less than that. Euclidean distance values ($D$) for the five patient models are reported in Table 5.1.

Since the hotspot location does not vary significantly between CTM and TDPM over the patient population, in the following analyses the same hotspot delineation was used for both CTM and TDPM. We also used the PoptS-CTM antenna settings to assess the effectiveness of time-multiplexing steering using TDPM.

Table 5.1: Euclidean distance between Hotspot 1-CTM (in constant thermal model distribution) and Hotspot 2-TDMP (in thermal dependent perfusion model) for five cases treated with the HYPERcollar3D.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>P1</th>
<th>P2</th>
<th>P3</th>
<th>P4</th>
<th>P5</th>
</tr>
</thead>
<tbody>
<tr>
<td>D (mm)</td>
<td>3.7</td>
<td>5.4</td>
<td>2.2</td>
<td>2.8</td>
<td>1.7</td>
</tr>
</tbody>
</table>

5.3.2 Cumulative Temperature-Volume Histograms and Thermal Indicators

5.3.2.1 Impact of thermal model: Static Performance

Static performance using CTM and TDPM was considered for all five patients using cumulative T-V histograms. The temperature in the CTV and in Hotspot 1 was calculated based on the static temperature distributions and the thermal quantifiers are reported in Table 5.2. The variation ($\Delta T_{\text{StaticS-TDPM vs CTM}}$) arising from the static CTM and the static TDPM performances is also shown in Table 5.2.

For all clinical records, the static performance obtained with TDPM provides a temperature increase of $T_{50}$ in CTV of between 1.5 °C and 2.1 °C compared to the static CTM performance. Figure 5.3 is an example of the cumulative T-V
5. Robustness of Time-multiplexed Hyperthermia to Temperature Dependent Thermal Tissue Properties

Figure 5.2: Patient 5. 3D temperature distribution on a transversal view obtained using StaticS settings with Constant Thermal Model (CTM) (z=43 mm) (a) and Thermal Dependent Perfusion Model (TDPM) (z=44 mm)(b). CTV and the location of maximum temperature achieved in the healthy tissue are are in the oral cavity in both cases but with a difference of 1 mm in the z-location.
histogram for the static thermal performance using CTM and TDPM. Similar trend are observed in all other patients.

Figure 5.3: CTV (red) and Hotspot 1 (violet) cumulative T-V histograms for Patient 3. The static thermal performance using CTM and TDPM are shown in (a) and (b) respectively.
Table 5.2: Thermal quantifier $T_{50}$ that is exceeded by 50 percent of all temperature readings in the CTV and $T_{max}$ in the hotspot for five cases treated with the HYPERcollar3D. Temperature changes from StaticS (single SAR steering) to TMS (time-multiplexed steering) obtained by CTM (constant thermal model) and TDPM (thermal dependent perfusion model) are given in bold.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Thermal model</th>
<th>Antenna settings</th>
<th>CTV</th>
<th>Hotspot 1</th>
<th>Hotspot 2</th>
<th>Hotspot 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>$T_{50}$ (°C)</td>
<td>$T_{max}$ (°C)</td>
<td>$T_{max}$ (°C)</td>
<td>$T_{max}$ (°C)</td>
</tr>
<tr>
<td>P1</td>
<td>CTM</td>
<td>StaticS</td>
<td>40.4</td>
<td>44</td>
<td>43.1</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TMS</td>
<td>40.7</td>
<td>42.9</td>
<td>43.9</td>
<td>43.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\Delta T_{TMS-StaticS}$ (°C)</td>
<td>+0.3</td>
<td>-1.4</td>
<td>+0.8</td>
<td>+1.5</td>
</tr>
<tr>
<td></td>
<td>TDPM</td>
<td>StaticS</td>
<td>42.1</td>
<td>42.6</td>
<td>42.6</td>
<td>41.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TMS</td>
<td>42.1</td>
<td>41.6</td>
<td>42.7</td>
<td>42.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\Delta T_{TMS-StaticS}$ (°C)</td>
<td>0</td>
<td>-1</td>
<td>+0.1</td>
<td>+0.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\Delta T_{StaticS-TDPM-CTM}$ (°C)</td>
<td>+1.7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2</td>
<td>CTM</td>
<td>StaticS</td>
<td>41.7</td>
<td>43.7</td>
<td>43.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TMS</td>
<td>42.7</td>
<td>42.2</td>
<td>43.7</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\Delta T_{TMS-StaticS}$ (°C)</td>
<td>+1</td>
<td>-1.5</td>
<td>+2.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TDPM</td>
<td>StaticS</td>
<td>43.2</td>
<td>43.5</td>
<td>43.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TMS</td>
<td>43.4</td>
<td>42.9</td>
<td>44.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\Delta T_{TMS-StaticS}$ (°C)</td>
<td>+0.2</td>
<td>-0.6</td>
<td>+0.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\Delta T_{StaticS-TDPM-CTM}$ (°C)</td>
<td>+1.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P3</td>
<td>CTM</td>
<td>StaticS</td>
<td>40.2</td>
<td>42.9</td>
<td>42.7</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TMS</td>
<td>40.7</td>
<td>41.4</td>
<td>43.6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\Delta T_{TMS-StaticS}$ (°C)</td>
<td>+0.5</td>
<td>-1.5</td>
<td>+0.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TDPM</td>
<td>StaticS</td>
<td>41.7</td>
<td>43.1</td>
<td>42.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TMS</td>
<td>42.5</td>
<td>42.5</td>
<td>43.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\Delta T_{TMS-StaticS}$ (°C)</td>
<td>+0.8</td>
<td>-0.6</td>
<td>+1.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\Delta T_{StaticS-TDPM-CTM}$ (°C)</td>
<td>+1.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P4</td>
<td>CTM</td>
<td>StaticS</td>
<td>40.3</td>
<td>43.7</td>
<td>43.6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TMS</td>
<td>41.5</td>
<td>43.1</td>
<td>43.7</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\Delta T_{TMS-StaticS}$ (°C)</td>
<td>+1.2</td>
<td>-0.6</td>
<td>+0.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TDPM</td>
<td>StaticS</td>
<td>42.4</td>
<td>43.7</td>
<td>43.7</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TMS</td>
<td>42.5</td>
<td>42.9</td>
<td>43.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\Delta T_{TMS-StaticS}$ (°C)</td>
<td>+0.1</td>
<td>-0.8</td>
<td>-0.6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\Delta T_{StaticS-TDPM-CTM}$ (°C)</td>
<td>+2.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P5</td>
<td>CTM</td>
<td>StaticS</td>
<td>39.9</td>
<td>43.7</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TMS</td>
<td>40.7</td>
<td>42.7</td>
<td>43.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\Delta T_{TMS-StaticS}$ (°C)</td>
<td>+0.8</td>
<td>-1</td>
<td>+1.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TDPM</td>
<td>StaticS</td>
<td>41.9</td>
<td>43.7</td>
<td>42.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TMS</td>
<td>42.5</td>
<td>43.1</td>
<td>43.8</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\Delta T_{TMS-StaticS}$ (°C)</td>
<td>+0.6</td>
<td>-0.6</td>
<td>+0.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\Delta T_{StaticS-TDPM-CTM}$ (°C)</td>
<td>+2</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
5. Robustness of Time-multiplexed Hyperthermia to Temperature Dependent Thermal Tissue Properties

### 5.3.2.2 Impact of thermal model: Time-multiplexed performance

In addition to the static settings, the performance of the time-multiplexed steering procedure using CTM and TDPM was considered for the five patient models. The median temperature in CTV, the maximum temperature in Hotspot 1 and the additional hotspot temperatures raising from time-multiplexed steering, Hotspot 2 and Hotspot 3 (following the definition of Hotspot 1 and Hotspot 2) are reported in Table 5.2, together with the variation resulting from static and time-multiplexed steering ($\Delta T_{TMS-Static}$) both for constant thermal and thermal dependent perfusion performances.

Figure 5.4 shows an example of cumulative T-V histograms for static and time-multiplexed steering using CTM and TDPM. Results obtained with time-multiplexed steering using the constant thermal model have been discussed in Section 4.3. The temperature simulations predicted an average improvement in target temperatures, i.e. 0.8 °C in $T_{50}$ and a reduction in the average maximum temperature of 1.2 °C in the healthy tissue. The time-multiplexed steering using TDPM provides an increase in $T_{50}$ of the CTV in the range of 0.1 °C and 0.8 °C for four out of five patients, and identical $T_{50}$ is achieved for Patient 1 compared to the static TDPM performance. Also, a hotspot reduction varying between 0.6 °C and 1 °C is observed for all patients studied.

Results show that the static performance arising from TDPM predicts higher $T_{50}$ values in CTV compared to the static performance obtained with CTM. Hence, the improvements achieved by TMS when using TDPM is not high as for the TMS using CTM. Nevertheless, there is still improvement and these findings demonstrate the robustness of time-multiplexed hyperthermia to temperature dependent thermal tissue properties and the benefit both in terms of CTV coverage and hotspot suppression.
Figure 5.4: CTV (red), Hotspot 1 (violet) and Hotspot 2 (green) cumulative T-V histograms for Patient 3. The static (solid line) and the time-multiplexed (dash-dot line) thermal performances are compared using CTM (a) and TDPM (b).
5.4 Discussion

The novelty of the work described in this chapter is the additional development of TMS by means of non-linear thermal simulations where the blood perfusion coefficient of selected tissues depends on the temperature itself. Results indicated that the temperature in the target could be increased by 0.8 °C while hotspots could be reduced by 1.2 °C on average between all patients. These results show that TMS using thermal dependent perfusion model still yields thermal distribution comparable with those obtained with constant tissue properties, with a lower improvement in the target temperature.

As described in Chapter 4, the predicted temperatures in the healthy tissue cannot exceed a specified temperature limit, i.e. 44 °C. Additional hotspots arise in the healthy tissue during time-multiplexed steering leading to higher maximum temperatures in some cases as compared to the maximum temperature of the hotspots obtained in the static simulation. For example, $T_{\text{max}}$ of Hotspot 2 and Hotspot 3 resulting from TDPM show increases in the range of 0.1-1.2 °C; however, their median temperatures are still below the CTV temperatures. While it is also possible in some cases that hotspot temperatures may exceed the specified limit of 44 °C with TMS (e.g. with Patient 2), these cases are relatively rare and the TMS method allows flexibility in controlling the steering rate to compensate for these effects if necessary. In an extreme case, if an increase in hotspot temperature was deemed to be clinically unacceptable relative to the beneficial increase in CTV, the steering rate may be set to zero so that treatment reverts to the static settings only for that patient. Further investigation of these factors will be the subject of future research.

In TDPM while the perfusion of the tumour with increasing temperature is reduced relative to CTM, the relative increase in the perfusion of muscle with increasing temperature is substantially larger, and likely dominates the thermal behaviour.

Clinical experience in Erasmus MC Cancer Institute suggests that increases in CTV temperature on the order of only 0.3 °C are beneficial [113], [114]. While
the relative increase in CTV temperature using TMS is smaller with TDPM; these increases are still clinically useful in many patients.

These findings demonstrate the general robustness and utility of time-multiplexed hyperthermia to temperature dependent thermal tissue properties and the benefit both in terms of CTV coverage and hotspot suppression.

5.5 Conclusions

In this chapter, the robustness of the time-multiplexed steering method for hyperthermia treatment planning presented in Chapter 4 with different thermal models of tissue behaviour was evaluated. In particular, the effects on performance as determined through thermal simulations of assuming that the thermal properties vary with temperature, as opposed to being constant, were examined. Multiple heating patterns, i.e. antenna phases and amplitudes, were generated by a multi-objective genetic algorithm and applied sequentially in thermal simulations.

The proposed strategy was compared with the particle swarm optimisation used in the clinic and the thermal performance was assessed. Using the temperature dependent perfusion model, an increase in $T_{50}$, i.e. 0.2-0.8 °C, and a decrease in the hotspot temperature, i.e. 0.6-1 °C was observed for four out of five patients.

The work presented in Chapter 4 has suggested that time-multiplexed hyperthermia can achieve higher temperatures in the tumour and decrease temperatures in the healthy tissue when constant thermal properties are used in thermal simulations. Similarly, the work presented in this chapter, has found that time-multiplexed hyperthermia increases the temperature in the tumour and lowers the temperature in the hotspot when using temperature dependent perfusion models. Overall, the results in this chapter indicate that time-multiplexed hyperthermia via MOGA optimisation is robust to variations in thermal properties due to temperature increases.
6 Conclusions and Future Work

The principal conclusions and findings of the thesis are described in this final chapter. The primary contributions are revisited and suggestions for future work are presented.

6.1 Summary of Thesis

This thesis dealt with the development of optimisation techniques for use in planning of non-invasive microwave hyperthermia treatment of cancer. The investigation was focused on the application of H&N cancers. Studies on SAR and temperature-based optimisation algorithms were carried out with the goal of focusing EM energy to heat tumours, while preserving the healthy tissue. The delivery of the desired heating in cancerous and healthy tissue was validated using thermal simulations.

Firstly, evolutionary optimisation algorithms were investigated to optimise the SAR distributions and find optimal antenna settings for antenna amplitude and phase. Then, a novel time-multiplexed steering approach was developed to further focus the heating into the target and reduce hotspot prominence. The robustness of the time-multiplexed hyperthermia to temperature dependent thermal tissue properties was also assessed. The performance of the various
6. Conclusions and Future Work

algorithms was evaluated using clinical patient data and through metrics informed
by clinical practice.

Chapter 2 of the thesis presented an overview of the anatomy of H&N cancer
and introduced the biological aspects of the hyperthermia treatment. Different
hyperthermia systems and modalities were discussed and the clinical benefits as
found in clinical trials were described. The stages of pre-treatment planning were
described, together with the performance metrics used in the clinic. Furthermore,
several objective functions and optimisation algorithms were reviewed.

Chapter 3 proposed the differential evolution algorithm for treatment planning,
and compared it with the particle swarm optimisation clinically used at the Erasmus
MC. Different optimisation settings were investigated to find the best antenna
configuration which provided optimal SAR distribution. The algorithms were
applied to a set of patients clinically treated with the HYPERcollar system in
clinical use at Erasmus MC. Thermal simulations were carried out to assess effective
target heating and hotspot reduction. The performance of both algorithms was
compared in terms of target coverage, SAR distributions, thermal indicators and
cumulative T-V histograms.

Chapter 4 presented the development of a novel time-multiplexed hyperthermia
strategy via MOGA optimisation to dynamically generate a heating distribution.
Similar to the DE optimisation, the proposed method was compared with the static
solution obtained by PSO and the results were presented in terms of SAR and
thermal indicators. For this analysis, data from patients treated with the next
generation HYPERcollar3D system at Erasmus MC were used. Given that some
uncertainty exists in relation to specific thermal behaviour of tissue, Chapter 5
evaluated the efficacy of the time-multiplexed steering system proposed in Chapter
4 in the presence of variation in thermal properties of tissues due to temperature
increase. The robustness was assessed based on thermal quantifiers and using data
from patients treated with the HYPERcollar3D system at Erasmus MC.
6.2 Main Contributions

The primary contributions of this thesis are as follows. A list of the publications derived from the research described in this thesis was given in Section 1.2.1.

1. A Differential Evolution (DE) algorithm for SAR optimisation was proposed to improve the SAR coverage of the target region, and compared with an existing algorithm (PSO) in clinical use. Evaluation indicated that while both algorithms are capable of finding the optimal power deposition, the proposed DE algorithm is more consistently superior to PSO in locating the optimum solution. DE performs better in terms of HTQ average and standard deviation, reporting a range of improvement of HTQ standard deviation of between 40.1-96.8% across six patients.

2. A Multi-Objective Genetic Algorithm (MOGA) for target focusing and hotspot suppression was proposed, involving optimisation of two objective functions. Furthermore, a novel objective function was formulated in such a way to find a tradeoff between the EM energy in the target and suppression of a pre-defined hotspot. The efficacy of the novel objective function was demonstrated in terms of SAR metrics and when applying TMS using thermal simulations. SAR results obtained by MOGA, in particular TC25 values greater than 75%, showed improved target coverage and hotspot energy reduction of 59-71% compared to PSO, indicated the feasibility of implementing time-multiplexed hyperthermia.

3. A new approach for phased array hyperthermia focusing was proposed, whereby multiple solutions produced by MOGA were applied in a time-multiplexed fashion in order to improve treatment planning. Studies were conducted to determine the best multiplexing parameters, in particular the steering rate. The results demonstrated that the predicted time-averaged temperature is increased when using time-multiplexing. Realistic steering periods of 10 seconds were found to stabilise temperatures within 0.04 °C. Target heating was
enhanced and hotspots reduced by the time-multiplexed approach, resulting in 0.3-1.2 °C improvement in $T_{50}$ and 0.6-1.5 °C reduction in hotspot temperatures compared to the static method currently used in clinic.

4. A SAR-temperature correlation analysis was carried out before applying time-multiplexed hyperthermia. A low correlation was found between EM energy and temperature values leading to the selection of the hotspots based on temperature distribution. This analysis showed the importance of thermal simulations as a means of treatment validation and that the selection of hotspots based on SAR distribution alone may not always be appropriate.

5. The time-multiplexed hyperthermia system proposed in Chapter 4 was evaluated using temperature dependent thermal tissue properties in order to determine its robustness to uncertainty in thermal model parameters. The novel technique was shown to be robust to variations in thermal properties.

6.3 Future Work

The primary conclusions of this thesis show that the proposed techniques have the potential to be used for the treatment of H&N cancer. However, several potential areas of research remain that may improve the effectiveness of the optimisation methods and more generally, the accuracy and reliability of the hyperthermia treatment planning.

Firstly, a larger population of patients should be tested to confirm the capability of the proposed focusing algorithms in heating H&N tumors. Moreover, the application of the optimisation methods can be extended to other types of cancers such as pelvic cancer and to different hyperthermia applicators such as BSD 2000 system.

The differential evolution algorithm proposed in this thesis was tested on a set of patients treated by the HYPERcollar system designed with a total of twelve antennas. Researchers at the Erasmus MC demonstrated that increasing the number of antenna elements, as in HYPERcollar3D, enhances heat focusing into the tumor; however, one of the limitations when applying H&N hyperthermia treatment with
HYPERcollar3D was that only twelve antennas out of twenty could be used due to a limited number of power amplifiers. The selection of the antennas was based on the highest mean SAR individually achieved in the target region. Further analysis could focus on evaluating the SAR distribution using different combinations or subgroups of antennas. This may result in a total field pattern characterised by a smaller number of hotspots in the healthy tissue and better target focusing.

An additional area of research concerns the application of time-multiplexed hyperthermia in larger CTV to exclusively enhance the target heating. The CTV volume could be divided in multiple sub-volumes and the multi objective genetic algorithm could be exploited for each sub-volume. Pareto optimal solutions could be obtained for each area of interest and selected in such a way to achieve substantial SAR coverage. Then, the Pareto antenna settings could be sequentially applied in thermal simulation to run time-multiplexed hyperthermia and evaluate the temperature distribution. For this approach, the number and the location of the selected antennas of the HYPERcollar3D system is critical to achieve good SAR coverage.

The accuracy of tissue thermal and dielectric properties represent another important challenge in hyperthermia treatment planning. While the robustness of the time-multiplexed steering has been tested in this thesis, further research can be devoted to evaluate the robustness of the proposed technique against dielectric properties uncertainties.

Finally, analysis conducted as part of this research shows a low correlation between SAR and temperature values. Hence, accurate modeling to predict as closely as possible the SAR and temperature distribution within the patient should be examined in future work. However, despite the uncertainties in thermal tissue properties, the lack of knowledge on the physiological response of the body to temperature increase, thermal modeling remains an important tool to evaluate the temperature distribution in the treated area.
References


[72] Recommended practice for determining the peak spatial-average specific absorption rate (SAR) associated with the use of wireless handsets - Computational techniques. Draft standard, IEEE-1529.

References


References


